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Introduction: Polymeric immunoglobulin receptor (pIgR) traffics 
Immunoglobulins (IgA and IgM) through epithelial cells in normal mucosae but neither 
are expressed in the normal pancreas. Recent work has demonstrated pIgR to be 
upregulated in hepatocellular carcinoma, even though it is not expressed in normal 
liver cells. High pIgR levels are associated with poor survival and distant metastases 
for a number of cancers such as nasopharyngeal cancers, lung and oesophageal 
cancers.  
Recent work from our laboratory suggested pIgR may be upregulated in 
pancreatic ductal adenocarcinoma (PDAC). My aim was to assess pIgR’s role in 
PDAC by interrogating human PDAC tissue samples as well using cell biology 
experimental tools.  
 
Methods: pIgR expression was manipulated (siRNA and shRNA) in cell lines to 
evaluate its subsequent effect on cell behaviour in 2D assays as well as 3D 
organotypics models. Tissue Microarrays of patients with PDAC were analysed after 
pIgR, αSMA, E-Cadherin and Picrosirius Red staining to assess their role as a 
combined bio-marker panel.  
 
Results: Cytokines such as interleukin 4 (IL4) and Tumour Necrosis Factor (TNFα) 
could not modulate pIgR expression in PDAC cell lines despite this effect being seen 
in other studies using colorectal and nasopharyngeal cancer cell lines. Down-
regulation in pIgR expression in Capan1 cell line resulted in reduction of cellular 
proliferation (n= 3, P<0.05, Friedman test), adhesion (n= 3, P<0.05, Kruskal-Wallis) 
and migration (n= 3, P<0.05, Kruskal-Wallis). In 3D organotypic models, pIgR 
downregulation resulted in reduced cancer cell invasion (n= 9, P<0.05, Kruskal-




In human PDAC, decreased E-cadherin expression correlates with increased pIgR 
expression through pancreatic intra-epithelial neoplasia (PanIN) progression. There 
was no IgA expression in PDAC. pIgR expression had no clinical correlation with 
routine prognostic measures such as differentiation, lymph node metastasis (n= 88, 
P=0.5012, Kruskal-Wallis). Even in combination with stromal indices (α-smooth 
muscle action (SMA) and Picrosirius red), low pIgR scores had no statistically 
significant impact on prognosis but had a trend towards better survival (n= 88, 
P=0.2791, Mann-Whitney U test).  
 
Conclusion: pIgR may be involved in progression from pre-neoplastic lesions such 
as PanIN to PDAC. pIgR may have a biological impact on cellular motility and 
invasion due to yet to be deciphered signalling cascades with marked effect on 
cellular phenotype. Careful analysis is required to study the impact of pIgR on 
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1.1  Pancreatic Cancer 
Encompassing two distinct functional units of cells, the pancreas can give 
rise to several different tumour types. These tumour types show distinct clinical 
behaviours and genetic profiles. Pancreatic ductal adenocarcinoma (PDAC), a 
tumour type with characteristic histology, is the most common type of cancer of the 
pancreas, accounting for greater than 85% of pancreatic neoplasms (1). 
 
1.1.1 Classification of pancreatic neoplasms 
Composed of exocrine and endocrine compartments, the pancreas regulates 
digestion and glucose metabolism (2). The pancreas consists of numerous small 
glands called acini, which constitutes the exocrine function of the pancreas. These 
smaller acini drain into small, intercalated ducts, which join to form the intra-lobular 
and then inter-lobular ducts, which eventually anastomose to the main pancreatic 
duct and onwards to the duodenum (Figure 1.1). Acini function to produce inactive 
enzymes such as trypsin, elastase, lipase and amylase, which are activated in the 
acidic environment of the duodenum. Interspersed within the exocrine tissue, are 
islets of endocrine cells (3). 
The classification of neoplasms is based on the presumed cellular origin of 
the cancer cells (ductal, endocrine and acinar cells) as well as the gross 
configuration of the tumour (solid, cystic or intraductal) (3). Since pancreatic ductal 
adenocarcinoma (PDAC) is the commonest tumour of the pancreas, the terms 





Figure 1.1: Normal pancreatic pathology demonstrated on Haematoxylin and Eosin (H&E).  
(A) Representation of Islet of Langerhans and the endocrine portion of the pancreas. (B) Representation 
of pancreatic acini and the exocrine portion of the pancreas. (C) The interlobular duct. Scale bar 100µm. 




PDAC has a dire prognosis and outcomes have not significantly improved in 
the last 40 years. It was the 10th most common cancer in 2011 (UK: 9.7 per 
100000), but its incidence is increasing  In 2008, there were 8085 new cases in the 
UK and by 2011, there were 8773 reported cases (4328 male and 4445 female) (4).  
Peak incidence for the disease is between the seventh and eight decade of 
life, approximately 80% of cases are seen in the over 60s (5) and there is no 
difference between sexes (6). The mortality rates of PDAC vary among countries; 
the five-year survival in the UK is 3%, which is a marginal increase in the last 40 
years. However, patients with localised, resectable disease have a 5-year survival 
of 15-18% (7). At present, only pancreatic resection can improve survival 
significantly. However, due to late presentation and aggressive tumour behaviour, a 
minority of patients (5-10%) can undergo potentially curative surgery (8). 
Although the causes of PDAC remain incompletely understood, development 
of late onset diabetes in patients over the age of 65 is associated with an eight-fold 
increase of developing PDAC within three years, compared to the normal population 
(9). Smoking is the only proven risk factor, with the risk of PDAC, in those who 
smoke 25 cigarettes or more per day, 3.1 times the risk of non-smokers (10).  
 
1.1.3 Diagnosis 
Signs and symptoms of PDAC are, at best, vague and non-specific. They 
include malaise, abdominal pain, and nausea or weight loss in early stages of 
disease. Tumours of the head of the pancreas often obstruct the common bile duct, 
resulting in obstructive jaundice, whilst tumours of the tail and body present later, 
usually with pain. Obstruction of the major pancreatic ducts can also cause 
malabsorption, steatorrhoea and/or pancreatitis. Tumour-secreted soluble factors 
affecting β-cell function results in new-onset diabetes in small tumours in 
approximately 40% of patients (11, 12). 
Blood tests are non-specific. Serum liver function and full blood counts may 
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demonstrate obstructive jaundice and normochromic anaemia. Biomarkers have 
been stipulated, but the only one with clinical usefulness is carbohydrate antigen 
19-9 (CA 19-9), with a sensitivity of 70-90% and specificity of 90%. CA 19-9 lacks 
the desired sensitivity and specificity for early detection (13). The accepted use for 
CA 19-9 remains in monitoring response to treatment and in identifying recurrence 
in treated patients with known PDAC (14).    
Evaluation of a patient with suspected PDAC is focused on confirming 
diagnosis and staging of disease.  Although a useful investigation, ultrasound does 
not exclude PDAC, thus the modality of choice in patients with suspected pancreatic 
cancer is pancreatic protocol computed tomography (CT), which is a tri-phasic 
cross-sectional imaging, with thin slices and specific aspect of venous phase of 
intravenous contrast. Sensitivity for detecting lesions more than 2cm is 90% with 
accuracy of determining resectability for 80-90% of patients (13, 15). 
Consensus on further staging and investigations has no uniformity. 
Endoscopic ultrasound (EUS) can accurately demonstrate small tumours (as small 
as 3mm) (16). In conjunction with fine needle aspiration (17), EUS provides a 
relatively safe method of tissue analysis, and has progressively replaced ERCP with 
brush cytology (18). EUS alone does not achieve the accuracy required sensitivity 
to distinguish between chronic pancreatitis and malignancy (75%) but with FNA, it 
rises to >90% (19). EUS has drawbacks such as user-dependency and being 
invasive; thus, it is associated with complications. 
Endoscopic retrograde cholangiopancreatography (ERCP) has classically 
been used for biliary obstruction and was the first choice imaging modality until 
EUS-FNA produced better and safer results. It is still used as an alternative for FNA 
aspiration tissue sampling and has the benefit of being able to pace a stent to 
palliate biliary obstruction when surgery is not elected or must be delayed  
Magnetic resonance imaging (MRI) scanning can be used to identify lesions 
less than 2cm. Magnetic resonance cholangiopancreatography (MRCP) with 
gadolinium enhancement allows tumour detection at an earlier stage, potentially 
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useful for screening individuals at high risk of PDAC (20). 
Positron emission tomography (PET) scanning uses fluorine 18-
fluorodeoxyglucose (FDG), which is the most widely used radioisotope to identify 
active tumour cells, especially in patients with metastases and post-chemotherapy 
progress imaging. FDG-PET sensitivity and specificity is variable: 46-71% and 63-
90% respectively, thus PET-CT is much more effective (92% sensitivity). PET-CT is 
most effective in diagnosing metastasis and post-treatment imaging (21); however, 
it is not in routine clinical use. 
Preoperative staging laparoscopy is the exploration of certain areas of the 
abdomen to check the extent of disease infiltration: mainly peritoneal seeding, small 
surface liver metastases and involvement of the coeliac/mesenteric vessels that are 
below the detection threshold of currently available imaging techniques, and can 
prevent unnecessary laparotomy (22). Depending on a center’s expertise, 
laparoscopic staging maybe appropriate in some patients, especially in those with 
lesions in the body or tail, or in patients with higher risk of Pancreatic cancer is 
staged according to the American Joint Committee on Cancer (AJCC) tumour-node-
metastasis (TNM) classification, however there are no universally accepted criteria 
for resection. Thus, decisions for further management of patients are based on 
outcomes by a multidisciplinary team. CT classification broadly categorises patients 
with PDAC as either resectable, borderline resectable, locally advanced or 
metastatic disease. Pancreatic staging guides potential treatment options, as shown 
in Table 1. Patients with locally advanced disease (Stage III) are ineligible for 







Table 1: Staging and TNM classification related to incidence, treatment and prognosis (23) 
1.1.4 Treatment 
The majority of patients present with distant metastasis, commonly to the 
liver and peritoneal cavity (13). 
Treatment is based on the extent of the disease, with the only potential 
curative treatment being surgical resection. Palliative surgery can be used to relieve 
symptoms of gastric outlet and/ or biliary obstruction, whilst endoscopic or 
percutaneous biliary stenting are preferred options. Chemotherapy and radiation 
therapy may be used as palliative treatment or in the adjuvant setting with surgery 
(16).      
1.1.4.1 Surgery 
About 10% of all patients with PDAC are fit patients with resectable disease. 
They should be referred to a high volume specialist centre for surgical resection, as 
there is considerable evidence that operative mortality can be kept to low single 
















IA T1, N0, M0 <2cm size, 
confined to 
pancreas 
IB T2, N0, M0 >2cm size, 
confined to 
pancreas 
IIa T3, N0, M0 Growth into 
adjacent organs  
IIB T1-3, N1, M0 Lymph node 
involvement 
III T4, any N, M0 Invasion into 





IV Any T, any N, 
M1 
Metastatic disease Metastatic 47.2 1.6 
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1.1.4.2 Chemotherapy 
The objectives of chemotherapy and radiotherapy in PDAC may be 
considered in three sections; neoadjuvant or adjuvant therapy (given during or after 
surgery to improve survival), management of locally advanced disease not 
amenable to surgical therapy and metastatic disease, where the primary objective is 
palliation and prolongation of a symptom free life.  
In the past three decades, the standard chemotherapies for management of 
palliative stages of PDAC consisted of fluoropyrimidines like F-fluorouracil (5-FU) 
and the antimetabolite drug gemcitabine, which were mostly equivalent in 
randomised clinical trials, contributing 0-10% to tumour response and with an 
overall survival (OS) of 4 to 6 months (25). Several combinations with other 
chemotherapies and/ or biological agents were studies, mostly with inconclusive or 
negative results. Gemcitabine alone, Gemcitabine-Capecitabine combination (26), 
Gemcitabine-nab Paclitaxel (27) and FOLFIRINOX (28)re all considered first-line 
therapy, whilst FOLFIRINOX provides better survival, it is only suitable for good 
performance status patients (28). As a second line treatment, 5FU-folinic acid and 
nanoliposomal Irinotecan combination provides the best results (29).  
Neoadjuvant therapy, with the aim to reduce size or extent of tumour prior to 
surgery to enhance successful surgical removal remains under investigation in the 
context of clinical trials (30). 
Adjuvant regimens had traditionally consisted of gemcitabine and 
fluorouracil-based chemotherapy. These have been shown to increase the median 
and 5-year survival compared to surgery alone (31) (32). Understanding the biology 
of pancreatic cancer with particular reference to genetic alterations and tumour-
stroma interactions could potentially alter the therapeutic landscape and improve 




1.2 Pathophysiology of pancreatic cancer 
Pancreatic ductal adenocarcinoma is speculated to originate in the ductal 
epithelium, presumably from small intra-lobular ducts, evolving from the pre-
malignant pancreatic intraepithelial neoplasia (PanIN) (33) to fully invasive cancer. 
The progression from minimally dysplastic epithelium (PanIN 1) and finally to 
invasive carcinoma is paralleled by the successive accumulation of mutations that 
include activation of the KRAS2 oncogene, inactivation of tumour suppressor gene 
CDKN2A and TP53 (34). Genetically engineered mouse models have demonstrated 
that targeted activation of KRAS2 with concomitant inactivation of Trp53 or CDKN2A 
results in development of PDAC (35) (36).  
Almost all patients with fully established PDAC carry one or more of the four 
common genetic alterations (37). Ninety per cent of tumours have activating point 
mutations in the KRAS2 oncogene. Transcription of the mutant KRAS gene 
produced an abnormal Ras protein that is “locked” in its activated form, resulting in 
aberrant activation of proliferative and surviving signalling pathways. Similarly, 95% 
of tumours have inactivation of the CDKN2A gene due to either loss of 
heterozygosity or point mutations, resulting in loss of the p16 protein (regulator of 
the G1-S transition of the cell cycle) and a corresponding increase in cell 
proliferation (16). TP53 is either mutated or there is loss of heterozygosity in 50 to 
75% of tumours, permitting cells to bypass DNA damage control checkpoints and 
apoptosis signals and contributing to genetic instability (38). DPC4 is lost in 
approximately 50% of cancers, resulting in aberrant signalling by the transforming 
growth factor β (TGF- β) cell-surface receptor (39). 
Recent work has demonstrated that PDAC contains an average of 63 
genetic mutations, the majority of which are point mutations (40). These alterations 
defined a core set of 12 cellular signalling pathways and processes that were each 
genetically altered in approximately 67 to 100% of tumours (41).  
1.2.1 Germline Genetic alterations found in PDAC 
A number of germline mutations have been associated with an increased 
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risk of pancreatic cancer; in the majority of families the genetic basis of familial 
occurrence is incompletely understood. History of BRAC1, BRAC2, familial 
adenomatous polyposis, Peutz-Jeghers syndrome and Lynch syndrome within 
families are also associated with higher prevalence of pancreatic cancer (42). 
Mutations in BRCA2 can be found in 6-12% of families with two or more cases of 
pancreatic cancer (42). Other inherited cancer syndromes are listed in Table 2. 
Table 2: Summary of germline mutations leading to familial pancreatic cancer (50) 
 
1.2.2 Precursor lesions and PanIN 
There are three types of precursor lesions in PDAC that follow a multistep 
progression from neoplasia showing mild dysplasia to invasive cancer. They are 
pancreatic intraepithelial neoplasia (PanIN); intraductal papillary mucinous 
neoplasm (IPMN); and mucinous cystic neoplasm (MCN). Some of these lesions 
may be detected on imaging, often incidentally and subsequently kept under 
observation or resected, to prevent development of invasive carcinoma. 
Gene with germline 
mutation 
Familial disorder Effect 
PRSS1 Recurrent acute 
pancreatitis (43) 
(autosomal dominant) 
Chronic pancreatitis and thus 
increased risk of PDAC (44) 
SPINK1 Hereditary pancreatitis 
(autosomal recessive)  
Chronic pancreatitis and thus 
increased risk of PDAC (45) 
CDKN2A FAMMM syndrome 
(autosomal dominant) 
20% increased risk of PDAC by age 
of 75 (46) 
STK11 Peutz-Jeghers 
(autosomal dominant) 
26% increased risk of PDAC (47) 
BRCA2 80% risk of breast cancer 3.5-fold increased risk of PDAC (48) 
APC Familial Adenomatous 
Polyposis 





3.7% risk of PDAC (49) 
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PanIN are microscopic proliferative epithelial lesions in the small calibre 
pancreatic ducts (51). The most common precursor lesion in pancreatic cancer, a 
four-tier classification system was established in 2001 (52). Histopathologically, the 
grading ranges from PanIN-1 to PanIN-3 with increasing dysplasia to invasive 
carcinoma (Figure 1.2). Telomere shortening (53) and mutations in KRAS, 
p16/CDKN2A, p53, SMAD4 and BRCA2 genes have all been identified in PanIN 
lesions (54). PanIN lesions are not radiologically detectable and early detection and 
prevention remains a theoretical possibility.  
Figure 1.2: PanIN progression demonstrating increasing genetic mutations with increasing 
dysplasia 
 
IPMNs are cystic lesions arising in the main duct or branch duct epithelium 
of the pancreas, characterised by papillary proliferation and mucin production. They 
are classified according to their malignant transformation from those with low-grade 
dysplasia to those with invasive carcinoma or according to their location (main duct; 
branch duct or mixed type with involvement of both main and branch ducts). IPMN 
lesions can be detected radiologically. Analysis of the cyst fluid via endoscopic 
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ultrasound to quantify amylase, Carcinoembryonic antigen (CEA) as well as 
cytology can differentiate between cystic lesions (55). 
MCNs are mucin-producing cystic lesions of the pancreas characterised by 
the presence of ovarian type stroma, usually solitary, incidental finding in younger 
female patients, located in the body or tail of the pancreas. Like IPMNs, MCN can 
be identified on cross-sectional imaging and with high CEA fluid levels and EUS 
aspirate. They are distinguished from IPMNs based on a lack of communication with 
the main pancreatic duct (56). 3.9-30% of MCNs will progress to invasive cancer, 
usually PDAC (57); thus surgical resection is recommended.  
 
1.3 Stroma of PDAC 
The formation of a dense stroma, termed a desmoplastic reaction is peculiar 
to PDAC (41) (58). Myofibroblasts (known to be derived from pancreatic stellate 
cells) play a critical role in the formation and turnover of the stroma. Alongside 
providing a mechanical barrier, the stroma also constitutes a dynamic barrier that is 
critically involved in the process of tumour formation as well as progression (59). 
Factors such as TGFβ1, platelet-derived growth factor (PDGF) and fibroblast 
growth factors can activate these cells to secrete collagen and other components of 
the extracellular matrix. Stellate cells regulate the reabsorption and turnover of the 
stroma via its production of matrix metalloproteinases (60) and are also implicated 
for the poor vascularity: a characteristic of PDAC (61). 
Stromal cells express multiple proteins such as cyclooxygenase-2, PDGF 
receptor, vascular endothelium growth factor, stromal cell-derived factor, 
chemokines, integrins, secreted protein, acidic, cysteine-rich (SPARC) and 
hedgehog pathway elements among others that have been associated with poor 
prognosis and resistance to treatment. 
Consequently, in experimental models, stromal disruption was studied by with 
Hedgehog inhibitor. This disrupted the stromal architecture, increasing tumour 
vascularity and facilitating efficient delivery of Gemcitabine. As a result, metastasis 
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decreased and the overall survival of mice treated with the combination of inhibitor 
and Gemcitabine was significantly increased compared to control (62), suggesting 
targeting the stromal component of PDAC may improve delivery and efficacy of 
chemotherapy. However, this approach failed in human clinical trials (63).  
Conversely, Ozdemir et al (64) used transgenic mice with deleted αSMA+ 
myofibroblasts in pancreatic cancer to investigate the potential role of tumours lacking 
stromal content and its potential effects on drug delivery. They identified mice that 
were depleted had diminished survival and did not respond to gemcitabine, 
underscoring the need for caution in targeting carcinoma-associated fibroblasts in 
PDAC. Rhim et al (65) also investigated the role of sonic hedgehog (66), a soluble 
ligand overexpressed by neoplastic cells in PDAC. It is established that Shh drives 
formation of desmoplastic stroma. Rhim investigated Shh deletion in mice and 
identified tumours with reduced stromal content were more aggressive and suggested 
stroma may, infact, act in restrain tumour growth. It is therefore proposed that 
homeostatic restoration of desmoplastic stroma rather than its ablation slows 














Table 3: Summary of cellular and non-cellular components of the desmoplastic reaction within 
the stromal component 
  
1.3.1 Pancreatic Stellate Cells 
Stellate cells have been found in a variety of organs, including the liver and 
intestine, but pancreatic stellate cells (PSCs) were first identified in 1998 by Apte 
(73) and Bachem (74). Since then, they have been shown to have a key role in 
maintaining tissue architecture through the regulation of ECM protein synthesis and 
degradation. 
In normal tissue, PSCs exist in a quiescent state, compromising 4-7% of pancreatic 
parenchyma, with an abundance of vitamin A droplets in their cytoplasm. In the 
normal pancreas, PSCs become activated in response to any form of insult, 
triggering fibrosis through various stromal interactions accommodating the wound 
healing process. On resolution, the PSCs return to their quiescent state until they 
are called upon in the damage limitation role (59). 




Most prominent role in 
desmoplastic reaction (59)  
Fibrous proteins Including collagen, elastin, 




Hypoxia, secondary to 
fibrosis and anti-angiogenic 
components, results in 
increased tumour growth 
and metastasis (69) 
Proteoglycans Hydrating and buffering in 





and T cells localise to 
stroma, secreting growth 
factors and cytokines with 
stimulate the desmoplastic 
reaction (71)  
 
Nerve cells Abundant nerve supply in 
the pancreas, making pain 
associated with disease a 
major challenge (72)  
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Table 4: Table summarising differing characteristics of activated and quiescent PaSC’s (75) 
 
Quiescent PSCs have a positive effect on epithelial integrity through integrin 
β1-dependent maintenance of the basement membrane, demonstrating a role in 
acinar functionality (76). An additional role in exocrine function has been 
demonstrated, whereby the gastrointestinal hormone cholecystokinin (CCK) induces 
acetylcholine secretion by PSCs, which in turn stimulates amylase secretion by 
acinar cells (77). Furthermore CCK has been shown to have direct activating effect 
on PSCs, and induces collagen synthesis (78). The exact source of activated PSCs 
(myofibroblasts phenotype) is still a matter of much debate; however a consensus 
exists that in the context of benign inflammation or malignancy, the surrounding 
cancer, immune or endothelial cells release various growth factors and 
inflammatory cytokines, that, in turn, activate PSCs through paracrine signaling 
networks (79).  
There are numerous potential pathways that exist to communicate between 
PSCs and cancer cells, emphasising the complex bi-directional relationship, which 
is not completely understood. An exciting prospect exists whereby if the PSCs can 
be targeted, one can exert an influential effect on the key and complex interplay 
between the cancer cells, ECM and tumour vasculature (80).    
 
Characterisation feature Activated PSC Quiescent PSC 
Appearance Star shaped Spindle shaped and smaller 
αSMA expression Positive (in >90%) Negative 
Desmin expression Positive in 20-40% Negative 
Vimentin expression Positive  Positive 
GFAP expression Positive Negative 
Adherence in tissue culture +++ + 
ECM protein secretion +++ + 
Receptor expression +++ + 
Density +++ + 
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1.4 Cancer-Stroma interactions 
Kadaba et al (70) investigated the role of desmoplastic stroma and the 
suggestion that dynamic stromal cell participation in cancer progression impacts on 
patient prognosis. By reconstructing tumour micro-environments in physio-mimetic 
organotypic cultures, the role of specific desmoplastic stromal cells, such as 
pancreatic stellate cells (PSC), in PDAC was studied. 
Progressive accumulation of desmoplastic stromal cells, believed to be 
triggered by cancer-induced activation of fibroblasts/ stellate cells to myofibroblasts 
has a pro-survival and pro-invasive effect on tumour cells, in addition to stiffening of 
the ECM gels.  
Laser-capture micro-dissection and gene-expression micro-array analysis as well as 
quantitative real-time RT-PCR validation in independent experiments (Figure 1.3), 
confirmed several of the most up-regulated and down-regulated genes across two 
PDAC cell lines (Capan1 and AsPC1) and clustered them into four groups affecting 
one or more key cellular functions. Polymeric Immunoglobulin Receptor (pIgR) was 
identified as a gene significantly upregulated in cancer cells upon exposure to PSCs. 
pIgR, involved in the transcytosis of molecules in epithelial cells, was hypothesised to 
provide the missing link between inflammation, EMT and metastasis (81). Kadaba et 
al noted pIgR expression was increasingly observed in cancer cells when PSCs were 
most predominant and was inversely correlated with E-cadherin expression, which 
was confirmed in human PDAC samples. I sought to take this work further by trying to 
understand the biological role for pIgR in pancreatic cancer and its potential 
prognostic impact, in a hypothesis driven manner. I would next introduce pIgR to the 
reader of this Thesis. 
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Figure 1.3: Gene expression changes as identified by gene-expression micro-array and verified 
by qRT-PCR. 
Kadaba et al (70)  identified pIgR as a gene involved in cellular functions such as cell signalling, 
inflammatory response, cell growth, death and movement. Figure produced from Kadaba et al (84). 
 
1.5 Role of pIgA/ pIgR 
Plasma cells are terminally differentiated B lymphocytes, play an integral 
role in the humoral immune response due to their ability to produce large volumes 
of antibodies which are antigen-specific. (82). Plasma IgA cell, are found throughout 
the lamina propria within organised mucosal-associated lymphoid tissues (83), 
underlying mucosal surfaces of the intestinal epithelium (84). 80% of the human 
body’s plasma cells are located in the gastrointestinal system, thus, emphasising 
their importance in gastro-intestinal immune barrier (85).  
Immunoglobulin A destined for the mucosal secretions is secretory IgA 
(SIgA) (86), which is produced by selective transport of polymeric IgA (pIgA) across 
epithelial cells lining mucosal surfaces (87). The transport of polymeric 
immunoglobulins (IgA, and to a lesser extent IgM) across mucosal epithelial cells is 
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mediated by virtue of its interaction with the polymeric immunoglobulin receptor 
(pIgR) (88), a trait only found in vertebrates (89).  
SIgA (90) contains dimer of IgA subunits with a  J-chain, covalently bound to 
a glycoprotein of about 80kDa (known as secretory component, which is 
synthesized by the epithelial cells lining mucous membranes and exocrine glands) 
(91). Further experimentation has identified the secretory component is a fragment 
of an integral membrane protein, called polymeric immunoglobulin receptor 
(pIgR)(88). Brandtzaeg and Prydz subsequently provided direct evidence for an 
integrated function of the J-chain and pIgR in the epithelial transport of 
immunoglobulins, by demonstrating that only polymeric IgA and IgM containing the 
J-chain (92) could bind to the surface of human intestinal epithelial cells expressing 
pIgR (91). Although IgA and IgM can be transported by pIgR at similar rates, the 
larger size of IgM restricts its diffusion to the receptor through the extracellular 
matrix and basement membrane, so the smaller polymeric IgA molecule is 
transferred more efficiently (93). 
pIgR is synthesized as an integral membrane protein in the rough 
endoplasmic reticulum and then travels to the Golgi apparatus. In the last station of 
the Golgi, known as the trans-Golgi network (TGN), pIgR is sorted into vesicles that 
deliver it to the basolateral surface of the epithelial cells (91), where pIgR can bind 
to pIgA (produced by plasma cells, most commonly found in the lamina propria 
underlying the epithelium (94)) (Figure 1.6). With or without bound pIgA, pIgR is 
endocytosed and delivered to basolateral early endosomes (BEEs) (95). The 
receptor and ligand then move through a common endosomal compartment (CE) 
and are sorted into apical recycling endosomes (AREs) for delivery to the apical 
membrane. At this point, the extracellular portion of the pIgR, comprising five Ig-like 
domains, is proteolytically cleaved, losing its C-terminal domain to form the 
secretory component (SC). This secretory component is then covalently linked to 
the (IgA)2-J-chain complex by a disulphide bond, thereby protecting the SIgA from 
denaturation and proteolysis in external fluids (96). The carbohydrate residues on 
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SC help to anchor SIgA to the mucous lining of the epithelium, thereby ensuring 
effective immune protection (97). By attaching to the dimeric backbone of the 
secretory IgA, the SC-SIgA complex molecule confers resistance to digestion by 
trypsin and pepsin (98). 
At this surface, cleavage of the extracellular ligand-binding portion of pIgR 
results in release of secretory component in free form or as part of the SIgA 
complex. A fraction of the pIgR at the apical surface may be re-internalised into the 
apical early endosomes (AEEs) and then delivered back to the apical surface 
through ARE. Mice with two disrupted alleles at the pIgR locus have markedly 
reduced IgA in external secretions (99), accompanied by elevated serum IgA, 
demonstrating pIgR is necessary for transcytosis of pIgA across epithelial in vivo 
(100). 
1.5.1 The pIgR gene 
The human pIgR gene, encoded by a single copy gene (101), is localised in 
the q31-q41 region of chromosome 1(102). Containing 11 exons, the gene spans 
18kb (102). Situated between exon 1 and 2, the first intron is the longest (Figure 
1.4). The initiation codon and the leader peptide are encoded by exon 2. Analysis 
has identified single-nucleotide polymorphisms in the human pIgR gene, some of 
which have been associated with increased risk of IgA nephropathy and 
nasopharyngeal cancer (103).    
 
1.5.2 Structure of pIgR 
The pIgR protein consists of three major functional regions: an extracellular 
ligand-binding region, a short hydrophobic membrane spanning domain and a 
relatively long cytoplasmic tail (Figure 1.5). The extracellular ligand-binding portion 
is comprised of five domains with homology to immunoglobulin variable domains, 
which is loosely connected by a structured linker peptide, sometimes called domain 
6, to the transmembrane domain. The cytoplasmic tail of pIgR contains elements 
that interact with intracellular signalling proteins to regulate cellular trafficking. 
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Within the five extracellular Ig-like domains, the Cys residues that form 
disulphide bonds stabilise the characteristic “immunoglobulin fold” which are 
invariant across species. Interspecies homology is greatest in domain 1, especially 
within segments that have been shown to be critical for binding of IgA and IgM. 
Domains 2 and 3 of pIgR are encoded by a single large exon in pIgR from 
mammalian species, which is sometimes spliced out in rabbit mRNA (104), but is 
invariably included in pIgR transcripts from other mammalian species. 
The sixth extracellular domain of pIgR has a more random structure than the 
five immunoglobulin homology domain and is poorly conserved across species. 
Proteolytic cleavage of pIgR within this domain leads to the release of secretory 
component from the apical surface of epithelial cells, either free or bound to SIgA or 
SIgM. Given the random structure and poor conservation of domain 6, it is likely that 
multiple proteases can cleave pIgR to secretory component. 
Membrane-bound pIgR and soluble secretory component have been shown 
to interact with a variety of physiological and pathophysiological ligands, through 
both peptide and carbohydrate-based motifs. The association of pIgR with 
polymeric IgA and IgM involves multiple structural elements that participate in both 
non-covalent and covalent bonds. Biochemical and mutagenesis studies have 
demonstrated that any domain of pIgR is both necessary and sufficient for binding 
of polymeric IgA and IgM (87).  
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The binding studies with isolated domain 1 suggest that structural 
determinants within this domain contribute to the specificity of pIgR for native pIgA, 
but the precise topology of the pIgR-pIgA interface and the role of the J-chain 
remain a mystery. The two N-glycan chains linked to domain 1 of pIgR do not 
appear to contribute to the interaction of pIgR with pIgA (105). 
  
Figure 1.4: pIgR structure.  
The pIgR is a transmembrane protein, which contains an extracellular ligand binding comprising five 
domains with homology to immunoglobulin variable regions and a long cytoplasmic tail. The tail also 
contains signals for intracellular sorting and endocytosis. The immunoglobulins 1, 4 and 5 (yellow) 
contain signals for non-covalent and disulphide bonding to polymeric IgA. The immunoglobulins 2 and 3 
(blue) are less important, and are even absent in rabbit pIgR. During transcytosis, a disulphide bridge is 
formed between domain 5 of pIgR and the Fcα region of dimeric IgA. A peptide of unknown structure 
links domain 5 to the membrane-spanning region and contains sites for proteolytic cleavage of pIgR to 
secretory component (SC) (106). Seven N-glycan residues on domains 1, 2, 4 and 5 contribute to innate 
immune function of SC and may facilitate transcytosis of pIgR. The cytoplasmic domain or tail or pIgR 
contains highly conserved signals for intracellular sorting, endocytosis and transcytosis (107). Figure 
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1.5.3 Regulation of pIgR expression 
pIgR expression is restricted to mucosal and glandular epithelial cells. Since 
pIgR makes only one trip across these cells before being cleaved and released at 
the apical surface and because of the 1:1 stoichiometry between secretory 
component and dimeric IgA in SIgA, one molecule of pIgR must be produced for 
every molecule of dimeric IgA that is transported across an epithelial cell. Thus, 
upregulation of pIgR expression would increase the capacity for epithelial 
transcytosis of IgA. Regulation of pIgR expression involves complex interactions 
among host-, microbial- and environmental-derived factors, involving transcriptional 
and post-transcriptional mechanisms (94). A variety of cytokines, hormonal and 
microbial influences have been investigated, and a summary is provided in Figure 
1.5. 
 
Figure 1.5: Molecular regulation of pIgR expression.  
pIgR expression can be up- or down-regulated. Pro-inflammatory cytokines, interferon-γ (INF-γ), tumour 
necrosis factor (TNF) and interleukin-1 (IL-1) play a role in upregulation of pIgR expression (109). The 
roles of Toll-like receptors (TLR) and Lymphotoxin beta receptor (LBTR) are incompletely understood. 
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Adapted from (110). Figure adapted from information in Haelens et al  
1.5.4 Transcytosis of pIgR 
Although epithelia act as a physical barrier, they possess the ability to 
transport specific molecules via several routes (111). As polarised cells, they have 
distinct plasma membrane domains, which are the result of polarised trafficking of 
proteins and lipids. Thus epithelial plasma membranes are divided into two 
components, an apical surface facing the lumen and a basolateral surface 
contacting adjacent cells and underlying connective tissue, with distinct protein and 
lipid composition. Apical and basolateral surfaces are separated by cellular 
junctions, thereby preventing mixing of proteins and outer-leaflet lipids between two 
surfaces (95).  
The polarised distribution of apical and basolateral components is the result 
of three processes. Newly synthesised proteins of the plasma are synthesised in the 
rough endoplasmic reticulum and transported through the Golgi to the trans-Golgi 
network (TGN), where they are sorted into vesicles that deliver them to apical or 
basolateral surfaces (112, 113). Some proteins are transported from the TGN to 
endosomes, and only then to the cell surface (114). Secondly, some proteins are 
selectively retained at the cell surface, often through an interaction of their carboxyl 
termini with PDZ-domain-containing proteins (115). The third step is that 
components not retained at the surface are rapidly endocytosed and delivered to 
early endosomes, from where they can be recycled back to the cell surface, 
transferred to late endosomes or transported across the cell and delivered to the 
opposite surface, in a process known as transcytosis (116). This provides the body 
a method of selectively uptaking and secreting molecules (95). All epithelial cells 
use biosynthetic sorting from the TGN and selective recycling or transcytosis to 





Although IgA is being discussed primarily, it is important to note that IgM can 
also bind to pIgR. Both IgA and IgM have the ability to form polymeric structures, 
thus are the only two immunoglobulins that can bind to pIgR. Their ability to bind 
with pIgR allows them to pass through the epithelial layer and subsequent reach the 
external secretions (117). Under normal conditions in vertebrates, IgA, IgM and IgA 
immune complexes have been shown to bind to pIgR (118).  
The process of pIgR mediated transport of pIgA begins in the rough 
endoplasmic reticulum of intestinal epithelial cells, where pIgR is synthesised as an 
integral membrane protein, and subsequently travels to the Golgi apparatus, which 
processes proteins produced by the endoplasmic reticulum. The Golgi apparatus, a 
wafer shaped stack in appearance, has two sides, one side facing the endoplasmic 
reticulum, cis, and the other facing the plasma membrane of the cell, trans (119). 
Proteins enter the cis side, and progress through a series of cisternae, which vary in 
number, shape and organisation in different cells types. Historically, the cisternae 
have been classified as three major groups, cis, medial and trans cisternae, but 
there are also two further groups called the cis and trans Golgi Networks, that have 
more variable structures. Having entered at the cis side and travelled one of the 
Golgi cisternae networks, the proteins gradually become modified and packaged. 
The final, packaged proteins exit at the trans side, ready for transport to various 
destinations by placement into one of three vesicles, dependent upon the molecular 
marker they carry (120).  
These vesicles are exocytic, secretory or lysosomal, and will deliver pIgR to 
the basolateral surface of the epithelial cell (121). Exocytic and secretory vesicles 
contain proteins destined for extracellular release, while lysosomal vesicles deliver 
digestive proteases destined for the lysosome.   
It was originally assumed that sorting of transmembrane proteins to the 
basolateral surface was the default pathway, and did not require a specific sorting 
signal. Further work has demonstrated that basolateral sorting requires a specific 
signal in the cytoplasmic domain, these being the 17 amino acids that lie closest to 
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the membrane (122). The 17 amino acid chain identified by Casanova et al was 
deemed necessary and sufficient for targeting of pIgR from the TGN to the 
basolateral surface, and is conserved across species. 
It is also now apparent that there are multiple biosynthetic pathways for 
trafficking and recycling in polarised epithelial cells. There are two basic routes by 
which proteins and lipids reach their correct destination surface, they being either a 
direct or indirect route. In the direct route, proteins are sorted in the trans-Golgi 
network (TGN) into carriers that take them directly to the apical or basolateral 
surface (114). In the indirect route, proteins are sent first to one surface, usually 
basolateral. From there, the proteins are endocytosed and delivered to early 
endosomes. Endocytosed proteins can either recycle to the surface of origin, be 
degraded in late endosomes and lysosomes or be transcytosed to the opposite 
surface (116). 
It is now agreed that material endocytosed from the basolateral surface 
enters basolateral early endosomes (BEE). These are largely vesicular structures 
that contain both membrane and fluid-phase markers fluorescein isothiocyanate 
(FITC) and horseradish peroxidase (HRP) (123), whilst also including material 







































Figure 1.6: pIgR through an epithelial cell.  
In the simplified epithelial cell illustrated, the apical surface is at the top and the basolateral surface at 
the bottom. Ligand binding occurs on newly synthesised pIgR that is targeted to the basolateral surface. 
Following receptor-mediated endocytosis, ligand-bound or unoccupied pIgR is transported through a 
series of intracellular vesicles, where neutralisation of pathogens and antigens can take place. At the 
apical surface, pIgR is proteolytically cleaved to secretory component (SC). At the mucosal surface and 
in external secretions, free SC and secretory IgA (SIgA) contribute to innate and adaptive immune 
defence. pIgA, polymeric IgA; BEE, basolateral early endosome; CE, common endosome; ARE, apical 
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The next compartment in this intra-cellular transportation pathway is the 
common endosome (CE), identified by Rab10 (124), consists of tubules orientated 
along the apical-basolateral axis. These contain both transcytosing proteins (e.g. 
pIgR) as well as recycling proteins, in concentrations that are equivalent to the BEE, 
thus suggesting that sorting of recycling and transcytosing molecules has not 
occurred in either of the BEE or CE. IgA and pIgR moves from the CE to the apical 
recycling endosome (ARE), identified by Rab11 marker (125), next, which contains 
tubulovesicular and C-shaped elements that are largely clustered around the 
centriole, located beneath the center of the apical surface. This is the last known 
stage in the transcytotic pathway. For molecules endocytosed from the apical 
surface, it is likely that they first enter an apical early endosome (126, 127) (Figure 
1.6).    
Transcytosis of pIgR is regulated at multiple levels (121). Song et al 
demonstrated binding of pIgA can augment the rate of transcytosis in rabbit pIgR 
(128), whilst Singer et al indirectly demonstrated binding of Polymeric IgA (pIgA) to 
pIgR causes dimerisation of pIgR (129). 
Within ten seconds of pIgA binding, several cytoplasmic proteins become 
tyrosine phosphorylated (130). Although the pIgR isn’t itself a tyrosine kinase or 
phosphorylated on tyrosine, but it acts to recruit p62yes, a non-receptor tyrosine 
kinase, to the plasma membrane. The exact role of p62yes remains inconclusively 
proven, but mice with deletions in both alleles for p62yes exhibit minor defects in 
basal transport of pIgA from blood to bile, and exhibit a marked defect when 
challenged with a large bolus of intravenous pIgA (131). 
Rab proteins are small GTPases that have been shown to regulate the 
formation of vesicles at the plasma membrane and the delivery of  endocytosed 
proteins to multiple cellular locations (132). It also transpired that bound Rab3b 
(Rab in its GTP-bound state) appeared to block the transcytosis of pIgR, which then 
recycles to the basolateral surface. 
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Subsequent to cleavage, the pIgA-pIgR complex releases SIgA into the 
lumen (133, 134). SIgA, the secretory form, binds to antigens within the lumen, thus 
protecting intestinal mucosal surfaces against colonisation and invasion by 
pathogens (135). 
The process of transcytosis of pIgA by pIgR promotes intracellular 
neutralisation and transcellular excretion of antigens and pathogens and ensures 
continuous delivery of SIgA to the epithelial surface and external secretions. 
Epithelial cells effectively sacrifice the extracellular domain of pIgR as cleaved SC, 
during each round of pIgA transport, as either free or complexed to pIgA. Although 
there is effective wastage and a metabolic cost of producing a new molecule of 
pIgR for each round of pIgA transport, this is effectively compensated for by the 
immune functions contributed by SC. 
The role of pIgR in transportation of complexes of pIgA and protein antigens 
from lamina propria to luminal surface of mucosal epithelial cells was originally 
identified by Mazanec et al (118). Locally produced pIgA antibodies within the 
mucosa might serve to trap antigens derived from the environment, diet or luminal 
microbiota in the mucosal tissue during infections and to target these antigens for 
excretion. Antigens remain bound to the pIgA antibody throughout transcytosis, 
escaping lysosomal delivery and degradation and are released along with SIgA at 
the apical surface (136). 
Despite considerable investigation and speculation during the past three 
decades, the exact mechanism by which pIgR is cleaved to SC remains a mystery. 
The previously described domain 6, that links the immunoglobulin-like domain 5 to 
the transmembrane region of pIgR, has demonstrated cleavage. Further 
investigation by purifying SC from human colostrum pooled from multiple women 
demonstrated a ragged C-terminus, with Ser552 as the dominant C-terminal residue 
(137). The main issue remains the length of the linker peptide is poorly conserved 
across species, and that the C-terminal protein sequence is only a trait found in 
humans.  
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Further difficulties remain with identification of the proteases that cleaves 
pIgR to SC. Ogura show that cleavage of pIgR was inhibited by leupeptin, but 
enhanced by PMA stimulation (138). Leupeptin has also been identified as an 
inhibitor of cleavage of pIgR to SC in rat liver and MDCK cells, thereby suggesting a 
requirement for a cysteine protease (139), but a SC protease remains elusive. This 
suggests that the protease (or indeed proteases) are not cell-specific and possibly 
that multiple proteases might participate in SC cleavage.  
 
1.51.6 Immunoglobulins 
Immunoglobulins are produced by plasma cells and belong to the 
immunoglobulin superfamily. Their structure is two large heavy chains and two small 
light chains (140), with various combinations of chains producing different types of 
immunoglobulin. IgA, which exists as two types, is predominately found in mucosal 
areas, such as the gut, respiratory tract and urogenital tract, and prevents 
colonisation by pathogens. To a lesser extent, it is also found in saliva, tears and 
breast milk (141). IgM is expressed on the surface of B cells, as a monomer, but is 
secreted in a pentameric form with very high avidity. It eliminated pathogens in the 








Figure 1.7: Immunoglobulins 
Formed from two heavy chains (blue) and two light chains (orange), whilst the black lines are O-linked 
sugars. The IgG, D and E all have similar configurations, only slightly different bonds between the chains. 
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Immunoglobulin A (IgA), an antibody that plays a crucial role in mucosal 
adaptive immunity (141) (142), has two isotypic forms (IgA1 and IgA2) (143). Unlike 
other immunoglobulins, it can exist in a variety of molecular forms, each with a 
characteristic distribution in various body fluids (144), the predominant form being 
the dimeric version. 
 
IgA1 predominates in serum (~80%), and most lymphoid tissues have a 
predominance of IgA-producing cells. IgA2 have their heavy and light chains linked 
with non-covalent bonds instead of disulphide bonds, and percentages are higher in 
secretions in serum (~35%) (145). In secretory lymphoid tissues, e.g. gut-
associated lymphoid tissue, the share of IgA2 production is larger than in non-
secretory lymphoid organs, e.g. spleen and peripheral lymph nodes (146).  
The first line of specific defence against environmental antigens is secretory 
immunoglobulin A (sIgA) (86), and is the main immunoglobulin found in mucous 
secretions. sIgA is transported in massive quantities, up to three grams per day in 
the average adult (147), and equates to 75% of the total immunoglobulin produced 
in the body (148).   
It is also possible to distinguish the forms of IgA based on their location, thus 
serum IgA or secretory IgA. Serum IgA, which is synthesised mainly in the bone 
marrow, is predominantly a monomer of IgA1. This IgA is composed of two α1 
chains, each of 60kDa and containing one variable domain, a hinge region, and 
three constant domains (CH1, CH2 and CH3). The α1 chains are linked by 
disulphide bonds to each other and the two light chains (λ or κ chains) that are 
identical to those found in other immunoglobulins (149). Approximately 10% of the 
IgA compromises dimeric and higher polymeric forms, and the proportion of these 
forms increases in a number of disease states (150).  
Secretory IgA (SIgA) is the form of IgA synthesised at mucosal surfaces and 
found in secretions, e.g. within the gut and respiratory tract, and is found as a 
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polymer of two to four IgA monomers. Dimeric and polymeric forms of IgA contain 
an additional protein known as the J-chain (91), which links the IgA monomers via 
the tailpiece (an 18 amino-acid extension of the α chain). In addition to the J-chain, 
dimeric and polymeric forms of IgA are complexed with a heavily glycosylated 
protein called the secretory component (SC). The secretory component is part of 
the cell surface receptor that mediates the transport of polymeric IgA across the 
epithelial barrier, and is thought to provide stability to the structure of SIgA to 
increase its resistance to proteolytic degradation (92). Secretory immunoglobulin A 
(SIgA), consisting of ten protein chains linked by disulphide bonds, forming the IgA-
J-IgA-SC complex. 
SIgA differs from IgG in two ways: it is polymeric in nature and it contains 
covalently bound secretory component, the cleaved extracellular portion of 
transmembrane secretory component which constitutes polymeric immunoglobulin 
receptor (151). SIgA is generated via the active transport of pIgA to the intestinal 
lumen by SC/ pIgR-expressing epithelial cells (152). 
 
1.5.7 J-Chain 
The J-chain, rich in acidic amino acids, comprises a single polypeptide chain 
containing eight Cys residues, six of which form intra-chain disulphide bridges 
(153). Its presence has been demonstrated in a wide range of vertebrate species, 
from mammals to fish and amphibians (154) and it is a highly conserved structure 
across different species.  
The J-chain is expressed by antibody-producing cells and is incorporated 
into polymeric IgA or IgM shortly before or at the time of secretion (155), and its 
presence promotes formation of pIgA and pentameric IgM (156). The J-chain is the 
key protein in the generation of SIgA because it promotes polymerisation of IgA and 
because its presence in these polymers is believed to be required for their binding 
to SC/pIgR (157, 158). 
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Since the immune system has a large role in elimination of pre-cancerous 
lesions and cancer mitigates the risk by escaping immune-surveillance, immune-
oncology is a burgeoning field of investigation (159-161). Currently, adaptive 
immunity is being studied with great zeal, with significant therapeutic benefit for 
patients with melanoma, and haematological malignancies (162, 163). 
 For epithelial tumours, study of innate immunity the first line of defence 
seems to be the most logical addition (164). In this context, studying 
immunoglobulins and its cognate receptor seems to be a valid avenue of 
investigation (165). 
 
1.6 The role of pIgR in cancer 
Initial work regarding the role of pIgR focused around Streptococcal 
pneumonia, which traverses the respiratory epithelial barrier to invade, allowing it to 
cause disease locally or disseminate via blood circulation throughout the body. S. 
pneumoniae choline-binding protein A, a pneumococcal surface protein, interacts 
specifically with the human polymeric immunoglobulin receptor, which is expressed 
by cells in the respiratory epithelium. Choline-binding protein A is required for 
efficient colonization of the nasopharynx in vivo. Additionally, a strain of S. 
pneumoniae invades a human pharyngeal cell line in a human polymeric 
immunoglobulin receptor-dependent manner. These findings raised the possibility 
that the interaction between choline-binding protein A and human polymeric 
immunoglobulin receptor may be a key determinant of S. pneumoniae pathogenesis 
(166).  
 This triggered an interest in nasopharyngeal cancers (167). More recently, 
the role of pIgR has gained more importance in its role in gastrointestinal cancers 
(Table 5). 
Agesen et al (168) investigated Affymetrix gene expression in 315 patients 
with colorectal cancer, stratifying patients based on stage of disease. They identified 
pIgR to be one of 13 genes for prognosis prediction specific to patients with stage II 
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colorectal cancer. Of the 13 genes, 5 demonstrated low expression, whilst 8 had 
high expression in stage II colorectal cancer disease. Poor prognosis and higher 
relapse rates were noted with low pIgR expression.  
Traicoff et al (169) investigated in vitro models of colon adenoma to 
carcinoma progression, alongside differential display RT-PCR. They identified pIgR 
was highly expressed in normal colon epithelium, but was decreased in 6 of 8 colon 
tumours, and negligible in 8 of 10 colon cell lines. Thus hypothesising low pIgR 
expression to correlate with progression from colon adenoma to carcinoma. 
Gologan et al (170) investigated pIgR expression in the upper 
gastrointestinal tract, investigating pIgR expression in 42 cases of adenocarcinoma 
of the distal oesophagus and gastro-oesophageal junction. They noted pIgR 
negative adenocarcinomas to be associated with lymph node metastasis and a 
trend towards reduced survival.  
Fristedt et al (171) further explored pIgR expression in adenocarcinoma of 
the upper gastrointestinal tract, investigating 173 patient samples, and separating 
them according to intestinal metaplasia and adenocarcinoma. pIgR expression was 
significantly higher in intestinal metaplasia compared to normal tissues, whilst 
reduced pIgR expression in primary tumours was significantly associated with more 
advanced tumour stage.   
 
Furthermore, loss of PIGR expression has been linked to tumour progression 
in non-small cell lung cancer (172), while overexpression of PIGR has been 
associated with the less aggressive type 1 endometrial cancer (173) as well as 
correlating with a better prognosis in bladder cancer (174) and epithelial ovarian 
cancer (175). 
PIGR has been described as a putative cancer biomarker in a few studies on 
different cancer forms, the majority of which indicate an association between low 
PIGR expression and more aggressive disease (Table 5). 
Table 5: Table summarising role of pIgR in other cancers 
 Year Organ Findings 
GASTROINTESTNAL CANCERS 
Fristedt et al (176) 2014 Pancreatic and 
periampullary 
High pIgR expression signifies more favourable tumour phenotype and low expression independently 
predicts a shorter survival in patients with pancreatic and peri-ampullary cancer.  
Liu et al (177) 2014 Hepatic colorectal 
metastasis 
Positive pIgR expression associated with poor prognosis of patients with colon carcinoma hepatic 
metastasis. There is scope for pIgR to be a predictor for poor prognosis of patients after resection 
Fristedt et al(171) 2014 Oesophageal and gastric High pIgR expression predicts a decreased risk of recurrence and improved survival in patients with 
adenocarcinoma of the upper GI tract. 
Kadaba et al (70) 2013 Pancreatic Stroma Reciprocal relationship of E-cadherin and pIgR in cancer cells. Demonstrate context-specific cancer-
stroma crosstalk required to be precisely defined for effective therapeutic targeting. 
Alvi et al (178) 2013 Barrett’s Oesophagus One of four genes noted to be used to distinguish between Barrett’s and dysplasia/ Oesophageal 
adenocarcinoma 
Agesen et al (168) 2012 Colorectal Cancer One of 13 genes noted to be present in patients with stage II colorectal Ca and the probability of relapse 
Ai et al (179) 2011 Hepatocellular Cancer pIgR plays a role in the induction of EMT. pIgR as a potential link between hepatitis B virus-derived 
hepatitis and HCC metastasis and provide evidence in support of pIgR as a prognostic biomarker for 
HCC and a potential therapeutic target. 
RESPIRATORY CANCER  
Su et al (180) 2011 Nasopharyngeal Cancer Missense mutation in human pIgR, A580V, is associated with IgA nephropathy and nasopharyngeal 
carcinoma 
Ocak et al (181)  2012 Lung tumourgenesis pIgR expression lost in pre-invasive and invasive respiratory lesions 
Chang et al (182) 2005 Nasopharyngeal Cancer Nasopharyngeal cancers show significant downregulation of pIgR 
Fan et al (167) 2005 Nasopharyngeal Cancer pIgR gene may be associated to risk of Nasopharyngeal cancer development 




1.7 The role of pIgR in Hepatocellular Carcinoma 
I have focused on hepatocellular carcinoma (HCC) because of its relevance 
to pancreatic diseases as well as the most detailed study published on pIgR thus 
far. HCC is the fifth most common cancer worldwide and the third leading cause of 
cancer related death worldwide (183). HCC has been associated with chronic 
hepatitis (184), secondary to inflammation due to hepatitis B virus (HBV) or hepatitis 
C virus (HCV) and alcohol consumption (185). Indeed, over half the cases of HCC 
worldwide have been attributed to chronic hepatitis B (186).  
Despite the strong association between chronic hepatitis and HCC being 
known for decades, the molecular mechanisms to the progression remain unclear. 
HCC progression develops against a backdrop of persistent inflammation, extensive 
tissue remodelling and excessive deposition of extracellular matrix components 
(187). Increasingly, links between inflammation and HCC tumourgenesis have 
begun to explain the development of metastasis. The epithelial-mesenchymal 
transition (EMT), in which epithelial cancer cells lose their apico-basal polarity and 
become motile mesenchymal cells (188), effectively endowing tumour cells with 
metastatic competence (189), has been implicated in cancer invasion and 
metastasis (190) and also resistance to therapy (191).  
Ai et al (81) identified pIgR as a possible inflammatory stimulus marker even 
though pIgR aberrant expression has previously been associated with HCC (192). 
Ai et al demonstrated pIgR over-expression is implicated in EMT initiated cross-talk 
mediated by transforming growth factor beta (TGF-ß) and TNF-α, interferon-δ and 
interleukin-4. TGF-ß is critical in promoting immune evasion and angiogenesis 
(193). Ai et al also noted, in vivo pIgR-overexpressing cells yielded higher extent of 
lung metastases compared with control counterparts in murine experiments 
associated with  decreased levels of epithelial markers (E-Cadherin, cytokeratins) 
and enhanced levels of mesenchymal markers, Vimentin and phospho-Smad2/3 in 
pIgR-over-expressing HCC human specimens (194), thus postulating a linkage 
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between pIgR over-expression and EMT and inflammation.  
.  
1.8 The role of pIgR in pancreatic adenocarcinoma 
Peri-ampullary cancers include those of pancreas (PDAC), extrahepatic bile 
duct, ampullary and small intestinal (including duodenal) adenocarcinoma (195). 
Survival after resection of adenocarcinoma of peri-ampullary location (pancreatic 
head, distal bile duct, ampulla, duodenum) differs greatly, with duodenal and 
ampullary displaying a much better survival than pancreatic head PDAC or distal bile 
duct cholangiocarcinoma (196).  
.  
Furthermore, there is differences in survival for ampullary cancers: intestinal 
versus pancreatobiliary (PB) histopathologic phenotypes demonstrates the 
importance of sub-types of cancers(197). The intestinal type proved to be associated 
with considerably better prognosis than the PB subtype, which has been confirmed by 
several recent series (196, 198, 199).  
To enhance this further, additional molecular-based biomarkers are needed, to 
better define clinically relevant sub-groups of these tumours, and, thus, pave the way 
for novel treatment strategies (176). One such example could be pIgR. 
Comparatively few studies have investigated the expression and prognostic 
significance of pIgR in human cancer, but the majority indicate associations of a high 
pIgR expression with a more favourable phenotype and an improved survival (168, 
170, 171, 175, 200). However, adverse prognostic implications of pIgR expression in 
human cancer have been observed in hepatitis B-derived hepatocellular carcinoma, 
where high pIgR expression was found to be associated with a greater metastatic 
potential and poor prognosis (179). One could speculate that if pIgR is naturally 
expressed in the particular tissue (epithelium), such as the gut or respiratory tract, 
then in the context of cancer, low expression confers poor prognosis. Should pIgR not 
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play a natural role in a particular tissue such as liver (or pancreas), then its 
expression in cancer may be associated with a poor prognosis (179). 
Kadaba et al demonstrated pIgR to be unregulated in pancreatic cancer cells 
upon exposure to stromal cells in vitro in 3D organotypic models (70). Using 
quantitative real-time RT-PCR, they investigated several of the most up-regulated and 
down-regulated genes across two pancreatic cancer cell lines (Capan1 and AsPC1). 
Kadaba et al then clustered them into four groups affecting one or more key cellular 
functions and identified pIgR as being significantly up-regulated in cancer cells upon 
exposure to stellate cells.  
Kadaba et al found that PIGR expression was predominantly observed in 
cancer cells when stellate cells were most predominant (stellate proportion of 0.66–
0.83) and was inversely correlated with E-cadherin expression. Thus, they confirmed 
the reciprocal changes in E-cadherin and PIGR changes in human PDAC samples. 
This reciprocal relation of E-cadherin and PIGR expression correlated with the 
stromal predominance in human samples (70). 
 
Fristedt et al (176) investigated pIgR expression in human pancreatic and peri-
ampullary adenocarcinomas. They sampled 175 patients who underwent 
pancreatoduodenectomy resection and separated patients according to intestinal and 
pancreato-biliary type, based on morphological origin of tumour. They also 
investigated and sampled lymph node metastasis and correlated with clinic-
pathological parameters. 
The study is large and all the patients have, surprisingly, distant metastasis-
free survival. Initial data in the manuscript focuses on pIgR expression in non-
malignant, benign pancreas and lymph node metastases. This is irrelevant of 
histological tumour type and 98% of all primary tumours expressed pIgR of some 
intensity. 89.5% of lymph node metastases also expressed pIgR. There is extensive 
variability in the pattern of pIgR staining, and although it is noted, no explanation is 
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given as to why the variability exists.   
The results and conclusion state that patients with low pIgR expression have 
adverse clinico-pathological characteristics, and a significantly shorter RFS and OS. 
pIgR expression was not predictive of response to any type of adjuvant 
chemotherapy, but the prognostic value of pIgR remained significant after adjustment 
for established clinico-pathological characteristics, including morphology, i.e. 
pancreato-biliary and intestinal type, and adjuvant treatment. Survival analyses, 
stratified by morphological type, demonstrated that the prognostic value of pIgR was 
significant in intestinal type tumours but not in pancreato-biliary type tumours.  
However, a significant down-regulation of pIgR in lymph node metastases 
compared to primary tumours in the entire cohort, was more evident in pancreato-
biliary type tumours than in intestinal type tumours, which supports a tumour 
suppressive role for pIgR in this type of tumours as well. The lowest expression of 
pIgR was seen in tumours of pancreatic origin, i.e. pancreato-biliary type and the 
highest in primary tumours of duodenal origin, i.e. intestinal type. 
The results and their discussion suggest pIgR appears to be strongly 
expressed in normal mucosa of the gastrointestinal tract, including the duodenum, but 
also in normal pancreatic ductal but not acinar cells. There is no quantifiable 
statement regarding the intensity of staining in normal and pancreatic 
adenocarcinoma.  
The finding that a high pIgR expression is associated with more favourable 
clinico-pathological characteristics and loss thereof with an adverse clinical outcome 
is in line with the vast majority of hitherto published studies in other cancer forms. 
However, the mechanistic basis underlying the potential tumour-suppressing role for 
pIgR in pancreatic and peri-ampullary adenocarcinoma, as well as in several other 
cancer forms, remains to be elucidated.  
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A theory remains that given the fact that an extensive desmoplastic stromal 
reaction is one of the hallmarks of pancreatic cancer (201), it may be hypothesized 
that elevated pIgR expression exerts tumour-promoting effects also in pancreatic and 
peri-ampullary adenocarcinoma. However, Kadaba et al (70) demonstrated a 
reciprocal relationship between expression of E-cadherin and pIgR in pancreatic 
cancer cells, and that this relationship, in turn, is dependent on the stromal content, in 
particular the proportion of activated stellate cells. The reciprocal relationship 
between pIgR and E-cadherin was also confirmed in an analysis of 51 human ductal 
pancreatic cancer samples (TMA), further indicating a link between pIgR and EMT 
also in pancreatic cancer.  
Alongside, the work from Ai et al (179) which supports a tumour-promoting 
role for pIgR, where high pIgR expression was found to be associated with early 
recurrence and chronic hepatitis B-virus (HBV)-infection. Moreover, pIgR was found 
to induce epithelial-mesenchymal transition (EMT) in vitro and in vivo through 
activation of Smad signalling, suggesting a role for pIgR as a mediator of 
inflammation-induced EMT.  
Thus, the work from Fristedt is contradicting to other stated work. However, 
their data remains the largest cohort of patients and further highlights the complexity 
and heterogeneous nature of tumours arising in the pancreas and peri-ampullary 
region. The raw data relating to individual histological diagnoses, especially primary 
pancreatic adenocarcinoma is not significant. Theoretically, the role of pIgR in 
carcinogenesis and tumour progression appears to differ by histological type and 
tumour origin. 
 
With a strong association with inflammation and pancreatic cancer, the 
investigation that we aim to answer is the role of pIgR in pancreatic cancer and its 
expression with metastases. The aim of this study was therefore to examine the role 




To investigate the role of pIgR in pancreatic ductal adenocarcinoma. 
 
1.10 Objectives 
1. Investigate expression of pIgR in human peri-ampullary cancers including 
pancreatic cancer (PDAC) and its correlation with systemic and tissue 
factors (CHAPTER III). 
2. Screen pancreatic cancer cells for pIgR expression and secretion 
(CHAPTER IV). 
3. Investigate expression of pIgR in 3D model of pancreatic ductal 
adenocarcinoma and its correlation with EMT (CHAPTER IV). 
























2.1 Tissue microarray  
Tissue Microarrays contain numerous cores from various patients and allows 
rapid analysis of multiple patients.  
Tissue microarrays were constructed from pancreatic tissues obtained, after 
establishing histological diagnosis, following surgical resection of the pancreas (in the 
form of pancreatoduodenectomy, distal pancreatectomy or total pancreatectomy).  
 
Specimens were collected from patients undergoing pancreatic resections at 
the Royal London Hospital, Whitechapel, England. The enrolment criterion was 
suspected or proven pancreatico-biliary diseases (Ampullary carcinoma (AC), 
cholangiocarcinoma (CC), chronic pancreatitis (CP), mucinous cystic neoplasm 
(MCN), duodenal carcinoma and biopsies or resections for pancreatic ductal 
adenocarcinoma (PDAC), with ability of complete clinico-pathological and follow-up 
data. Overall survival was defined as the interval between surgery and either death. 
Data were censored to the last clinical observation made on 31st December 2015. 
Patients gave written informed consented for the tissues obtained (City and 
East London Local Research Ethics Committee 07/H0705/87). 157 patients were 
sampled in total and two sets of microarrays were constructed. The first set (Batch A) 
had been constructed by Froeling and Mirza (59, 202), whilst the second set (Batch 
B) were constructed by Ene-Obong (203) and both had been used for previous 
published work. The number of patients with each disease on the two sets of TMA’s is 









Pancreatico-biliary disease Number of patients 
Batch A Batch B Total 
Ampullary Carcinoma  0 9 9 
Cholangiocarcinoma  9 12 21 
Chronic Pancreatitis  0 4 4 
Mucinous cystic neoplasm 0 6 6 
Duodenal carcinoma 0 5 5 
Normal 0 14 14 
PDAC (resected) 63 0 63 
PDAC (biopsy) 0 35 35 
Total 72 85 157 
Table 6: Pancreatico-biliary disease: patient numbers incorporated within respective TMAs. 
 
In order to construct each TMA, a representative slide of each patients donor 
block was cut and stained with haematoxylin and eosin (H&E). Prof Hemant Kocher 
and A. Ene-Obong identified multiple regions of tumour, stroma and normal pancreas 
on each slide and these were circled, using the Axiophot microscope (Carl Zeiss 
Micro Imaging LLC, New York, USA). The regions were colour coded, red represented 
stroma, blue represented normal and black represented tumour regions (203). 
Once regions of slides had been identified, a map for each TMA slide was 
constructed on Excel (Microsoft, Seattle, USA), in order to aid TMA construction and 
for referencing during TMA analysis.   
 
At least three cores from tumour and a further three from adjoining stroma, 
each being 1mm in diameter were obtained from the donor blocks and transferred to 
the recipient paraffin block at defined positions, according to the TMA map. 
Furthermore, three cores of adjacent normal tissues were sampled from patients with 
duodenal cancer and cholangiocarcinoma. One core of normal human spleen was 
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inserted in the recipient block in order to aid guiding and orientation of the TMA slide.  
I ensured that always at least 3 cores were available for analysis per patient. 
On an average 6 cores were arranged on TMA per patient, but some cores were not 
analysed because of artefacts, loss of cores (dropouts), folded cores, missing 
cancerous tissues as the core goes deeper into the tissue. 
TMA construction was performed using Tissue Arrayer Minicore® (Alphelys, 
Plaisir, France). Upon completion, recipient blocks were kept at 37°C overnight to 
ensure bonding of the cores with paraffin wax of the recipient block and sent to 
pathology for sectioning to multiple slides. 
 
My involvement was to complete all clinic-pathological parameters. I reviewed 
all clinical data relating to all 157 patients. I started by reviewing clinic letters, 
assimilating histopathology reports, date of operations and survival, along with pre-
operative blood test results. These results were added to the TMA map up until 31st 
December 2015. The clinico-pathological parameters acquired were as follows: 
• Date of birth 
• Date of operation 
• Age at operation 
• Date of death 
• Survival (days) 
• Histological diagnosis 
• Histological differentiation 
• TNM staging 
• Resection status (R0/1/2) 
• Nodal count and positivity 
• Pre-operative total and differential While cell count (≤3 days from 
operation) 
• Pre-operative CRP (≤3 days from operation) 
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• Pre-operative Ca19-9 (≤7 days from operation) 
 
More than fifteen years after its introduction (204), the TMA technique can be 
considered a well-established platform for tissue biomarker studies, providing similar 
or even better prognostic information than full-face tissue section based analyses 
(205). However, issues related to suboptimal sampling remain. In our cores, we have 
observed loss of cores, folding of the tissue core and reduction of representative 
tumours in the tumour cores. Stroma was also sometimes noted in cores labelled at 
tumour. 
There are a variety of possible explanations, such as technical errors made 
during sectioning and the three-dimensional nature of tumours. In order to minimise 
the errors, an abundance of tumour cores from each patient were taken to ensure 
confident analysis.   
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2.2 Cell Culture 
2.2.1 Cell Lines, media and culture reagents 
2.2.1.1 Pancreatic Cancer Cells 
The following pancreatic cancer cell lines were used (Table 10) 
Cell Line Source Differentiation Mutation 
Capan 1 Liver metastasis Well  KRAS, TP53, INK4A, SMAD4, BRCA2 
(206) (207) 
Capan 2 From primary 
tumour 
Well KRAS, TP53, silent mutation of INK4A, 
SMAD4 (207) 
CFPAC1 Liver metastasis in 
a patient with 
pancreatic cancer 
and cystic fibrosis 
Well KRAS, TP53, SMAD4 and methylated 
INK4A, CFTR (CFTRΔF508) (206) (208) 
PaTu8988T Liver metastasis Well KRAS, TP53 with methylation of the 5’CpG 
island of INK4A (209)   
AsPC1 Ascites Moderate  KRAS, TP53 and INK4A (210) (211)  
HPAF Ascites Moderate  KRAS, TP53 and INK4A (211)   
PaCa3 Primary tumour Poor  Methylation of 5’CpG island of INK4A (212) 
Panc1 Primary tumour Poor  KRAS, TP53 and INK4A (211) (213) 
PaTu8988S Liver metastasis Poor KRAS, TP53 with methylation of the 5’CpG 
island of INK4A (214) 





  69 
2.2.1.2  Stromal Cells 
Using the outgrowth method (74), pancreatic stellate cells were isolated from 
an unused, normal, adult male human pancreas (donation for transplantation) 
donated by the UK Human Tissue Bank (Ethics approval; Trent MREC 
(05/MRE04/82)). The resulting cell strain, designated FS1, was verified as being of 
stellate cell origin based on the expression of characteristic stellate cell markers, such 
as presence of lipid droplets in the cytoplasm and expression of cytoskeletal proteins 
GFAP, Desmin, Vimentin and αSMA (73). FS1 stellate cells were immortalised, using 
ectopic human telomerase reverse transcriptase (hTERT) expression by Dr Fiona Li 
and Ms Jennifer Sandle previously from our laboratory (215). Cells were labelled as 
PS1 after confirmation of immortalised cell telomerase activity and continuous 
passage without loss of phenotypic characteristics over the last nine years.   
 
2.2.1.3  Pancreatic ductal epithelial cells 
hTERT immortalised human ductal epithelium (DEChTERT) cell lines were 
used as control pancreatic ductal cell lines (216). 
 
2.2.1.3  MOCRI cells 
Using the Ethics approval in 2.2.1.2, pancreas from patients with PDAC were 
initially digested and centrifuged. The cells that were obtained were sorted by Flow 
Cytometry, by isolating EPCAM negative and CD45 negative cells; thus we 
theoretically excluded epithelial and lymphocytic cell lines. The resulting population of 
cells were tested for expression of cytoskeletal proteins, as described above. This 
was performed by Mo Ghallab and Christina Ghirelli (unpublished data) and therefore 
named MOCRI.  
 
2.2.1.4  Culture conditions and routine cell culture 
Pancreatic cells were cultured as adherent monolayers in sterile tissue culture 
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flasks in a humidified atmosphere at 37°C, 8% CO2 in either RPMI (PAA Laboratories, 
E15-842; AsPC1, PaCa3, Capan1) or Dulbecco’s Modified Eagle’s Medium (DMEM, 
PAA Laboratories, E15-843; Capan 2, CFPAC1, Suit 2, HS766T, Panc1, Colo357, 
Mia, BxPc3, 818, PaTuT/ PaTuS) medium. This was supplemented with 10% foetal 
bovine serum (FBS, Biosera). PS1 stellate cells, after hTERT immortalisation were 
grown, at the same humidified culture conditions as PDAC cells, in DMEM: F12 
(Invitrogen, 11320-074) medium, respectively, supplemented with 10% FBS and 
1µg/ml Puromycin as a selection agent. Pancreatic ductal epithelial cells were grown 
in DMEM supplemented with 10% FBS (DEChTERT).  
 
  When cells reached 80% confluency, medium was aspirated off and Trypsin-
EDTA (PAA Laboratories, L11-003) was added for 3-5 minutes at 37°C to detach cells 
from the surface. Once cell detachment was confirmed under a light microscope, the 
trypsin was deactivated with medium containing 10% FBS. The cell suspension was 
centrifuged for 3 minutes at 1200 revolutions per minute (rpm), followed by removal of 
supernatant and re-suspension of the cell pellet in standard medium. If counting cells 
was required, 20µl of cell suspension was pipetted into a haemocytometer prior to 
centrifugation and cells were counted manually under a light microscope. Cells were 
sub-cultured at various ratios (1:2 to 1:5) depending on their growth rate.  
 
For storage of cells, cell pellets were re-suspended in a mixture of 90% FBS 
with 10% dimethyl sulphoxide (DMSO) which acts as a cryo-protectant. In one 
millilitre aliquots in a cryovial, cells were slowly frozen, first at -80°C to prevent ice 
crystal formation and then transferred to liquid nitrogen for long-term storage. 
 
When recovering cells from liquid nitrogen stocks, cell suspensions were 
thawed as quickly as possible at 37°C in a water bath. Once thawed, cell suspensions 
were transferred to a 15ml falcon tube containing standard medium. To remove 
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DMSO, the cell suspension was centrifuged at 1200rpm for 3 minutes, the 




2.3.1 Cells cultured on coverslips 
Cells were seeded onto a 13mm diameter coverslips in a 6 well plate as a 
monoculture at a density of 2.5x105 per well. 
For immunofluorescence, cells were fixed with 4% formaldehyde, 
permeabilised with 0.1% saponin/ PBS, blocked with 6% BSA and incubated for 1 
hour at room temperature with primary antibody (Table 8) followed by appropriated 
fluorescently labelled secondary antibody (Table 8). Nuclei were stained with 4’,6-
diamidino-2-phenylindole (217). Negative controls were incubated with isotype 
specific immunoglobulins at the same concentrations as the primary antibody used.    
 
2.3.2 Paraffin embedded gels and patient tissues 
For Immunofluorescent staining of paraffin embedded gels and patient tissue, 
4µM sections were dewaxed in xylene (twice for 5 minutes) and rehydrated (in 
reducing concentrations of ethanol; 100%, 80%, 70%, 50% and distilled water). 
Antigens were retrieved by boiling sections in 10mM citrate buffer (pH 6.0) for 20 
minutes. Sections were blocked with 6% BSA/PBS and incubated with primary 
antibody overnight at 4°C, followed by one hour incubation at room temperature with 
the appropriate secondary antibody and DAPI. Negative controls were incubated with 
isotype specific immunoglobulins at the same concentration as the primary antibody 
used. Positive controls for normal human pancreas whole sections, treated as 
described with pIgR primary antibody.   
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2.3.3 Immunofluorescence 
For all experiments where pixel intensity was analysed, three separate 
experiments were carried out and at least three random fields were analysed. For 
every experiment, there were three biological and three experimental repeats.  
To ensure that the replicate experiments for immune fluorescence staining had 
comparable images, a number of precautions were taken. All technical replicates had 
same antibody mastermixes and staining was carried out simultaneously. Image 
acquisition was done with same laser strength and offset/gain thresholds across 
experiments. The normalisation was set to respective negative control (IgG) and 
positive control (e.g., normal human duodenum) to ensure that the best signal to 
noise ratio was set. These setting were then kept constant for all image acquisition 
taken at same sitting on microscope. All post-image acquisition analysis was done in 
Image J or Photoshop with same settings across various replicates using standard 
operating procedure and pre-set formulae. 
Total pIgR and E-Cadherin levels were quantified with Image J “Analyze” 
software function. Images were taken at x40 magnification; the area of green or red 
stain within the region of interest was determined. Colour images had colour channels 
split, using the ‘Split channel function’. The ‘Threshold’ function then provided initial 
thresholds that were set and kept constant for all images. The intensities in the green 
and red channel were normalised with IgG controls and background fluorescence and 
calculated in an unbiased, blinded manner The ‘Analyze’ function enabled small 
particles, less than 25µm to be omitted from calculation. Small sized particles maybe 
debris or dead cells, thus accounting for some background staining. Calculation of 
pixel intensity for each channel background was calculated using the “Process and 
subtract background” in Image J, to calculate background intensity staining and then 
subtract that from the final image staining pixel intensity. By utilising the subtract 
background macro, the mean of the region of interest (ROI) is subtracted from the 
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image, plus an additional value to equal the standard deviation of the ROI, multiplied 
by a scaling factor. 
For organotypic staining, this method provides variable scales due to the 
relative intensity of staining and amount of cells staining positive. 
 
2.3.4 TMA core Analysis 
Expression of pIgR was analysed via Immunofluorescence using tissue 
microarrays. Immunofluorescence was performed as described in Section 2.3.3. The 
staining extent score was a scale of 0-4, corresponding to the percentage of 
immunoreactive tumour cells (0%-5%, 6%-25%, 26%-50%, 51%-75% and 76%-100% 
respectively. The staining intensity was scored as negative (score=0), background 
(score=1), mild (score=2), moderate (score=3) or intense (score=4). A score ranging 
from 0-8 was calculated by adding the staining extent score with the intensity score 
(Table 7).  
There are numerous options relating to type of staining and method of 
immunoscoring. Whilst immunohistochemistry is a more established method for 
ascertaining staining patterns as this preserves architectural context, 
immunofluorescent staining gives added advantage of getting information from more 
than two channels (wavelengths) simultaneously in the same area or cell or even at 
sub-cellular level for example, membrane versus cytoplasm with little interference 
from other channels (wavelengths). Immunofluorescent is disadvantaged by transient 
signal as well as loss of architectural context which requires more training. 
However, I chose immunofluorescence and the above system as it had been 















Table 8: Staining scoring Criteria 
 
A normal process for validation of scoring involves two clinicians scoring the 
data set. To confirm my ability to score the TMAs appropriately, a second consultant 
clinician (Prof Hemant Kocher) was recruited to score one TMA. The TMA slide 
contained 88 cores. Both my scores for pIgR expression and the second clinician’s 
scores for the one TMA were validated against ARIOL. The scanner is an automated 
process that distinguishes intensities of cell staining and provides a numerical value, 
thereby providing a semi-quantitative result. Comparison is made between each core 
and sequential slides were used between each analysis process.   
2.3.4.1 ARIOL imaging 
ARIOL ® (Leica Microsystems, Milton Keynes, UK) is a high throughput 
automated scanning microscope and image analysis that is able to capture, store and 
analyse terabytes of imaging data (220). It has applications in clinical, genomic and 
research industries (203, 221) and has previously been used in our group for 
publication.  
The ARIOL system consists of a computer connected to a server, in order to 
handle the large amounts of imaging data generated and is equipped with a barcode 
scanner, microscope, with automated mechanical stage embedded and a lighting 
system (Olympus BX, UCB). The system can be programmed to capture whole tissue 
sections and tissue microarrays.  
Median  Percentage 
0 No Stain 0 0-5% 
1 Background 1 6-25% 
2 Mild 2 26-50% 
3 Moderate 3 51-75% 
4 Intense 4 >75% 
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The ARIOL system has been documented in primary colorectal 
adenocarcinoma (222), breast cancer (223), follicular lymphoma (224) and pancreatic 
adenocarcinoma (203) research. Automated systems can produce results in 
concordance with pathologists scoring, especially for markers with nuclear staining 
patterns and can provide standardised quantitative measurements of 
immunohistochemical staining (225). 
2.3.4.2 Methods of Immuno-scoring 
Biomarker quantification has relied exclusively on visual scoring performed by 
a pathologist or trained reviewer, which is semi-quantitative and can be limited by 
inter-observer agreement (226) . However, this system is still largely used in 
publications to date.  
Additionally, visual analysis of tissue samples is time consuming and prone to 
human errors, which has led to a method for absolute quantification that is potentially 
consistent, replicable, time saving and have high throughput capabilities. 
Theoretically, automated image analysis may offer solutions. The microscope 
component of the ARIOL ® is equipped with an automated mechanical stage, which 
can hold 8 slides sequentially; whilst the barcode scanner on the system ensures that 
every slide is unique, allowing for the programming of different assays per slide, all of 
which aid high throughput analysis.  
The embedded software is equipped with applications to make it easy to parse 
scanned images into regions, allowing for calculations within regions. It also has 
controlled thresholds for scoring based on size, colour, intensity, pattern and shape 
with which the trained user can teach the Ariol to discriminate a false positive from an 
actual positive stain.  
The high magnification of pixels also make it possible to differentiate shades of 
colours and cells juxtaposed to each other, thus cells maybe counted individually and 
enabling sufficient stringency to produce highly accurate, reproducible results.  
The output is quantitative with values for useful parameters such as counts 
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(positive and negative), analysed area (µm2), area of positive and negative staining 
(µm2) and mean intensity of colours. 
2.3.4.3 Limitations of Ariol 
Despite the exceptional capabilities of Ariol, it is limited by its lack of user 
friendliness, inflexibility and ancient design, which consumes time and effort. Whilst a 
region can be selected and cells quantified, it is impossible to quantify the excluded 
region simultaneously, thus requiring the user to perform arithmetic to calculate the 
cell counts of the excluded regions by performing lengthy analysis and deducting the 
selected region from the whole region. 
The system is also expensive; the system cost $300,000 in 2005. Most users 
have to spend hours on the system to gain expertise and to perform the many 
analyses that must be executed to overcome its inflexibilities. For accurate results, 
thresholds on what to quantify must be set, which is also time consuming. Scanning a 
series of TMA slides is also a very long process, taking up to six to seven hours. 
Based on the time to train and scan, the Ariol works out as being an expensive 
research tool. 
2.3.4.4 Application 
I used Ariol to perform quantitative analysis of pIgR expression in TMA’s using 
the TMAsight assay on Ariol. I trained the software to distinguish and quantify positive 
and negative cells by their colour, size, shape and staining intensity. I was aiming to 
gain a representative intensity score for entire TMAs, thus I did not distinguish tumour 
from non-tumour within each core. The entire core area was marked with the marking 
tool on Ariol. Afterwards, the amount of positive cells in the core was quantified and 
divided by the amount of negative cells in the same core. This provides a ratio of 
density within each core. 
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2.3.5 Identification of PanIN for assessment 
Pancreatic intraepithelial neoplasias (PanINs) are pre-invasive neoplasms that arise 
within the intralobular ducts of the exocrine pancreas. PanINs are small microscopic 
lesions that are less than 5mm. They are composed of a flat or papillary neoplastic 
epithelium. Depending on the extent of the cytological atypia, they are classified as 
PanIN 1 (low-grade dysplasia), PanIN 2 (moderate dysplasia) or PanIN 3 (high grade 
dysplasia) (227).  
 
Figure 2.1: PanIN progression. Figure sampled from Brosens et al (228).  
A simple cuboidal layer of cells characterises normal pancreatic ductal epithelium. PanIN 1 demonstrates 
columnar cell change and mucinous differentiation, but minimal nuclear atypia. PanIN 2 lesions lose the 
mucinous epithelium but demonstrate nuclear pleomorphism and crowding and some mitotic figures may 
be present. PanIN 3 relates to carcinoma in situ, with pseudopapillary formation, nuclear atypia, 
apoptotic debris and frequent mitotic figures (228).  
 
2.3.6 Survival and Statistical analysis 
Survival analysis to dichotomise groups according to high and low pIgR 
expression was performed using X-Tile (Rimm Lab, Yale University, 
http://medicine.yale.edu/lab/rimm/research/software.aspx). 
Statistical analysis and graphical data representation were performed using 
the software PRISM V.6 (Graphpad, La Jolla, USA). Summary data are expressed as 
the median with interquartile range since the distribution was non-Gaussian. 
Comparisons were performed using Kruskal-Wallis test with Dunn’s multiple 
comparison test. The level of significance was set at P < 0.05. 
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2.3.7 Picrosirius Red staining 
Picrosirius Red staining was used to detect collagen fibres in tumours. Briefly, 
to obtain a 0.1% Picrosirius Red solution, 0.5 gram of Sirius Red (Sigma Aldrich 
Direct Red 80, 365548) was dissolved in 500 mL saturated aqueous solution of picric 
acid (1.3% in distilled water). Sections were de-waxed and hydrated as described 
previously, incubated with Picrosirius red solution for an hour at room temperature, 
after which, sections were washed twice in acidified water (0.5% acetic acid in 
distilled water), dehydrated through graded alcohols to xylene and mounted in DPX 















Figure 2.2: Quantification of Picrosirius Red stain  
Unlike Masson’s Trichrome, nuclei remain unstained, thus the stain is only a demonstration of collagen. 
Due to the variation, I used the panoramic scanner to scan the images and also provide a quantitative 
result for the intensity of the stain. By changing the core into an effective heat map, I could then map and 
mark the intensity of the red stain. This provides strongly positive areas. I excluded moderately and low 
expression of the red. The program counts the number of pixels within each core that are strongly 
expressing the red. Scale bar 200µm.   
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Figure 2.3: Picrosirius Red staining in human PDAC sections. 
The intensity of the red colour varies hugely across various PDAC subtypes. As shown in the variety of 
images and the number below represent the numerical value of the intensity of stain. There is a large 
variability in the score, but as a general observation, values under 300 are largely negative, whilst values 
over 5000 are strongly positive for collagen. Scale bar 200µm.   
2.4 Western Blotting 
2.4.1 Isolation of protein 
After relevant treatments, cells were washed with PBS and lysed at room 
temperature with lysis buffer. Scrapping with a rubber policeman collected cells. Cell 
debris was collected and added to an eppendorf tube and homogenised briefly using 
a sonicator. Protein concentration was determined with a Bio-Rad Dc protein assay 
(Bio Rad Laboratories) according to the manufacturer’s instructions. Following protein 
concentration determination, sample buffer (4X) (Novex, NP0007) was added and 
samples stored at -80°C to avoid protein degradation. 
 
2.4.2 Western blot analysis 
Cell lysates in sample buffer were boiled at 100°C for 5 minutes to denature 
proteins before brief centrifugation to collect contents. Equal amounts of denatured 
protein (15-25µg) were loaded onto 10% Bis-Tris gels. After protein separation by 
electrophoresis, proteins were transferred to a nitrocellulose membrane (GE 
Healthcare Life Sciences, 10401196). Ponceau S (Sigma-Aldrich, P7170) was used to 
confirm adequate transfer. Non-specific binding was blocked by incubation with 5% 
milk, followed by incubation with primary antibody (Table 2) in 5% milk at 4°C 
overnight. Membranes were washed with 0.1% Tween20-TBS (TBST) (Applichem, 
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A13890500) and subsequently incubated with secondary HRP-conjugated antibody 
for one hour at room temperature. Specific protein bands were visualised using an 
Amersham ECL Western Blotting Detection Kit (GE Healthcare, RPN2106) and 
photographic film (Super RX, 4741019230). 
 
2.4.3 Stripping membranes 
Membranes were stripped using Reblot plus mild (Millipore, 2502) for 10 
minutes, washed with PBS, blocked with 5% milk in PBS for 15 minutes and washed 
again in PBS. Membranes were then reprobed with primary antibody as above.  
2.4.4 Densitometry and analysis 
For Western blotting, densitometric analysis of specific bands was carried out 
using Image J software (Rasband, National Institute of Health, 
(https://imagej.nih.gov/ij/). To obtain a semi-quantitative measurement of the level of 
total protein, band densities were normalised to the loading control HSC70 
housekeeping genes on the same membrane. 
 
2.5 Quantitative real-time PCR 
For reverse transcription PCR, cells were lysed with Quick-RNA Mini Prep 
(Cambridge Bioscience, #R1054A). Quantity and purity of RNA was measured with 
NanoDrop spectrophotometer (OD 260/280 ratio > 1.80).  
cDNA was amplified in a reaction mix with the forward and reverse primer 
(Table 2.3) and quantified SensiFAST SYBR Hi-ROX One-Step Kit (Bioline, #BIO-
73005). Briefly, kits formulated for first strand cDNA synthesis and subsequent real-
time PCR in a single tube. The antibody-mediated hot-start DNA polymerase system 
reduces the chances of primer/ dimers formation.  
Cycle numbers of denaturing at 95°C, annealing at 55°C and DNA extension 
at 72°C. For each gene, the first cycle when exponential amplification could be 
detected (CT) was normalised to the endogenous expression of the housekeeping 
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gene GAPDH (glyceraldehyde 3-phosphate dehydrogenase).  
 
Gene Forward Primer Reverse Primer Tm Size 
pIgR 
(Kaetzel) 
GGTCCCGAGGAGGTGAATAGTG CTGACCTCCAGGCTGACATCAA 67 22 
pIgR 
(Kadaba) 
CTCTCTGGAGGACCACCGT CTCTCTGGAGGACCACCGT 65 19 
GAPDH CCATGACCCCTTCATTGACC TTGATTTTGGAGGGATCTCG 65 20 
Table 9: Primers used for quantitative reverse transcription PCR (qRT-PCR). Two pIgR primers 
were used for sequencing, Kaetzel primers have been used elsewhere for pIgR sequencing (229), 
whilst the other pIgR primers were used previously in our group (70).  
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2.6  Antibodies 
All antibodies are summarised in Table 10. 
Antibody Species 








αSMA Mouse Dako Clone 1A4 (M0851) 1:300 1:100 
α Tubulin Goat Abcam (ab7291)  1:1000 
Cytokeratin Mouse Dako (Z0662) 1:200  
E-Cadherin  Mouse Abcam (ab1416) 1:100 1:500 
Fibronectin Mouse Sigma (F0916) 1:300  
HSC70 Mouse Santa Cruz (SC7298)  1:1000 
IgA Goat Sigma Aldrich (I0884) 1:100  
Ki67 Rabbit Abcam (ab15580) 1:100  
pIgR Rabbit Sigma Aldrich (HPA012012) 1:200 1:1000 
pIgR Rabbit Santa Cruz (H-300) (SC20656) 1:200 1:1000 
Twist1 Mouse Abcam (ab50887) 1:500  
Vimentin Mouse Dako Clone V9 (M0725) 1:50 1:250 
Zeb1 Rabbit Santa Cruz (SC25388) 1:500  
Secondary Antibodies 
Anti-rabbit HRP Mouse Dako (P0448)  1:1000 
Anti-mouse HRP Goat Dako (P0447) 1:1000 
Anti-goat HRP Rabbit Dako (P0160) 1:1000 
Fluorescein Goat 
Anti-rabbit (488) 
Rabbit Invitrogen (F2765) 1:400  
Fluorescein Goat 
Anti-mouse (546) 
Mouse Invitrogen  
(A-11030) 
1:400 
Table 10: Antibodies used for experiment. HSC70 (Heat shock cognate 70kDa protein); αSMA (α-
smooth muscle actin); pIgR (polymeric immunoglobulin receptor); HRP (horseradish peroxidise); 
IF (immunofluorescence); IHC (immunohistochemistry); WB (Western blot) 
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2.7  Modulation of pIgR in cell lines 
2.7.1 Small interfering RNA (siRNA) oligos 
Cells were transfected with a pool of siRNA oligos (ON-TARGET plus SMART 
pool human pIgR, Dharmacon, L0017729-00-0010). Non-targeting siRNA was used 
as a control (Dharmacon, D-001810-10-05). 
 
2.7.2 Collection of supernatant 
For conditioned medium to be used in the Western blot analysis cells were 
cultured in serum free medium for 12 hours, after which time the medium was 
collected, filtered and concentrated 20X using centrifugal pore size filter units 
(Millipore UFC 800324 NMWL 3000) according to manufacturer’s instructions. The 
nature of the filter membranes means that solutes with molecular weights below 
3000kDa were excluded from the membrane and collected in the centrifuge tube 
while the supernatant was collected from the filter device sample reservoir. Culture 
medium (serum free) was used as a negative control. Sample buffer (4X) (Novex, 
NP0007) was added to the concentrated condition medium and boiled at 100°C for 
western blotting.  
 
2.7.3 Introduction of siRNA into Capan1 cells 
PDAC cell line, Capan1, was plated into 6-well plates at a confluency of 5x104 
cells per well (50%) in standard medium containing FBS. The following day, the 
medium was removed from the cells and replaced by 1ml of fresh standard culture 
medium to achieve the correct final concentration of siRNAs. The Capan1 cancer 
cells were transfected with a pool of siRNAs targeting pIgR at a final concentration of 
20nM, or with a pool of non-targeting siRNA at the same concentration, using 
INTERFERin™ (Polyplus, 409-10) as a transfection reagent. Transfection complexes 
were prepared in OptiMEM (Invitrogen, 51985-042), to which 4µl INTERFERin™ was 
added, vortexed for 10 seconds and incubated for 10 minutes at room temperature. 
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155µl of the mixture was added to the cell line in culture medium. Cells were 
incubated with the siRNA complex for 24, and cell lysed between 48 to 144 hours and 
subsequent confirmation of knockdown by Western blot. 
 
2.7.4 Introduction of shRNA into pancreatic cancer cells 
pIgR shRNA plasmids were kindly donated by Jing Ai, Shanghai Institute of 
Materia Medica (179). A total of three shRNA plasmids were donated; non-targeting 
shRNA (5’-UUCUCCGAACGUGUCACGUTT-3’), pIgR shRNA 1 (5’-
GAACGUCGACCGAGUUUCA-3’), pIgR shRNA 2 (5’-CGUCGACCGAGUUUCAAUC-
3’). Each plasmid was transformed using 50µl E. Coli bacteria (Thermo Fisher, 
C404010); heat shocked at 42°C for 45 seconds and streaked onto pre-warmed agar 
plates containing 100µg/ml Ampicillin. The plates were left to incubate overnight at 
37°C and individual colonies were selected the following day and incubated in L-Broth 
with 100µg/ml Ampicillin overnight. The following day, the liquid broth was centrifuged 
for 10minutes at 5400rpm, half of the product being retained for glycerol stock (500µl 
glycerol and 500µl broth media) for long-term storage. The other half was 
subsequently processed using QIAprep Spin Miniprep Kit (QIAGEN, 27104) as per 
manufacturers’ protocol, to generate enough DNA for subsequent introduction into 
cancer cell lines. 
In order to transfect PDAC cells, AM12 Phoenix cells (ATCC, CRL-3214) were 
used as an amphotrophic vector to aid the transfection. AM12 cells are amphotrophic 
retroviruses and are cultured in DMEM supplemented with 10%FBS. AM12 cells were 
plated into 10cm petri dishes to a confluency of 60%, requiring one petri dish for each 
eventual shRNA construct. 24µg of each shRNA construct was added to 60µl of 
Lipofectamine® 2000 (Life Technologies, 11668027) and 10mls of OptiMEM 
(Invitrogen, 51985-042). The mixture of each shRNA and Lipofectamine® 2000 was 
added to each respective petri dish of AM12 cells. After 24 hours, the media was 
replaced with DMEM containing FBS. After a further 24 hours, the 5mls of 
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supernatant was collected, filtered with a 0.45µm filter and 6.25µl of Polybrene (Merck 
Millipore, TR-1003-G) added. 2mls of the mixture was added to Capan1 cells plated 
into 6 well plates at a confluency of 5x104 cells per well (50%) in standard medium 
containing FBS. The 6-well plate was left at room temperature on a plate shaker at 
1800rpm for 20 minutes before being left overnight at 37°C. The following day, media 
was changed to RMPI with 10%FBS and 1µg/ml Puromycin. Transfected cells were 
subsequently lysed and confirmation of knockdown by western blot. 
 
2.7.5 Incubation of pancreatic cancer cell lines with cytokines  
PDAC cell line, AsPC1, was plated into 6 well plates at a confluency of 5x104 
cells per well (50%) in standard medium containing FBS. AsPC1 cells were treated 
with 5µg, 10µg or 20µg of Interleukin 1β (Peprotech, 200-01B), Interleukin 4 
(Peprotech, 200-04) or Tumour Necrosis Factor α (Peprotech, 300-01A). Cells were 
incubated with the relevant cytokine from 24 to 72 hours before cell lysis and 
confirmation of overexpression by Western blot. 
 
2.7.6 Introduction of plasmid DNA into pancreatic cancer cells 
2.7.6.1  pIgR cDNA from Addgene 
In an attempt to elicit over expression of pIgR, pIgR cDNA was obtained (pBS-
pIgR cDNA was a gift from Pamela Bjorkman (Addgene plasmid #12109)). Stab 
culture overnight elicited colonies, which were picked and processed using QIAprep 
Spin Miniprep Kit (QIAGEN, #27104) as per manufactures protocol, to generate 
enough DNA for subsequent introduction to mammalian cloning vectors.  
Gel digestion using Xba1, HindIII and Bsa1 binding sites to ligate a 2900 base 
pair sequence of pIgR. Digestion products were purified from an agarose gel using 
QIAquick gel extraction kit (Qiagen, #27104). The desired band was excised from the 
ethidium bromide-stained agarose gel and three volumes of Buffer QG were added to 
1 volume of the gel slice. The mixture was incubated at 50°C for 10 minutes followed 
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by adding 1 gel volume of isopropanol. The mixture was then applied onto a spin 
column and was centrifuged at 14,000 rpm for 1 minute (Eppendorf centrifuge, 
#5415C). This was followed by a wash with 0.75 mL buffer PE and centrifuged again 
as described above. Bound DNA was eluted from the spin column by adding 50 L 
buffer EB (10 mM Tris-Cl, pH 8.5). Eluted DNA was stored at 4°C until ready to use. 
The cloned sequence was introduced into pCDNA4/TO (Invitrogen) in the 
presence of T4 DNA ligase (NEB) and transformed into TOP10 (DH5α) Escherichia 
coli (E. Coli) cells (Thermo Fisher, C404010). Transformed cells were selected on a 
LB plate containing 100 µg/mL ampicillin at 37°C for 16 hours. Positive transformants 
were inoculated into LB broth containing 100 µg/mL ampicillin for plasmid 
propagation. The following day, the liquid broth was centrifuged for 10minutes at 
5400rpm, half of the product being retained for glycerol stock (500µl glycerol and 
500µl broth media) for long-term storage. The other half was subsequently processed 
using QIAprep Spin Miniprep Kit (QIAGEN, 27104) as per manufactures protocol, to 
generate enough DNA for subsequent introduction into cancer cells. 
In order to transfect PDAC cells, AM12 Phoenix cells (ATCC, CRL-3214) were 
used as a viral vector to aid the transfection. AM12 cells are amphotrophic 
retroviruses and are cultured in DMEM supplemented with 10%FBS. AM12 cells were 
plated into 10cm petri dishes to a confluency of 60%. 24µg of pIgR plasmid construct 
was added to 60µl of Lipofectamine® 2000 (Life Technologies, 11668027) and 10mls 
of OptiMEM (Invitrogen, 51985-042). The mixture of plasmid pIgR and 
Lipofectamine® 2000 was added to the petri dish of AM12 cells. After 24 hours, the 
media was replaced with DMEM containing FBS. After a further 24 hours, the 5mls of 
supernatant was collected, filtered with a 0.45µm filter and 6.25µl of Polybrene (Merck 
Millipore, TR-1003-G) added. 2mls of the mixture was added to PDAC cancer cell 
lines plated into 6 well plates at a confluency of 5x104 cells per well (50%) in standard 
medium containing FBS. The 6-well plate was left at room temperature on a plate 
shaker at 1800rpm for 20 minutes before being left overnight at 37°C. The following 
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day, media was changed to DMEM with 10%FBS and 150 µg/ml Zeocin (Invitrogen). 
Despite valiant attempts, introduction of pIgR into pancreatic cancer cells lines 
was unsuccessful. Trails initially with PCR based splicing failed to produce sufficient, 
high quality cDNA. Hence the attempt changed to gel based digestion. The sequence 
identified eventually and sequenced was a segment of pIgR, but again, we were 



























Figure 2.4: Representative image of pcDNA 4/T0 vector 
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2.7.6.2  Other methods of pIgR over-expression  
In an attempt to confirm over-expression, three further vectors were used. 
Human pIgR cDNA-containing pcDNA3.1 (+) was a generous gift from Dr Finn-Eirik 
Johansen (Rikshospitalet University Hospital, Oslo, Norway) (179). For stable 
transfections, AM12 cells were grown to 60% confluency in 10cm petri dishes plates 
and transfected with 4 μg of full-length pcDNA3.1 (+) vector or pcDNA3.1 (+)-pIgR, 
using 10 μl of Lipofectamine 2000 (Invitrogen) following the manufacturer’s 
instructions. As described in section 2,9,1, supernatant was collected and added to 
pancreatic cancer cells. A monoclonal population of stably transfected cells was 
selected using 500 μg/mL geneticin (G418) (Invitrogen).  
TrueORF pIgR plasmid was purchased from OriGene Technologies (Rockville, 
MD, USA; Cat. no. RC212006). TrueORFs have a C-terminal fusion of MYC/DDK tag. 
The cloning expression vector is pCMV6-Entry. Transfection of cancer cells was 
performed using Lipofectamine 2000 (Life Technologies), according to the 
manufacturer's instructions. Briefly, DNA (0.2 μg/well) and Lipofectamine 2000 (1 
μl/well) were separately diluted in 25 μl of Opti-MEM (Gibco). Next, DNA was added 
to the Lipofectamine 2000 reagent and the lipid/DNA mixtures were allowed to form 
complex for 5 min at room temperature. Cells were washed once with 100 μl of PBS 
and 100 μl of DMEM containing 15% FBS/well was added to each well. Next, lipid/ 
DNA mixture was added and cells were incubated at 37°C, 5% CO. After 24 h, 
transfection medium was removed and replaced with DMEM containing 10% FBS to 
start differentiation. To validate the expression of pIgR, anti-DDK mouse monoclonal 
antibody (1:1,000, OriGene, Cat#TA50011-100) was used. After 4 days of 
differentiation, differentiation was confirmed visually to observe the GFP under a 
fluorescent microscope. 
The HaloTag® protein was purchased from Promega (Madison, WI, USA; Cat 
no. FHC20797). It is a genetically engineered derivative of a dehalogenase that forms 
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a covalent bond with various synthetic HaloTag® ligands. The 34 kDa monomeric 
protein can be fused at either the N-or C-terminus to proteins of interest and enables 
expression in both prokaryotic (E. coli) and various eukaryotic cells. Transfection of 
cancer cells was performed Lipofectamine 2000 (Life Technologies), according to the 
manufacturer's instructions. After 4 days of differentiation, differentiation was 
confirmed visually to observe the GFP under a fluorescent microscope. 
 
2.8  Functional Assays 
2.8.1 Cell Counts 
Cancer cells were plated onto 6 well plates in triplicate at a density of 5x104 
and the next day treated with a pool of siRNAs targeting pIgR at a final concentration 
of 20nM, or with a pool of non-targeting siRNA at the same concentration, using 
INTERFERin™ (Polyplus, 409-10) as a transfection reagent (section 2.4). Untreated 
Capan1 cells were used as a control. For shRNA, cells were plated as above, but no 
additional treatment was provided.  At 72, 96, 120 and 144 hours following treatment, 
cells were detached with Trypsin-EDTA, 500µl of cell suspension was added to 9.5ml 
of Isoton and counted with a Casy counter (Schärfe Systems, Germany). Based on a 
coulter counter principle, the Casy system detects electrical signals that are 
generated when cells pass through a measuring capillary. 
 
2.8.2 Cell Proliferation Assay 
Cancer cells (untransfected or transfected with relevant shRNA) were plated 
(5,000 cells per well) in a 96-well plate for 24 hours. Cell proliferation was analysed 
with Cell Proliferation Reagent WST-1 (Roche, #5015944), added 2 h before 
spectrophotometric reading, according to the manufacturer's instructions. This is also 
known as MTS assay. 
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2.8.3 Scratch Assay  
  Cancer cells (untransfected or transfected with relevant shRNA) were plated in 
triplicate onto a six-well plate at a density of 5×104 per well. 48 hours later (when cells 
had formed a confluent monolayer), a wound was administered across the cell 
monolayer using a pipette tip. Three areas were selected and marked for imaging, 
cells were washed twice with a medium so as to remove any cell debris, and images 
were taken from the marked area and repeated at 48 hours to assess wound closure 
by phase contrast microscopy. ImageJ was used to quantify the percentage of cells 
(pixel intensity) that had migrated across the wound over 48 hours; results are an 
average of three separate areas measured.  
 
2.8.4 Adhesion Assay  
Cancer cells (untransfected or transfected with relevant shRNA) were plated 
for half an hour on fibronectin (10 mg/ml)-coated 96-well plates. Non-adherent cells 
were washed off with PBS. Adherent cells were stained with Crystal Violet and 
dissolved in 1 % SDS, and adhesion was quantified using absorbance at 560 nm. 
This “adhesion index” was normalized to the adhesion of untransfected cells for each 
biological repeat (at least three) which contained at least three technical repeats. 
 
2.8.5 Transwell Migration Assay  
Cancer cells (untransfected or transfected with relevant shRNA) were cultured 
in triplicate in serum free medium on top of an 8μm Transwell® membrane (Corning 
#3428) coated with Fibronectin (Sigma Aldrich #F1141) at a density of 5x104. After 24 
hours, cells counts were calculated from cells that had invaded through the 
membrane for each biological repeat (at least three) which contained at least three 
technical repeats.  
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2.9 Organotypic culture 
To investigate the invasion and proliferation of cancer cells in 3D, an air-liquid 
interface model was used (230) (231). The stromal, extracellular matrix (ECM) 
equivalent was composed of 75% collagen type 1 (BD Bioscience 354236) and 25% 
Matrigel (BD Bioscience 354234). Gels were composed of 10 parts; 5.25 parts 
collagen type 1, 1.75 parts Matrigel, 1 part 10X DMEM, 1 part DMEM and 1 part 
filtered FBS. The mixture was plated into 24 well plates coated with diluted collagen 
type 1 (1:100 in PBS). Gels were made in triplicate. Capan1 cancer cells were treated 
as previously described with either pooled non-targeting or on-targeting pIgR siRNA. 
Once the gels had polymerised, 1.7x105 cancer cells mixed with 3.3x105 stellate cells 
or 5x105 cancer cells alone (control) were added to the gels in 1ml of medium and left 
to adhere overnight at 37°C. The next day, the gels were lifted onto a metal grid 
covered by a nylon membrane pre-coated with seven volumes of collagen type 1, one 
volume 10X DMEM, one volume DMEM and one volume FBS. 250µl of the mixture 
was pipetted onto the nylon membrane and allowed to polymerise for 15 minutes at 
37°C, cross-linked with 1% glutaraldehyde/ PBS and left for one hour at 4°C. 
Glutaraldehyde was removed by washing the membrane 3 times with PBS and once 
with medium, then covering in medium and leaving overnight at 4°C. The following 
day, the submerged organotypic was raised to grids and fed from below with RPMI 
medium. Medium was changed every other day and gels were harvested at day 10 
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Figure 2.6: Quantification of Organotypic cultures. 
H&E images were scanned using panoramic scanner. Areas of interest were marked manually, as 
shown. Panoramic scanner would then provide details such as area and number of nuclei within the 
marked line. 
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Figure 2.7: Quantification of Organotypic culture cell area. 
Manual selection of areas of interest provided panoramic scanner program necessary information to 




Figure 2.8: Quantification of Organotypic culture gel thickness. 
Manual measurement of organotypic gel area thickness was performed using panoramic scanner.  
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Figure 2.9: Quantification of Organotypic culture cell layer thickness. 
Manual measurement of organotypic cell area thickness was performed using panoramic scanner. 
 
 2.10 Statistics 
The quantification of all cell counts and intensity of staining in the organotypic 
sections was performed on six representative pictures per organotypic gel of which 
there were at least three technical replicates for each of the biological replicates 
(minimum three). For the human TMA, either individual cores or the whole section 
was scanned using either Axioplan microscope (Zeiss 40 V 4.8.10, Carl Zeiss 
MicroImaging LLC, New York, US), confocal laser scanning microscope LSM 710 
(Carl Zeiss MicroImaging LLC, New York, US), Pannoramic 250 High Throughput 
Scanner (3DHISTECH Ltd., Budapest, Hungary) or ARIOL (Leica Biosystems, 
Wetzlar, Germany). The intensities of fluorescence in the green/red channels were 
normalized with IgG controls and positive controls (such as normal duodenum)and 
background fluorescence and calculated in an unbiased, blinded manner using either 
Adobe Photoshop CS6 (San Jose, CA USA) or Pannoramic Viewer Software 
(3DHISTECH Ltd., Budapest, Hungary) and Image J software (NIH, Maryland USA). 
Specifically regarding immunofluorescence quantification, the numbers of pixels for 
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green and red channels were counted using LSM710 software at a threshold above 
100 intensity (100–255) per high-power field, with size (total pixels) and cellularity in 
the field kept constant across the various shRNA conditions. All analyses were 
performed either Prism 5 (Graph- Pad Inc., LaJolla, CA) and images organized in 
Adobe Photo- shop. Significance was defined as P < 0.05 using appropriate statistical 
tests (Mann–Whitney U test or Student t test). 
Organotypic culture length and thickness was measured by summating the 
length of serial low-power fields across the gel from end to end, limiting to within the 
area of cellularity to avoid edge artifacts (70).  
All statistical analysis was done using GraphPad Prism software. First data 
were ascertained to be normally distributed or not using Shapiro-Wilk test. Most data 
were not normally distributed or too low a sample size. Hence, non-parametric tests 
were used. All tests and post-hoc comparisons were applicable are described. 
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3.1 Immunofluorescence staining of human paraffin sections 
Previous work by Kadaba et al from my laboratory (70) noted pIgR expression 
in 3D organotypic models of PDAC. Furthermore recent publication by Fristedt 
suggested enhanced pIgR expression in pancreatico-biliary cancers (176). pIgR is 
involved in transport of IgA and IgM in epithelial tissues. It is assumed that there is no 
physiological role for IgA within normal pancreas or liver, and therefore pIgR is 
unlikely to be of importance in normal pancreas or liver, as they are not exposed to 
gut pathogens. However, recent work with hepatocellular cancer (179) has 
demonstrated that pIgR aberrant expression correlated with poor patient survival. I 
therefore studied expression of pIgR in a number of patient samples with pancreatico-
biliary pathologies. 
 
3.2 Normal human expression of pIgR and immunoglobulins 
In order to confirm expression, normal pancreas and duodenum were 
identified in TMAs and historical tissue sections (n=15) were utilised as controls. 
Normal duodenum expresses pIgR and IgA naturally. Thus duodenum has been used 
as a positive control for staining. 
Normal duodenum shows strong expression of IgA and pIgR, yet normal 
pancreas shows neither expression, whilst PDAC samples demonstrate expression of 
pIgR but not of IgA (Figure 3.1). This suggests a role of pIgR in PDAC apart from 
transport of immunoglobulins. 
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Figure 3.1: IgA is not expressed in human pancreas.  
Representative images of H&E and immunofluorescence staining of normal human duodenum (A) and 
pancreatic cancer (B) sections. Sections were stained for IgA (green) and pIgR (red). Scale bar 20µm. 
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Figure 3.2: pIgR is not expressed in normal human pancreas. 
Representative images of normal human duodenum and pancreas stained with pIgR (green) and E-
Cadherin (red). Scale bar 20µm. 
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3.2.1 Confirmation of expression of pIgR in PDAC  
pIgR and E-cadherin expression has been investigated by Kadaba et al in 
organotypics, who noted an inverse correlation. I sought to confirm this in human 
tissues (70). Having noted previously negative expression in normal pancreas, human 
TMA sections of PDAC were stained to confirm pIgR expression and E-Cadherin 
expression (Figure 3.2 and 3.3). 
 
 
Figure 3.3: pIgR and E-Cadherin expression in human PDAC. 
Representative images of TMA cores normal human duodenum and PDAC stained with pIgR (green). 
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3.2.2 Validation of staining intensity  
Prior to investigating patient data, the intensity of staining quantification 
described in the Methods section was to be validated between manual scores and 
automated scores (ARIOL)  systems. In order to test these methods, all 
independently scored one slide, containing 28 TMA cores. The distributions of the 
scores by each method are shown in Figure 3.4 and 3.5. A further correlation analysis 
was performed (without consensus meeting). Analysis of the scores given by 
clinicians shows a weighted Kappa of 0.675, which is a good (but not excellent) 
correlation of grading staining intensity, but there was no correlation between manual 
(clinicians) and ARIOL scoring (Figure 3.5). 
 Automated scoring seemed to give skewed scores because of background 
auto-fluorescence from Collagen which could not be corrected despite multiple 
attempts to compensate and train the ARIOL. Newer software, available since, may 
be able to compensate for this auto-fluorescence, but I did not have access to that 
technology (232). All scoring was therefore performed manually as described in 
Methods section.  
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Figure 3.4: Distribution of pIgR expression scores across three independent scoring methods.  
28 cores within a TMA with pancreatic cancer patient samples were stained and scored at the same time 
by different methods. Median score for Clinical 1 was 4 (Interquartile Range (IQR), 3-7), for clinician 2 
was 5 (IQR, 3-5) and for ARIOL was 3 (IQR, 2-11). All scores for ARIOL more than 20 (n=2) were 
truncated to 20. 
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Figure 3.5: Inter-observer variability of scoring methods.  
A-C Demonstrates inter-observer variability across the 3 methods of quantification. A) Clinician 1 vs. 
clinician 2 (Kappa 0.219, SE 0.096; weighted Kappa 0.675). B) Clinician 1 vs. ARIOL (Kappa 0.096, SE 
0.077; weighted Kappa 0.265). C) Clinician 2 vs. ARIOL (Kappa 0.088, SE 0.064; weighted Kappa 
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0.175). 
3.3 pIgR expression across peri-ampullary lesions 
Having observed lack of pIgR expression in normal human pancreas and the 
subsequent expression in PDAC, I sought to explore pIgR expression in other human 
peri-ampullary pathologies because of the recent work by Fristedt et al (176). 
pIgR is naturally expressed in intestinal or duodenal mucosa, thus loss in 
intestinal or duodenal sub-type of peri-ampullary cancer is expected. 
 
Current classification of peri-ampullary tumours is complex due to a variety of 
reasons. This is mainly due to the common anatomical features and embryological 
origin of the periampullary region. Correct classification with respect to location of 
origin of cancer remains challenging to the pathologist, as there are no definitive 
markers to distinguish these different subtypes, if the tumour is not centred on one 
particular anatomical feature. 
The differentiation of tumours is important because of the observed 
differences in survival. A major step was the recognition of the intestinal (INT) versus 
pancreatobiliary (PB) histopathologic phenotypes of ampullary carcinoma by Kimura 
et al (197). The INT type proved to be associated with considerably better prognosis 
than the PB subtype, which has been confirmed by several recent series (196, 198, 
199) (Figure 3.6).  
I could demonstrate pIgR expression in all cancers of the peri-ampullary origin 
(Figure 3.7). pIgR signal was dominant over the E-cadherin signal predominantly in 
the ampullary and duodenal cancers, where E-cadherin was markedly attenuated. 
Manual intensity and percentage of area scores were assimilated for pIgR staining to 
allow comparison between different pathologies. Not all patients had requisite 
minimum number of cores (n≥3) to derive a composite score. This was due to mal-
folded TMA core or TMA drop-out or pre-dominantly stromal composition of core or 
absence of cancer in that particular section, all well appreciated drawbacks of TMA 
analysis. For the data available, staining intensity of pIgR did not differ amongst these 
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sub-types (Figure 3.8). PDAC (62%) and cholangiocarcinoma (13%) accounted for 
the majority of patients within the TMA. Unfortunately, there were insufficient patient 
numbers across all sub-types to provide comparative survival.    
 
 
Figure 3.6: Cancers of the peri-ampullary region 
Cancers of the peri-ampullary (PA) area can be divided into those arising from pancreatic, biliary, 
ampullary and duodenal tissues.  Ampullary cancers are further subdivided into pancreaticobiliary (PB) 
and Intestinal subtypes (INT), based on pathological differentiation. In resected periampullary carcinoma, 
morphological type seems to provide more important prognostic information than the tumour origin, with 
pancreatobiliary versus intestinal differentiation being associated with significantly shorter survival rates 
(199, 233). Lesions of duodenum and Intestinal-type ampullary lesions generally have a better prognosis 
than the pancreaticobiliary type of cancers. Image assimilated based on Fristedt et al (176).    
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Figure 3.7: Representative images from TMA of human sections.  
The cores are from the pancreas of patients with the relevant diagnosis. Sections stained with pIgR 
















Figure 3.8: pIgR expression across peri-ampullary lesions using manual scoring system.  
Dot plot with median and interquartile range demonstrated no statistical significance in differences in 
median pIgR staining score (Kruskal-Wallis, p=0.1318). Chronic Pancreatitis (n=3), PDAC (n=90), 
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3.4 pIgR expression and PanIN lesions  
Previous work in PDAC in vitro models in our laboratory had suggested that E-
cadherin (202) and pIgR (70) expression changes with increasing stromal activity. 
Also, it is well established that as PDAC progresses through the PanIN stages, 
stromal activity increases (234). Hence I choose to study a relationship between pIgR 
and E-cadherin activity during PanIN evolution. To do this, I explored each TMA core 
and sought to investigate pIgR and E-cadherin expression within individual ducts, 
within cores containing PDAC. It is appreciated that in every instance of PDAC, there 
are ducts with PanIN morphology which can be assessed individually. 
Assessing PanIN on immunofluorescent staining is challenging. I received 
training in assessing PanIN by Prof Kocher and Dr ChinAleong. JPEG images of 
corresponding H&E sections of TMA were also used to ascertain the presence of 
PanIN as well as the grade of PanIN. Normal ducts were scored from normal adjacent 
pancreas from pathologies other than PDAC. Examples are provided in Figure 3.9. 
Each duct was graded based on pathological appearance as normal, PanIN 1, 
2 or 3 and PDAC and each duct was then scored as previously (Section 2.3.4) for 
pIgR and E-cadherin expression (Figure 3.9). Each duct was then individually scored, 
thus giving rise to many more ducts than the cores or patients available. 
Increasing expression of pIgR was noted in progressive PanIN progression 
stages. However expression of pIgR expression virtually disappeared in invasive 
PDAC (Figure 3.10). It must be mentioned here that the pIgR scores for PDAC 
analysis in Figure 3.8 are composite scores accounting for all PanIN within the cores 
and all cores for the same TMA. This would explain the apparent discrepancy in 
PDAC composite scores in Figures 3.8 and 3.10.  
Furthermore, as expected a decreasing expression of E-cadherin was seen in 
PDAC evolution, which validated the methods I have used for identification of ducts 
as well as the scoring system I have used. (Figure 3.10) I demonstrate that pIgR 
expression is inversely related to E-Cadherin expression, thus validating findings of 
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Kadaba et al (235) from our laboratory in in vitro systems (Figure 3.10). 
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Figure 3.9A: Inverse relationship of pIgR and E-Cadherin. 
Representative images of sections from human PDAC samples stained with pIgR (green) and E-
Cadherin (red), comparing progression from normal pancreatic ducts to invasive PDAC via different 
PanIN stages. Scale bar 20µm.  
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Figure 3.10B: Nuclear features of PanIN 
A) PanIN 1 demonstrates columnar cell change and mucinous differentiation, without much nuclear 
atypia but some overlapping of nuclei (arrow). B) PanIN 2 lesions lose the mucinous epithelium but 
demonstrate nuclear pleomorphism and crowding (arrow) and some mitotic figures may be present. C) 
PanIN 3 relates to carcinoma in situ, with pseudopapillary formation, nuclear atypia (arrow), apoptotic 
debris and frequent mitotic figures. D) PDAC is invasive carcinoma and represents cancer breaching the 
basement membrane (arrow). Scale bar 20µm. 
 
 
Figure 3.11C: PanIN and PDAC variability 
Representative image of part of TMA cores from human PDAC, stained with pIgR (green) and E-cadherin 
(red) and demonstrating PanIN lesions admixed with PDAC. Scale bar 100µm. 
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Figure 3.12: Inverse relationship of pIgR and E-Cadherin expression. 
Figures A&B demonstrate changes in expression of pIgR and E-Cadherin in precursor lesions and 
invasive PDAC. Data is represented as dot-plot with median and inter-quartile range. Highest mean pIgR 
score noted in PanIN 2 (6.690, 95% CI 6.387-6.994), whilst highest mean E-Cadherin score was noted in 
normal ducts (7.074, 95% CI 6.794-7.354). 
A) pIgR expression in pancreatic ducts. Normal (n=55), PanIN 1 (n=93), PanIN 2 (n=71), PanIN 3 (n=63), 
PDAC (n=155). Kruskal-Wallis with Dunn’s multiple comparison tests. All other comparisons show 
p<0.0001. 
B) E-Cadherin in pancreatic ducts.  Normal (n=54), PanIN 1 (n=81), PanIN 2 (n=55), PanIN 3 (n=46), 
PDAC (n=155). Kruskal-Wallis with Dunn’s multiple comparison tests. PanIN 3 versus PDAC,** 
p=0.0004. All other comparisons show p<0.0001. 





  115 
3.5 pIgR and patient survival  
Median pIgR score was calculated for all ducts for each PDAC patient. 
Patients with incomplete follow up or unable to score at least three TMA cores 
accurately were removed from survival analysis. I therefore had 88 patients (of which 
46 were male) to evaluate for the impact of pIgR expression on overall survival.  
 
Figure 3.13: Patient characteristics. 
A total of 88 patients had sufficient data for analysis. A) Age distribution amongst all PDAC patients in the 
cohort. Median age 67 (IQR, 60-73) years. B) Kaplan-Meier survival curve for patient cohort. Median 
survival 481 (IQR, 273-802) days.  
 
 Patient demographics confirm a peak age of 60-70 years and the survival 
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curve similar to other studies (236) (Figure 3.11).  
Table 11: Association of pIgR expression in PDAC with clinicopathological parameters. 
Statistical tests performed are; * t-test, ** Mann-Whitney U test, *** Chi-square test 
 
 The dichotomisation process in X-Tile allocates 0 to 3.5 as a low pIgR score, 
whilst 3.6 to 8 is considered high as the optimal cut-off (Figure 3.12 A). There was no 
difference in survival between patients expressing high or low pIgR staining scores 
(Figure 3.12 C). No difference was found in patient or pathological features based on 








N = 88 N = 60 N = 28  
Age Median 67 67 67 0.8534* 
 Range 43 – 83 46 – 83 43 – 80 
Survival (days) Median 518 486 583 0.2791** 
 95% CI 535 - 905 474 - 961 444 - 1008 
Gender Male 46 32 14 0.8950** 
 Female 42 28 14 
T Stage pT1-2 32 22 10 0.5857** 
 pT3-4 56 38 18 
Nodes pN0 36 25 11 0.8941*** 
 pN1 52 35 17 
Invasion None 22 13 9 >0.9999*** 
 Venous 7 6 1 
 Neural 20 13 7 
 Both 39 28 11 
Resection R0 59 40 19 0.3816*** 
 R1 29 20 9 
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Figure 3.14: Correlation between pIgR and survival.  
(A) Histogram of distribution of pIgR intensity scores for expression. (B) Pictorial representation of 
various population dichotomisations to determine the most optimal cut-off for differences in survival for 
high- and low-expressing pIgR patients. (C) Comparison of survival between high (grey line) and low 
(blue line) pIgR expressing patients. Log Rank, p=0.1117.  
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3.6 pIgR and systemic factors 
Having proven that pIgR is not an independent prognostic marker in PDAC in 
my limited sample of patients, I investigated its association with systemic factors to 
evaluate the association of pIgR with patient, inflammatory and tumour invasive 
characteristics.  
Theoretically, younger patients may be more able to cope with the insult of a 
larger operation and may be prone to lower rates of inflammatory complications. 
However, there have been no significant differences shown in 30-day survival and 90-
day readmission rates according to age (237). Separating the patient cohort 
according to age does not show a difference in pIgR intensity staining (Figure 3.13 
A). 
Dividing the cohort according to male and female shows no difference in pIgR 
staining intensity (Figure 3.13 B). 
The patient sample data was investigated for tumour characteristics, such as 
local invasion, differentiation of tumour and nodal involvement. Alongside this, I also 
collated patient data for pre-operative blood tests. With pIgR related in normal 
physiology to IgA and inflammatory processes, I collated data of WCC and C - 
reactive protein. These markers are currently used as an indicator of inflammation, 
thus a potential correlation between pIgR and these inflammatory markers may 
indicate a correlation with earlier stages of PDAC development. 
Dividing tumours according to pathological differentiation showed no 
difference in pIgR median intensity staining scores (Figure 3.14 A). Invasion into 
neural and venous structures confers poor survival. However, there is no association 
between pIgR staining intensity and local invasion (Figure 3.14 B). 
 
Figure 3.15: Association of pIgR expression and patient cohort. 
A) Median pIgR staining intensity score according to age does not show a difference in pIgR staining. 44-
59 (n=24), 60-69 (n=31), 70-84 (n=33). Kruskal-Wallis test, p=0.7344.  (B) Dividing the cohort according 
to male and female gender shows no difference in pIgR staining intensity. male (n=46), female (n=42). 
Paired T test, p=0.2683. 
  
Tumour resection margin involvement confers poor survival (238). R0 
resection refers to no cancerous cells seen macroscopically and R1 means 
cancerous cells seen. R2 mean gross inspection demonstrates tumour at the potential 
resection margin. R2 resections are incomplete resections.  
I have chosen to only include complete resections in R1 and R0, as R2 
resection samples were not seen in our cohort. Again, there is no association 
between pIgR and resection margin (Figure 3.14 C).  
Lymph node (LN) involvement is also known to be prognostic and as a result, 
the extent of lymphadenectomy and LN ratio has been areas of active research and 
debate (239). There is no clear consensus or guidelines on the minimum number of 
nodes that should be examined during PDAC resection, as well as the prognostic 
significance of number and ratio of involved nodes (240). Separating nodal metastasis 
negative, less than 50% nodal positive and more than 50% nodal positive also shows 







Figure 3.16: Association of pIgR expression and systemic factors. 
A) Comparing pIgR staining intensity with tumour differentiation shows no significant difference across 
the groups. Well (n=12), Moderate (n=44), poor (n=32). Kruskal-Wallis test, p=0.9184. B) Comparing 
pIgR with tumour invasion into local structures shows no significant difference across the groups. No 
Invasion (n=22), Venous invasion (n=7), Neural invasion (n=20), venous and neural invasion (n=39). 
Kruskal-Wallis test, p=0.0631. C) Comparing pIgR with resection margin shows no significant difference 
across the groups. R0 (n=59), R1 (n=29). Mann Whitney U test, p= 0.0912. D) Comparing pIgR with 
positive node ratio shows no significant difference across the groups. Node negative (n=27), under 50% 














Figure 3.17: Correlation of pIgR expression with length of In-patient stay.  
Comparing pIgR staining expression with length of in-patient stay shows no significant correlation. <10 
days (n=11), 11-20 days (n=15), >21 days (n=13), Kruskal-Wallis test, p=0.9749. Accurate data for 
hospital stay was not available for 45 patients. 
 
Length of In-patient stay is an important factor when comparing the benefits of 
different types of operative procedure as this maybe a surrogate marker for post-
operative complications (241). I did not see any correlation between pIgR staining and 
length of in-patient stay (Figure 3.15). 
 
Figure 3.18: Correlation of pIgR staining intensity and pre-operative Ca19-9 result.  
Comparing pIgR expression with pre-operative Ca19-9.  <35 (n=7), 36-99 (n=5), >100 (n=17), Kruskal-
 
 
Wallis test, p=0.1433. Data was not available for 55 patients within 3 days pre-operatively. 
Carbohydrate antigen 19-9 (Ca19-9) is currently accepted as a prognostic 
marker for survival after resection (242). I identified 29 patients who had a pre-
operative Ca19-9 within 7 days of operation. Ca19-9 value less than 35 IU/ml is 
considered normal at the Royal London Hospital. Again, there is no correlation 
between pre-operative Ca19-9 and pIgR staining intensity (Figure 3.16). 
 
Figure 3.19: Association of pIgR staining intensity and inflammatory markers. 
A)  Comparing pIgR staining score with CRP. <5 (n=8), 5-20 (n=13), > 20 (n=5), Kruskal-Wallis test, 
p=0.8871. B) Comparing pIgR with Neutrophil/ lymphocyte ratio. <2 (n=19), 2-5 (n=37), > 5 (n=15). 
Kruskal-Wallis test, p=0.0449. Dunns post comparison test; <2 vs. 2-5 p=0.0659, <2 vs. >5 p>0.999, 2-5 
vs.>5 p=0.2991.Data was no available for CRP for 62 patients and for blood counts for 15 patients within 
3 days pre-operatively. 
 
C-reactive protein is a pentameric protein found in blood plasma whose levels 
rise in response to inflammation. Although used as a sign of acute inflammatory 
response clinically, it is of minimal significance as a prognostic marker, especially in 
the post-operative period (243). However, with a correlation to potential influx of 
inflammatory mediators in the initial phase on tumour development (203), I sought to 
explore a correlation with pIgR and CRP taken within 12 hours pre-operatively. 




In order to exhaust the inflammatory association of pIgR with patient 
characteristics, I sought to investigate neutrophil and lymphocyte values. Neutrophils 
are generally considered the first line of defence and are the most abundant 
granulocyte, accounting for up to 70% of total White Cell Count. Lymphocytes account 
for B cell, T cells and Natural Killer cell populations amongst others (244).  Again, 
neutrophil and lymphocyte counts were measured within 12 hours of operation and a 
ratio was also determined (Neutrophils/ Lymphocytes), as this may have a prognostic 













3.7 pIgR and tissue factors 
PDAC is characterised by intense desmoplastic stroma containing cancer-
associated fibroblasts. These activated fibroblasts express alpha-smooth muscle 
(αSMA) and a large amount of extra-cellular matrix (79). The stroma in PDAC 
promotes tumour formation, invasion and metastasis (79). By providing a physical 
barrier, it can also be considered to aid in radio- and chemo-resistance (245). 
However, this is not universally accepted. By investigating sonic hedgehog (66) in 
PDAC and genetically engineered mouse models, Rhim et al demonstrated some 
components of the stroma can act to restrain tumour growth (65).  
 
3.7.1 αSMA Immunofluorescence staining of paraffin sections 
αSMA has been investigated previously as a potential prognostic marker for 
PDAC (246, 247), by attempting to identify a correlation between αSMA and patient 
survival. As an independent prognostic marker, no one has yet found a correlation 
with αSMA and survival. However, Sato et al noted palladin (247), which is an actin 
binding protein and has been used recently as a cancer associated fibroblast is a 
surrogate indicator of treatment after chemoradiation therapy. 
I sought to confirm previously noted findings related to αSMA, but also if there 
was any correlation with αSMA staining and pIgR expression (Figure 3.18). 
 
 
Figure 3.20: Representative images of sections from human PDAC.  
Samples stained with pIgR (green) and αSMA (red), comparing progression from normal pancreatic ducts 








3.7.2 Comparing survival with αSMA staining  
Kadaba et al investigated the role of desmoplastic stroma in the context of 3D 
organotypic models, noting in vitro a reciprocal relationship between E-cadherin and 
pIgR in cancer cells was dependent on the stromal content of human pancreatic 
cancer. I sought to corroborate these findings in vivo. 
Tumour specimens were collected from 88 PDAC patients during curative 
resections in the Royal London Hospital, Whitechapel, England, as discussed 
previously. 
TMA stained for pIgR and αSMA were scored and collated scores were 
compared to patient survival as discussed previously in Materials section. Sequential 
sections of TMA blocks were stained for pIgR and E-cadherin then αSMA and pIgR. 







Figure 3.21: Correlation between αSMA and survival.  
 (A) Histogram distribution of αSMA expression. (B) Pictorial representation of various population 
dichotomisations to determine the most optimal cut-off for differences in survival for high- and low-
expressing αSMA patients. (C) Comparison of survival between high (grey line) and low (blue line) 
expressing patients. Log Rank, p=0.341, Corrected Miller Seigmund, p=1. 
Using the X-tile program, as explained previously, the patients that had been 
scored for αSMA were dichotomised. The light blue colour represents low αSMA 
expression cohort whilst grey is the high expression cohort (Figure 3.19 A). The 
dichotomisation process allocates 0 to 4 as a low score, whilst 4.5 to 8 are considered 
high. The low scoring group had 54 patients whilst the high scoring group had 34. 
Reviewing pictorial representations of the correlation between patient survival 
and αSMA scoring, should there be a positive correlation, we would expect to see 
patches of bright red or green, based on a positive or negative correlation. The lack of 
colour indicates a poor relationship between level of score and eventual survival 
(Figure 3.19 B)  
Overall survival was assessed using the Kaplan-Meier method, where by low 
scores of combined αSMA (blue line) and high scores (grey line) are represented. 
αSMA staining intensity score alone has no impact on patient survival in this cohort 





Figure 3.22: Association of αSMA and gender. 
Dividing the cohort based on gender shows no difference in αSMA staining intensity. Male (n=46), 




Dividing the cohort according to male and female shows no difference in 
αSMA staining intensity (Figure 3.20). 
Tumour necrosis and hypoxia has been considered to be a result of systemic 
inflammation (248). Patients with neutrophil infiltration around the tumour may have a 
poorer prognosis than those without infiltration, whereas patients with lymphocyte 
around the tumour may be associated with a better prognosis (249). Circulating 
neutrophil-lymphocyte ratio is a reflection of systemic inflammation and was explored 
in 3.5. However, αSMA is a marker for activated pancreatic stellate cells (PSCs) in 
PDAC. PSCs affect cancer growth, survival, metastasis, angiogenesis and 
immunosurveillance through the secretion of various cytokines, such as CXCL12 and 
secreted protein acidic and rich in cysteine (SPARC) (250). My theory was higher 
circulating cytokines in the presence of activated stellate cells may therefore have a 
correlation. Thus I only compared the total white cell count (WCC) with αSMA 
expression. Again, blood results were included if within 12 hours pre-operatively. 
There is no correlation with αSMA staining and WCC (Figure 3.21).  
 
Figure 3.23: Association of αSMA and White cell count (WCC). 
Comparison of pre-operative WCC, with WCC results separated according to <5 (n=5), 5-7 (n=36), 7-10 
(n=33) and >10 (n=13). There is no correlation with αSMA staining and WCC. Kruskal-Wallis test, 




Correlating αSMA with pathological differentiation, i.e. well, moderate and 
poorly would attempt to demonstrate an association with increasing activated PSCs in 












Figure 3.24: Association of αSMA and tumour differentiation. 
Correlation of αSMA staining intensity with pathological tumour differentiation shows no significant 
difference. Well (n=11), Moderate (n=44), Poorly (n=33). Kruskal-Wallis test, p=0.5661.
 
3.7.3  Association of pIgR and αSMA staining 
Having investigated αSMA and pIgR independently as prognostic markers in 
PDAC, I sought to explore a direct correlation between the two. Does increasing 
activated PSCs relate to increasing pIgR expression? For each core, scores were 
given as previously described for pIgR and αSMA staining intensity. A direct plot of the 
two scores was made to investigate any association (Figure 3.23 A). 
As there are a finite number of values, each dot can represent many tens of 
cores (Figure 3.23 B). However, there is no linear progress of the dots and thus 
signifying no correlation between the two markers. Pearson r correlation coefficient 
0.504 demonstrates no direct correlation between these two markers. 
 
Figure 3.25: Correlation of pIgR and αSMA staining  
(A) A total of 375 cores had sufficient staining to be included in the analysis. Both markers ranged from 0 
to 8 for staining intensity. pIgR median score was 2; αSMA median score was 3 (B) Each core score for 








3.7.4 Picrosirius Red staining of paraffin sections 
PSCs have been identified as the main producers of abundant extracellular 
matrix (ECM) (74) associated with pancreatic desmoplastic stroma. In PDAC, several 
components of the ECM, including collagen-type1, have been shown to promote 
tumour growth, therapy resistance, and metastasis (251). Although the desmoplastic 
tissue in PDAC is a product of activated PSCs, the highest ECM deposition is not 
always found where the highest stromal activity is detected. In peri-tumoural areas, 
PSCs may outnumber the cancer cells without significant ECM deposition (252). In 
contrast, vast amounts of desmoplastic tissue may contain only a few PSCs (251).  
With regard to the temporal sequence of events, αSMA expression, which 
reflects PSC activity, should precede collagen deposition because it is the product of 
the activated PSCs (234). Through their production of matrix metalloproteinases, both 
PSCs and cancer cells can degrade the previously deposited ECM (253). Thus, 
turnover of the ECM is a dynamic process, and immunohistochemical analysis of a 
specimen may give a static picture of disparity between different disease duration and 
stromal activity.  
I have already investigated PDAC specimens in relation to the PSC marker 
αSMA. However, a relevant marker for collagen used in our lab is Picrosirius Red, 
whilst others have used Masson’s Trichrome (246). Developed by Junqueira et al in 
1979 (254), Picrosirius red has proved a useful stain to study collagen networks 
across various tissues. Debate remains over its usefulness to distinguish different 
collagen types, but it remains an accepted method of collagen analysis (255).  
It has been demonstrated previously that pancreatic cancer cells activate 
stellate cells and that PSCs in turn promote tumour growth and chemoresistance 
through excessive ECM production in vitro (256). I sought to confirm previously noted 





Figure 3.26: Picrosirius Red stains in tissue sections of human PDAC.  
Scale bar 150µm  
 
As previously described in with pIgR and αSMA, I attempted to identify a link 
between Picrosirius red and survival of PDAC patients. I performed the observation 
with 56 patients and I used X-tile, as described previously to dichotomise the group. 
With results ranging from 15 to 12566, X tile identified low expression as 15 to 313 
(n=24). Whilst 320 to 12566 was the high expression (n=32) (Figure 3.25 C).  The 
middle pictorial representation of correlations between patient population and 
Picrosirius red scoring demonstrates patches of bright red, identifying a potential 
correlation.  
Overall survival was assessed using the Kaplan-Meier method, where by low 
scores of combined Picrosirius red (blue line) and high scores (grey line) are 
represented. There is a clear separation of the blue and grey lines, with a supposed 
poor prognosis with lower Picrosirius red staining. 
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Figure 3.27: Association of Picrosirius red and survival. 
(A) Histogram distribution of Picrosirius Red expression. (B) Pictorial representation of various population 
dichotomisations to determine the most optimal cut-off for differences in survival for high- and low-
expressing Picrosirius Red patients. (C) Comparison of survival between high (grey line) and low (blue 
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line) expressing patients. Log Rank, p=0.0942, Corrected Miller Seigmund, p=0.517473. 
 
My data demonstrates high collagen deposition showed a trend towards better 
survival which has been demonstrated previously (234). Erkan et al also noted a 
paradoxical correlation with αSMA and collagen (234). I could find no correlation 
between αSMA and collagen deposition (Figure 3.26).  
 
Figure 3.28: Correlation of Picrosirius Red and αSMA staining.  
Correlating the two markers shows a Pearson correlation co-efficient of -0.085. n=53 
 
3.7.4 Association of pIgR and Picrosirius Red staining 
Having investigated Picrosirius red and pIgR independently as prognostic 
markers in PDAC, I sought to explore a direct correlation between the two. Does 
increasing stromal content relate to increasing pIgR expression? For each core, 
scores were given as previously described for pIgR and Picrosirius red staining 
intensity. A direct plot of the two scores did not show a correlation (Figure 3.27 A). 
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Figure 3.29: Correlation of pIgR and Picrosirius red.  
(A) pIgR staining ranged from 0-8, whilst Picrosirius red ranged up to 45000. (B) Normalised Picrosirius 
red values compared to pIgR score. Pearson’s correlation coefficient r= -0.1758.  
 
A total of 260 cores had sufficient staining to be included in the analysis. 
Picrosirius Red values range up to 45000. In an attempt to normalise the Picrosirius 
red data, I scaled the data using X-tile. Staining intensities were rationalised as 
follows:  0-99:   1 
  100-1199:  2 
  1200-6999: 3 
  >7000:  4 
The main aim for normalising the Picrosirius red data was to enable me to 
potentially combine the already investigated markers to form a potential panel to 
investigate PDAC. Picrosirius red had such a large scale of effectively infinite 
numbers, that it would have been difficult had I not. However, investigating correlation 
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with pIgR and Picrosirius red staining intensity shows no direct correlation; even with 
the normalised score (Figure 3.27 B). 
 
3.7.5 Comparing survival of combined pIgR, αSMA and Picrosirius Red  
Having independently investigated pIgR, E-cadherin, αSMA and Picrosirius 
red expression and their relationship to PDAC, I sought to explore the correlation of 
the markers and the potential for a potential prognostic marker for PDAC. Sequential 
sections of the TMAs were stained for pIgR, E-cadherin, αSMA and Picrosirius red 
and staining scores for each core were recorded, as described previously.  Having 
normalised Picrosirius red scores, these values were used rather than raw values. 
Scores for each marker were combined and median scores taken to compare with 
survival characteristics. 
Two combinations of markers were investigated: 
1) pIgR, αSMA and Picrosirius red 





Figure 3.30: Panel 1 (pIgR, αSMA and Picrosirius Red combined score) biomarker for PDAC.  
(A) Histogram distribution of Panel 1 biomarker expression. (B) Pictorial representation of various 
population dichotomisations to determine the most optimal cut-off for differences in survival for high- and 
low-expressing Panel 1 biomarker patients. (C) Comparison of survival between high (grey line) and low 
 
 
(blue line) expressing patients. Log Rank, p=0.0568, Corrected Miller Seigmund, p=0.4305. 
 
Figure 3.31: Panel 2 (pIgR, αSMA, Picrosirius Red and E-cadherin) biomarker for PDAC  
(A) Histogram distribution of panel 2 expression. (B) Pictorial representation of various population 
dichotomisations to determine the most optimal cut-off for differences in survival for high- and low-
expressing Picrosirius Red patients. (C) Comparison of survival between high (grey line) and low (blue 
 
 
line) of panel 2 expressing patients. Log Rank, p=0.8745, Corrected Miller Seigmund, p=1. 
For simplicity, the 3 marker variant (pIgR, αSMA and Picrosirius red) will be 
referred to as Panel 1, whilst the version with all four markers (pIgR, αSMA, 
Picrosirius red and E-cadherin) will be referred to Panel 2.   
Figure 3.28 A demonstrates an X-tile based histogram showing population 
division. The light blue colour represents low Panel 1 expression score cohort whilst 
grey is the high expression cohort. The dichotomisation process allocates up to 9.5 as 
a low score, whilst 10 to 15.5 is considered high. The low scoring group had 30 
patients whilst the high scoring group had 26. 
Unlike in previous correlation, a pictorial representation of correlations 
between patient population and Panel 1 scoring demonstrate patches of bright red. 
This indicates a potential correlation (Figure 3.28 B).  
Overall survival was assessed using the Kaplan-Meier method, where by low 
scores of combined Panel 1 (blue line) and high scores (grey line) are represented. 
High combined expression of Panel 1 is associated with a trend towards poor 
prognosis (Figure 3.28 C).  
In Figure 3.29 A, the light blue colour represents low Panel 2 expression score 
cohort whilst grey is the high expression cohort. The dichotomisation process 
allocates up to 12.5 as a low score, whilst 13 to 19 is considered high. The low 
scoring group had 25 patients whilst the high scoring group had 25. 
Unlike Panel 1, the addition of a forth marker shows no obvious bright patches 
and one would assume no direct correlation (Figure 3.29 B).  
Overall survival was assessed using the Kaplan-Meier method, where by low 
scores of combined Panel 2 (blue line) and high scores (grey line) are represented. 
High combined expression is associated with poorer survival, but the data is not as 




3.8 Discussion  
 
3.8.1 Role of pIgR in gastrointestinal cancers 
I have summarised the finding on pIgR expression in all cancers to date, 
suggesting a different role in various cancers studied. This may be related to 
baseline, physiological pIgR expression as a requirement for mucosal defences 
where mucosal surfaces are exposed to high antigen load. Consequently it is not 
surprising that the initial work regarding the role of pIgR focused around 
Streptococcal pneumonia, suggested a possible role in oropharyngeal cancers 
(182).  The hypothesis that pIgR was being used by cancer cells as a mechanism to 
spread or metastasise could, however, not be proven (257). 
Subsequently, Ocak et al (258) investigated pIgR in lung cancers, noting 
down-regulation of pIgR in lung cancer, suggesting that loss of pIgR expression 
occurs early and is associated with enhanced cancer cell proliferation and poor 
prognosis. Fristedt et al (171) investigated pIgR in the context of oesophageal and 
gastric adenocarcinoma, noting high pIgR expression independently predicted a 
decreased risk of recurrence and an improved survival in patients with 
adenocarcinoma of the upper gastrointestinal tract.    
In locations where pIgR is naturally expressed within the gastrointestinal 
tract, loss of expression is correlated with reduced survival such as the observation 
made in colorectal and oesophageal cancers (168, 178). In those normal tissues 
where pIgR is not expressed, cancers of those tissues expressing pIgR are 
associated with a poor prognosis, for example hepatocellular carcinoma (176, 179). 
Three studies have investigated pIgR with regards to different pancreatic 
lesions using unique approaches. Fristedt et at investigated the role of pIgR in all 
peri-ampullary and pancreatic lesions by studying human tissue samples. They 
identified that high pIgR expression signifies a favourable tumour phenotype and 
 
 
low expression independently predicts a reduced survival in patients with pancreatic 
and periampullary cancers (176). However, this correlation combined survival data 
for all peri-ampullary lesions, which I have demonstrated are different in pIgR 
expression. This includes duodenal lesions (duodenum normally expresses pIgR) 
along with cancers from pancreatic and biliary tract (mucosa of these organs 
normally do not express pIgR). Moreover, data from Fristedt et al relating solely to 
PDAC lesions only did not demonstrate any correlation with survival, which was in 
keeping with my observations, that there was no impact on survival based on pIgR 
expression in human PDAC. Thus, it is important to ensure histologically different 
entities are not considered together, and a dedicated research group is involved in 
such studies. 
Park et al identified nine candidate biomarkers, including pIgR to distinguish 
between mucinous pancreatic and non-mucinous cysts using mass-spectrometry 
(259). Accurate differential diagnosis of mucinous cysts from non-mucinous cysts is 
extremely important, because mucinous cysts have a malignant potential and 
requires surgical resection. Park et al noted pIgR was increased in mucinous cystic 
lesions, compared to non-mucinous lesions. However, I did not have access to 
study mucinous cystic lesions.  
Kadaba et al (70) briefly investigated pIgR in organotypic models, but to the 
best of my knowledge, this is the first detailed study on the potential prognostic 
value of pIgR expression in human PDAC, alongside differential expression in other 
peri-ampullary cancers. It is important to demonstrate or refute correlation with other 
known prognostic features within PDAC such as differentiation or stage or resection 
margin or nodal involvement. With diligent data collection I was able to demonstrate 
that at least in my small sample size (n=88) there was no correlation between these 




3.8.2 Association of pIgR in the pre-malignant phases of PDAC 
Evaluating pIgR expression in human PDAC has provided intriguing 
observations. Whilst there was no demonstrable correlation between pIgR expression 
and survival, detailed analysis into PanIN lesions demonstrated its expression 
appears most prominent during pre-malignant phases of PDAC. Eventually the pre-
ponderance of PanIN lesions within a given histological slide for PDAC may influence 
the overall score for that section, as invasive cancer ducts or poorly differentiated 
cancers do not seem to express pIgR. 
A valid criticism would be identification of PanIN lesions in 
immunofluorescence slides where the morphological aspects of PanIN may be lost. 
However, with adequate training on H&E sections, and understanding nuclear 
arrangement as well as nuclear atypia, and overall ductal morphology (260, 261) on 
DAPI stain of immunofluorescence slides, alongside verification from corresponding 
H&E slides, one can ascertain PanIN lesions within immunofluorescence slides as 
demonstrated by me.  
The proof of this approach perhaps lies in the analysis of E-cadherin 
expression, which has been demonstrated before {Froeling, 2009 #3115}, to be lost 
as PanIN progress from normal duct to invasive cancer. 
Loss of E-cadherin is also noted with increased stromal activity (202). 
As E-cadherin expression decreases during PanIN progression, pIgR 
expression increases. However, expression of both pIgR and E-cadherin are reduced 
in invasive PDAC. Since IgA is not expressed in PDAC or normal pancreas, then 
enhanced expression of pIgR in PanIN could not be associated with immunoglobulin 
response during PanIN formation. Therefore, I investigated the association of PDAC 
with stromal content. Since stromal content could not be assessed at PanIN level due 
to proximity of varying grade of PanIN lesions, I had to resort to summary pIgR 





3.8.3 Effect of pIgR on stromal content 
αSMA was used to investigate active PSCs and Picrosirius red to identify 
collagen content.  
  The combination of activated PSCs and collagen representing desmoplastic 
stroma has been suggested to be a potential prognostic marker for patients 
undergoing surgery in PDAC (234). The indication from the data is that independently, 
low collagen expression in PDAC samples is perhaps, associated with a better 
prognosis, whilst there is no direct correlation with αSMA, at least from the analysis of 
these TMA cores.  
There may be a number of explanations why the data are not in agreement with the 
activated stromal index published by Erkan et al (234) and Fokas et al (246). The 
cores focused on the cancer aspect of the PDAC. Therefore, the prominent stromal 
index is not, perhaps, fully represented within the TMAs analysed. Furthermore the 
rigorous and independent nature of dichotomisation used by X-tiles may not allow for 
minor statistical differences. Moreover, we can speculate that the stromal activity is a 
dynamic process, and there may be differences in patients recruited in various 
institutions.  
Lastly, I tried to reconcile the stromal activity and pIgR expression with PDAC 
progression as demonstrated in in vitro experiments by Kadaba et al (70). Since, the 
summary score of cores were used for Picrosirius Red, αSMA and pIgR or E-cadherin 
expression; I lost the micro-environmental cues pertinent to each PanIN lesion. It was 
impossible to attribute regional stromal activity to a particular PanIN in a 3D PDAC 
tissue. Hence, I could not confirm the relationship between stromal activity and pIgR 




3.8.4 Role of pIgR as a biomarker in PDAC 
Pancreatic cancer remains one of the most difficult cancers to treat with the 
poorest prognosis. The key to improving survival rates in this disease is early 
detection and monitoring of disseminated and residual disease. However, this is 
hindered due to lack reliable diagnostic, prognostic and predictive biomarkers which 
mean that the majority of patients succumb to their condition within a few months  
The most commonly used tumour biomarker in PDAC is carbohydrate antigen 
19–9 (CA 19–9), the sensitivity is around 79 % and specificity 82 %. However, CA19-
9 levels increase in other non-malignant pancreatic disorders such as chronic 
pancreatitis and other gastrointestinal malignancies (262).  
Histopathological prognostic factors include tumour size and grade, lymph 
node status, resection margins and vascular or neural invasion (263). Molecular 
tumour markers such as MUC5A, CEACAM, E-cadherin, β-catenin, Ki-67 index, 
oestrogen receptor, HER2 expression, have been studied as potential prognostic 
markers. Unlike breast and other carcinomas, no molecular markers have been 
established to guide treatment and decision-making in patients with PDAC (264).  
Identification of biomarkers that accurately predict disease recurrence or 
response to chemotherapy would be of substantial aid in individual risk assessment 
and treatment selection, and may even lead to novel therapies by becoming targets 
for molecular intervention in specific subsets of patients (265). Immunohistochemical 
(IHC) analysis is used widely for evaluating molecular markers in clinical tissue 
specimens. Although several more sophisticated methods, such as cDNA microarray, 
fluorescence in situ hybridization and quantitative reverse transcriptase–polymerase 
chain reaction, are being translated into clinical practice. 
A potential issue with establishing a reliable biomarker has been the genetic 
basic of PDAC. PDAC tumours arise through an accumulation of a large number of 
genetic and epigenetic aberrations (266). No two cancers may have the same profile 
 
 
of genetic mutations. The dependence on an independent prognostic genetic marker 
then becomes difficult. However, the idea of combining multiple markers, that 
independently have no direct survival benefit, makes more logical sense. 
In combination, my chosen four biomarkers (pIgR, αSMA, Picrosirius red and 
E-cadherin) did not show as good a correlation with survival as three biomarkers 
(pIgR, αSMA, Picrosirius red). E-cadherin is usually expressed in normal pancreas 
and is not well expressed in development to PDAC and is lost relatively early in PDAC 
progression. 
  However, using pIgR in combination with αSMA and Picrosirius red 
demonstrates that a low combined score may confer a survival benefit.     
As an independent prognostic marker in PDAC, pIgR does not show any 
survival benefit, however I have demonstrated it is expressed during pre-malignant 
stages of PDAC. Due to the inherent complex nature of PDAC progression and co-
existence of various stages of PanIN lesions with invasive malignancy, as well as the 
multiple genetic mutations involved, pIgR may however provide more use in 
combination with other biomarkers, such as stromal activity and content.  
In order to get additional cues as to drivers of and consequences of pIgR 
expression in pancreatic cancer, I next explored the role of pIgR and cancer cell and 
stromal behaviour in in vitro systems.   
 














The epithelial–mesenchymal transition (EMT), in which epithelial cancer cells 
lose their polarity and become motile mesenchymal cells, has been implicated in 
cancer invasion and metastasis (190). Cancer cells undergoing EMT appear to exhibit 
properties of cancer stem cells (267), override oncogene-induced premature 
senescence and apoptosis (268), and contribute to immunosuppression. Ai et al 
identified pIgR and its role in EMT induction in vitro (81). Having explored pIgR 
expression in vivo in Chapter 3, I now sought to understand the function of pIgR in 
vitro.  
I initially determined baseline expression of pIgR in pancreatic cell lines. I had 
access to a panel of PDAC cell lines, which have all been Short Tandem Repeat 
(STR) profiled and screened for mycoplasma (269, 270).  
Alongside cancer cells, we also have an immortalised pancreatic stellate cell 
(PS1) created by previous members in the group (215). As described in Materials and 
Methods chapter, these were STR profiled and verified with stellate cell markers 
GFAP, Desmin, Vimentin and αSMA (73). 
To further our understanding of the role of stellate cells in different tumours, 
we aimed to isolate stellate cells from patients with periampullary cancers (as 
previously documented in Chapter 2). The method of collection initially started via 
outgrowth and developed to tumour digestion (unpublished observations). Each 
patient we could obtain viable stellate cell populations were given numerical values, 
with the MOCRI prefix. Cells were validated with stellate cell markers GFAP, Desmin, 






4.2 pIgR expression in pancreatic cancer cells  
Initial work with PDAC cell lines focused on extraction of protein from lysate, 
as described in Section 2.10, which identified Capan 1 as the only positive line for 
pIgR expression at protein level (Figure 4.1 A). This was despite attempts using all 
pancreatic cancer cell lines in our laboratory. Western blotting had previously also 
identified expression was at 110kDa, significantly higher than the 83kDa according to 
manufacturer’s documentation (Sigma Aldrich, HPA012012). Treatment of Capan 1 
with Tunicamycin demonstrated a specific band to be placed at 83kDa (Figure 4.1). 
This confirmed the 110kDa band to be a true representative band of pIgR, but with 
glycosylation. No expression of pIgR was seen in PS1 cells or in primary pancreatic 
stellate cells (Figure 4.2). 
 
 
Figure 4.1: Protein expression of pIgR in PDAC cell lines.  
(A) pIgR expression across all PDAC cells confirms only protein expression with Capan 1 cells. (B) 
Treatment with Tunicamycin confirms post-translation glycosylation of pIgR, demonstrating an effect of 
breaking down glycosylation bonds renders molecular weight at 83 kDa. HSC70 was used as loading 




Figure 4.2: Protein expression of pIgR in primary pancreatic stellate cells.  
No expression of pIgR was seen in primary pancreatic stellate cells. Β-Actin was used as loading control. 
Representative of three biological replicates. 
 
 
Figure 4.3: mRNA expression of pIgR in pancreatic cancer cells and PS1 cells. 
qRT-PCR of pancreatic cancer cells and PS1 cells. CT values were normalised to Capan1 (positive at 
 
 
protein level). Summary of three biological replicates. No significant difference in CT expression across 
cell types.  
 
Immunofluorescent staining of various PDAC cancer cells on coverslips produced 
variable results that were not easily reproducible. Despite Capan1 being positive at 
protein level, a valid expression was not obtainable by immunofluorescence at 2D. 
This was true for all cell lines, and after numerous attempts to optimise, the technique 
was abandoned (results not shown). Despite Capan1 showing positive expression at 
protein level, there was a similar expression of pIgR at mRNA level across all 
pancreatic cancer and PS1 cell lines tested (Figure 4.3). Thus pIgR is present in 
pancreatic cancer cells at an mRNA level, but is not translated to protein, except in 
Capan1 cells.   
 
4.3 Upstream precursors to pIgR in pancreatic cancer cells 
Regulation of pIgR expression involves complex interactions among host-, 
microbial- and environmental-derived factors, involving transcriptional and 
posttranscriptional mechanisms (94). A variety of cytokines, hormones and microbes 
influence have been investigated (92), and previous work from Froeling et al (59) 
identified Interleukin 1, 4 and Tumour Necrosis Factor Alpha to be secreted by 
pancreatic stromal cells.  
Our group has investigated the role of ATRA in modulating PSC phenotype 
previously. Quiescent PSCs store retinol, which is lost upon activation (59). ATRA, in 
combination with certain cytokines has been shown to enhance pIgR expression 
(271).   
Previously negative cell lines for pIgR protein expression, HT29 (colorectal 
cancer cell line chosen because of use by other groups (272)), AsPC1 (PDAC cell 
line, used by Kadaba et al) and DEChTERT (normal pancreatic cell line, used as 
 
 
normal control), were treated over various time courses with IL1, IL4, TNF-α and in 
combination with ATRA, at various concentrations in order to elicit an upregulation in 
pIgR protein expression. 
HT29 cells have been used by others as a control for pIgR expression. As a 
cell line originating from a human colorectal adenocarcinoma, the expression of pIgR 
is likely to be varied. As such, some groups have demonstrated it expresses pIgR 
(81), whilst others have proved that HT29 does not express pIgR (271).  
Takenouchi-Ohkubo et al demonstrated ATRA-treated HT-29 cells 
constitutively expressing pIgR, showed a significantly high expression of pIgR in the 
presence of IL-4 and/or IFN-γ, compared to ATRA-untreated cell (271).  
My wild type HT29 cells did not naturally express pIgR, and this was checked 
with samples of other passages of HT29 from other groups within the laboratory (data 
not shown). These cells were also STR profiled to confirm true HT29 origin. After 48 
hours of treatment with either 70% ethanol (control), 10µg of IL4 or TNFα with or 
without ATRA, cells demonstrated no expression or upregulation of pIgR expression 
(Figure 4.4 A).  
AsPC1 cells had 48 hours of treatment with either 70% ethanol (control), 10µg 
of IL4 or TNFα with or without ATRA. No expression or upregulation was seen in pIgR 
expression (Figure 4.4 B). DEChTERT cells were exposed to varying concentrations 
of IL1, IL4 and TNFα (known upstream regulators of pIgR) for 48 hours, but no 












Figure 4.4: Effect of introduction of cytokines and ATRA to PDAC cells.  
(A) HT29 cells had 48 hours of treatment with either 70% ethanol (control), 10µg of IL4 or TNFα with or 
without ATRA shows no upregulation of pIgR in HT29 cells (B) AsPC1 cells had 48 hours of treatment 
with either 70% ethanol (control), 10µg of IL4 or TNFα with or without ATRA. No up-regulation of pIgR is 
seen in AsPC1 cells.  (C) DEChTERT cells were exposed to varying concentrations of IL1, IL4 and TNFα, 
with no effect on pIgR expression. Representative of three biological replicates. 
 
Figure 4.5: Other attempts at over-expression of pIgR.  
(A) Culturing PS1 cells, at a ratio of 2:1 with AsPC1 cells in 2D causes no change in pIgR expression. (B) 
PS1 cells cultured for 72 hours had their media collected and the collected media (CM) was added 




Kadaba et al noted pIgR expression in 3D organotypic models with AsPC1 and 
PS1 cells (70). However, culturing PS1 cells, at a ratio of 2:1 with AsPC1 cells in 2D 
shows no expression of pIgR (Figure 4.5 A). 
Stellate cells are known to secrete cytokines (59), and as there is no 
correlation in 2D culture, but it is seen in 3D, I sought to investigate if PS1 secretions 
provided any upstream effect. PS1 cells cultured for 72 hours had their media 
collected and the collected media (CM) was added directly to AsPC1 cells with or 




4.4 Effect of pIgR siRNA on Capan1 pancreatic cancer cells 
Initial work with PDAC cell lines focused on extraction of protein from lysate, 
as described in Section 2.10, which identified Capan1 as the only positive line for 
pIgR expression at protein level.  
Kadaba et al (70) identified pIgR to be a gene upregulated in PDAC by qRT-
PCR. Their work suggested that pIgR may be involved in numerous cellular functions, 
such as cell signalling, inflammatory response, cell growth, death and movement. In 
order to investigate the effects on proliferation on Capan1 cancer cells, siRNA was 
used to knockdown pIgR. I could successfully down-regulate pIgR expression in 
Capan1 cells for up to five days (Figure 4.6 A & B). 
Conditioned media from cells treated with siRNA (Figure 4.4) was collected 
with or without Tunicamycin treatment to show down regulation of pIgR secretion, but 
no pIgR glycosylation (Figure 4.7).  
Cells treated with pIgR siRNA were plated in 6 well pates and cell counts were 
determined for up to six days. Untreated Capan1 and non-targeting siRNA acted as 
controls, demonstrating a reduction in cell counts after pIgR RNAi suggesting a 








Figure 4.6: Effect of pIgR siRNA on Capan 1 pancreatic cancer cells.  
Capan1 cells alone, non-targeting (NT) or pooled siRNA of pIgR represented at protein level, confirming 
down-regulation. (A) siRNA treatment of Capan 1 over 3, 4 and 5 days demonstrating down-regulation of 
pIgR at day 4. (B) Quantification of Western blot analysis over 3, 4 and 5 days at 20nm concentration of 
siRNA. Values are mean and SEM (n=4).  Comparisons made by Kruskal-Wallis test followed by Dunn’s 













 Figure 4.7: Secreted pIgR after siRNA with or without Tunicamycin treatment.  
siRNA treated cells with or without Tunicamycin treatment. Collected media was concentrated and 




Figure 4.8: Cell proliferation after pIgR siRNA. 
Cells treated with pIgR siRNA were plated in 6 well pates and cell counts were taken at 3, 4, 5 and 6 






4.5 Effect on pIgR expression in cancer cells after RNAi and co-culture 
with PSC in 3D 
The tumour stroma has been shown to play a definitive role in PDAC 
progression. 3D organotypic models also provide a more physiologically relevant 
system to reproduce the stroma effect on cancer cells (219). The raised air-liquid 
model, which was used to investigate PDAC cell invasion and the effect pIgR has, is 
fed from below creating a gradient that stimulates cancer cells to invade. Due to the 
assumed short -acting nature of the RNAi, the organotypic cultures were harvested on 
day 5, much shorted than previously observed (231). Once harvested, sections were 
immunostained for pIgR and E-cadherin. 
In order to be able to distinguish between the direct effect of pIgR on cancer 
cells or an indirect effect via changes occurring in PSC, the results were compared 
with an organotypic culture of cancer cells alone. 
Capan1 cells demonstrated that pIgR down-regulation after RNAi could not be 
maintained in 3D mono- and co-culture models (Figure 4.9 and 4.10). There was no 
difference in cancer cell number either upon RNAi and PSC co-culture (Figure 4.11). 
There was also minimal stellate cell invasion, possibly due to the short (five days 














Figure 4.9: Effect of pIgR expression in cancer cells alone after RNAi in organotypics.  
Representative images of organotypics with cancer cells only, compared with relevant H&E images. pIgR 
(green) and E-Cadherin (red). (n=3). Scale bar 20µm. Representative of two biological replicates with 





Figure 4.10: Effect of pIgR expression in cancer cell co-cultures after RNAi in organotypics.  
Representative images of organotypics with stellate cells, compared with relevant H&E images. 
pIgR (green) and E-Cadherin (red). (n=3). Scale bar 20µm. Representative of two biological replicates 
 
 
with three technical replicates each. It should be noted that the number of stellate cells is low due to 
delayed proliferation of stellate cells in these conditions. 
 
 
Figure 4.11: Effect of pIgR knockdown in Organotypics. 
A) Comparing intensity of pIgR intensity stain. B) Comparing cell counts. Shown is median with inter 
quartile range. All observations were normalised to control (Capan1). Six experimental repeats were 
carried out resulting in 18 high power field measurements. Comparisons made by Kruskal-Wallis test 








4.6 Optimisation of pIgR shRNA  
Since it was possible that the short-interfering RNA was not a valid approach 
in 3D co-culture models, I investigated long-term knockdown after shRNA.  pIgR 
shRNA plasmids were kindly donated by Jing Ai, Shanghai Institute of Material 
Medica (179). 
Puromycin dose was based on historical work in our group and the 
recommendation from the Ai group in order to retain the shRNA construct. However, 
immediate addition of Puromycin within 24 hours of shRNA transfection led to 
inexplicable cell death. It was assumed that the stress of manipulating RNA and 
immediate addition of Puromycin may have caused cell death. This shortcoming was 
addressed by delayed addition of Puromycin 48 hours after introduction of shRNA, 





4.7  Effect of pIgR shRNA on Capan1 pancreatic cancer cells  
Capan1 cells successfully transfected with relevant shRNA were selected with 
RPMI media 10%FBS and 1µg/ml Puromycin, as their P-BABE vector backbone 
contained Puromycin resistance. Transfected cells were subsequently lysed and 
confirmed pIgR knockdown by Western blot (Figure 4.12). 
 
Figure 4.12: Confirmation of pIgR knockdown. 
A)  Western blot confirming knockout at protein level of shRNA. B) Quantification of shRNA Western blot 
analysis. Values are mean and SEM (n=4).  Comparisons made by Kruskal-Wallis test followed by 
Dunn’s post-hoc analysis. *** p<0.001, ** p<0.01. 
 
Figure 4.13: qRT-PCR of wild type and transfect shRNA.  
CT values were normalised to housekeeping gene GAPDH. In order to further quantify the result, a fold 
change, relative to positive and negative controls provided and expression fold change. Delta CT values 
normalised to wild type (Capan1). Values are median and Interquartile range (n=3).  Comparisons made 





Figure 4.14: Phase contrast microscopy of pIgR shRNA cells  
Phenotypic effect of pIgR shRNA on Capan 1 pancreatic cancer cells. Representative of multiple cultures 
and passages. Scale bar 20µm. 
 
Western blot and quantification analysis confirms knockdown of pIgR in 
Capan1 cells (Figure 4.11). qRT-PCR further confirms knockdown of pIgR at mRNA 
level (Figure 4.13). Morphology of Capan1 cells stably expressing pIgR shRNA 
causes cells to lose the luminal forming ability and become colony forming (Figure 
4.14). Capan1 cells and cells with relevant shRNA were plated in 6 well plates at a 









Figure 4.15: Cell counts after 7 days of shRNA transfection. 
Cells treated with pIgR shRNA were plated in 6 well pates and cell counts were taken every days for 7 
days. Values represented as mean and SEM (n=3). Capan1 vs. NT, Friedman test, p>0.9999, Capan1 
vs. shRNA1, Friedman test, p=0.0021, Capan1 vs. shRNA2, Friedman test, p=0.0437. 
 
Sequential cell counts demonstrate loss of pIgR correlate with reduced rate of 
cell proliferation as demonstrated after RNAi (Figure 4.15). Loss of pIgR however 
shows no association with changes in EMT markers expression, such as E-cadherin 
and Vimentin (Figure 4.16). Further functional analysis of cells depleted of pIgR 
demonstrates reduced migration, adhesion and viability (Figure 4.17). pIgR knockout 
in scratch assay demonstrates a delay in wound closure, and also an apparent lack of 
luminal formation demonstrated in wild type cells (Figure 4.18).  
Taken together, these results demonstrated the Capan1 cells after pIgR 
knockdown seem to proliferate less and are less invasive, suggesting stabilisation of 
epithelial phenotype. 





Figure 4.16: Association of pIgR knockdown and EMT. 
Capan1 wild type and Capan1 cells transfected with relevant shRNA were lysed as discussed in 
Materials section 2.4. Probing membranes for E-cadherin and Vimentin show no change, despite pIgR 







Figure 4.17: Functional effects of pIgR shRNA on Capan1 cells. 
A) MTS assays (WST-1 reagent), carried out in triplicates, demonstrates viability, normalised to Capan1 
cells. (Kruskal-Wallis P=<0.0001). Capan1 and shRNA2, 0.0003 for Capan1 and shRNA1. N=3. B) After 
24 hours in transwell, a significantly lower percentage of cells that hat pIgR knockout had migrated 
compared to WT and NT Capan1 cells. (Kruskal-Wallis P=<0.0001) or Capan1 and shRNA2 0.0019, 
0.0034 for capan1 and shRNA1. N=3. C) After 30 minutes incubation with fibronectin, remaining cells 
with pIgR knockout were significantly lower compared to WT and NT. (Kruskal-Wallis P=<0.0001). N=3. 




















Figure 4.18: Effect of pIgR knockdown on scratch assay. 
A) Comparison images taken at day 0 and 72 hours later. shRNA variants have a tendency to form 
islands of cells, rather than wild type and non-targeting variants. B) Statistical analysis is based on area 
of surface not covered by cells, normalised to Capan1 cells. Comparisons made by One-way ANOVA 











4.8 Effect of pIgR shRNA on cancer cell phenotype using organotypic 
model 
Capan 1 cells successfully transfected with relevant shRNA were selected with 
RPMI media 10%FBS and 1µg/ml Puromycin, as their P-BABE vector backbone 
contained Puromycin resistance, whilst Capan 1 cells alone were used as a control. 
The treated or control Capan 1 cells were admixed with PS1 stellate cells in a 2:1 
ratio (shown previously (70) ) to be the optimum PS1: cancer cell ratio for invasion in 
this organotypic model). Gels were raised to a grid and fed with fresh medium every 
other day for 10 days in total. I could confirm enhanced proliferation of cancer cells 
upon addition of stellate cells. However, this effect was abrogated upon pIgR 
knockdown. In order to be able to distinguish between the direct effect of pIgR on 
cancer cells or and indirect effect via changes occurring by stellate cells, the results 
were compared with an organotypic culture of cancer cells alone. 
Representative H&E stained images of sections of Capan1 and shRNA 
variations with and without co-culture of stellate cells are shown in Figure 4.19 and 
4.20. Overall, organotypic gels containing stellate cells are more contracted and 
thicker, with a more significant cancer cell layer thickness. Wild type Capan1 and NT 
organotypics with stellate cells also appear to form more luminal structures compared 
to pIgR depleted gels. More interestingly, lack of pIgR in Capan1 cells causes less 
contracted gels with a reduced cancer cell layer thickness. These interactions suggest 
that pIgR expression may increase stellate cell activity. I therefore sought to quantify 
these preliminary observations.    
Capan1 cells have been noted to form luminal structures in organotypic 
models, and this is more pronounced when cultured with PS1 cells, which has been 
noted previously (70). However, cancer cells with pIgR knockdown form smaller and 
fewer luminal structures, and this was not revoked after addition of stellate cells 
(Figure 4.21). 
Organotypic gels cultured with PS1 cells are more contracted and have thicker 
gels than compared gels containing only cancer cells (219). Knockout of pIgR in 
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cancer cells co-cultured with PS1 cells had thinner and longer gels confirming activity 
of stellate cells was affected (Figure 4.22).   
Cancer cell and stellate cells proliferate at various rates and knockout of pIgR 
caused reduction in cancer cell proliferation as confirmed by total cell area and 
quantitating analysis of nucleic staining. The layer of cells formed at the top of the 




















Figure 4.19: Haematoxylin and Eosin stained sections from organotypic cultures. 
Representative images of H&E stained sections with organotypics of cancer cells alone or in co-culture 





Figure 4.20: Close up cross sectional H&E stained sections from Organotypic cultures.  




















Figure 4.21: Effect of pIgR knockout in cancer cell lumen formation. 
Summary data from organotypics with and without PS1 cells. Data is from three experiments, all 
performed in replicate, thus a total of 9 organotypics per condition. A) Box and whisker plot with median 
interquartile range of diameter of luminal structures formed. Luminal structures were defined as having 
epithelial cells circumferentially. n=9.  Comparisons made by Kruskal-Wallis test followed by Dunn’s post-
hoc analysis. ** p<0.01.B) Box and whisker plot with median interquartile range of number of luminal 
structures formed. Luminal structures were defined as having epithelial cells circumferentially. N=9. 

















Figure 4.22: Effect of pIgR knockout in Organotypic gel structure. 
Summary data from organotypics with and without PS1 cells. Data is from three experiments, all 
performed in replicate, thus a total of 9 organotypics per condition. A) Box and whisker plot with median 
interquartile range of organotypic gel thickness. N=9. Comparisons made by Kruskal-Wallis test followed 
by Dunn’s post-hoc analysis. ** p<0.01. B) Box and whisker plot with median interquartile range of 
organotypic gel length. N=9. Comparisons made by Kruskal-Wallis test followed by Dunn’s post-hoc 
analysis. *** p<0.001, ** p<0.01, * p<0.05. 
 







Figure 4.23: Effect of pIgR knockdown in cancer cell layer.  
Summary data from organotypics with and without PS1 cells. Data is from three experiments, all performed in 
replicate, thus a total of 9 organotypics per condition. A) Box and whisker plot with median interquartile range 
of organotypic cell area (as explained in Materials 2.9). N=9. Comparisons made by Kruskal-Wallis test 
followed by Dunn’s post-hoc analysis. *** p<0.001, ** p<0.01, * p<0.05. B) Box and whisker plot with median 
interquartile range of organotypic nucleic staining. N=9. Comparisons made by Kruskal-Wallis test followed by 
Dunn’s post-hoc analysis. *** p<0.001, ** p<0.01, * p<0.05. C) Box and whisker plot with median interquartile 
range of organotypic cell layer thickness. N=9. Comparisons made by Kruskal-Wallis test followed by Dunn’s 
post-hoc analysis. *** p<0.001, ** p<0.01, * p<0.05. 
  
4.9 Changes in epithelial and stromal activity upon pIgR knockdown  
First of all, I wanted to confirm sustained knockdown of pIgR in organotypic 
cultures. Addition of PSC seems to enhance pIgR expression in parental and NT cancer 
cells, but not after pIgR knockdown in cancer cells. pIgR knockdown remains apparent in 
3D models, even after addition of stellate cells, although addition of stellate cells seemed 
to increase the intensity of pIgR staining (Figures 4.24 – 4.26).  
 pIgR deplete and wild type Capan1 organotypics with and without stellate cells 
were stained with numerous markers to investigate the effect of pIgR in a 3D model of 
PDAC. E-cadherin had been demonstrated in Chapter 3 to have an inverse interaction 
with pIgR to a degree furthermore Froeling et al had demonstrate loss of E-cadherin upon 
addition of stellate cells (202). E-cadherin is noted to be reduced upon addition of stellate 
cells, but there is no change after pIgR knockdown (Figure 4.27). 
 Cytokeratins are proteins of keratin-containing filaments in epithelial cells. There 
numerous subtypes and loss of cytokeratin can be associated with malignant 
transformation (273). Addition of stellate cells bears no effect on cytokeratin expression; 
however, loss of pIgR is associated with an increase in cytokeratin expression (Figures 
4.28 - 4.30). This is likely to represent that loss of pIgR has stabilised Capan1 cells to a 
more stable epithelial phenotype. 
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αSMA has been used as a marker of stellate cell activity (59). Upon pIgR 
knockdown in cancer cells, αSMA is significantly reduced. Therefore it is possible that 
pIgR expression may modulate PSC activity (Figure 4.31). 
The ZEB family interacts with other transcriptional regulators and their activities are 
modulated by post-translational modifications and phosphorylation. These proteins trigger 
and EMT by repression of epithelial markers and activation of mesenchymal properties 
(273). Modulation of pIgR had no effect on Zeb1 expression, but its expression seems 
inversely associated with E-cadherin, and increases with stellate cell activation (Figure 
4.32 – Figure 4.34). 
Picrosirius red was also investigated in Chapter 3 and is used as a surrogate 
marker for ECM content. Its expression was increased in organotypics with stellate cells. 
Although not significant, it appears that lack of pIgR seems to reduce expression of 
Picrosirius red (Figures 4.35 and 4.36). This observation maybe in keeping with reduced 
αSMA activity noted in Figure 4.31. 
Ezrin has been used as a marker for apico-basal polarity and for lumen formation 
(274), since my observations noted reduced luminal formation in organotypics lacking 
pIgR in cancer cells. Ezrin expression in cancer cells is markedly reduced upon pIgR 
knockdown (Figures 4.37 and 4.38).  












Figure 4.24: pIgR and E-cadherin interaction in pIgR knockdown 3D models. 









Figure 4.25: pIgR and E-cadherin interaction in pIgR knockdown 3D models. 








Figure 4.26: pIgR expression in organotypic models. 
Box and whisker plot with median and interquartile range of pIgR staining intensity. N=9. Comparisons made 




Figure 4.27: E-cadherin expression in organotypic models. 
Box and whisker plot with median and interquartile range of E-cadherin staining intensity. N=9. Comparisons 




Figure 4.28: Cytokeratin interaction in pIgR knockdown 3D models. 
















Figure 4.29: Cytokeratin and αSMA interaction in pIgR knockdown 3D models. 
















Figure 4.30: Cytokeratin expression in organotypic models. 
Box and whisker plot with median and interquartile range of Cytokeratin staining intensity. N=9. Comparisons 




Figure 4.31: αSMA expression in organotypic models. 
Box and whisker plot with median and interquartile range of αSMA staining intensity. N=9. Comparisons made 






Figure 4.32: Zeb1 interaction in pIgR knockout 3D models. 




Figure 4.33: Zeb1 interaction in pIgR knockout 3D models. 
Representative images of organotypics with pIgR shRNA. Zeb1 (green). Scale bar 20µm. 
 
 
Figure 4.34: Zeb1 expression in organotypic models. 
Box and whisker plot with median and interquartile range of Zeb1 staining intensity. N=9. Comparisons made 




Figure 4.35: Picrosirius Red expression in pIgR knockout 3D models. 
Representative images of organotypics with pIgR shRNA. Scale bar 20µm.  
 
 
Figure 4.36: Picrosirius red expression in organotypic models. 
Box and whisker plot with median and interquartile range of Picrosirius red staining intensity. N=9. 







Figure 4.37: Ezrin expression in pIgR knockout 3D models. 
Representative images of organotypics with pIgR shRNA. Scale bar 20µm.  
 
 
Figure 4.38: Ezrin expression in organotypic models. 
Box and whisker plot with median and interquartile range of Ezrin staining intensity. N=9. Comparisons made 




4.10 Optimisation of pIgR over-expression 
Since there was only one pancreatic cancer cell line with endogenous pIgR 
protein expression, and there was no induction of pIgR protein expression on other 
pancreatic cancer cell lines, I wanted to confirm my observation of pIgR knockdown 
with pIgR over-expression in cancer cells not expressing pIgR. pIgR cDNA was 
obtained (pBS-pIgR cDNA was a gift from Pamela Bjorkman (Addgene plasmid 
#12109)). Stab culture overnight elicited colonies, which were picked and processed 
using QIAprep Spin Miniprep Kit (QIAGEN, #27104) as per manufacture’s protocol, to 
generate enough DNA for subsequent introduction to mammalian cloning vectors.  
 
4.10.1  Optimisation of Digestion 
In order to extract the 2900 base pair sequence of pIgR, attempts were made 
to optimise its extraction. Initial work focused on PCR based digestion, to ligate and 
amplify volumes. However, multiple reading errors in the PCR process gave negligible 
amounts of DNA (data not shown). 
Next I focused on gel digestion with ligation enzymes. Again, multiple issues 
arose. Initial digestion with ECOR1 alone and double digestion with Xba1 and HindIII 
revealed a large band around 3000 base pairs. The assumption was that this band 
contained both pIgR (2900 base pairs) and the vector pBluescript (3200 base pairs). 
To further the protocol, an additional third enzyme, Bsa1, was added, in an attempt to 
split the transport vector and reveal pIgR. Although simple in theory, based on each 
enzyme having different optimal temperature and buffers, optimizing the reaction 
proved troublesome in real terms. However, addition of further bovine serum albumin 
(NEB, #B9000) provided stable digestion conditions (Figure 4.39). 
 
4.10.2  Optimisation of Cloning 
Having successfully ligated the pIgR segment, the aim was to introduce it into 
a mammalian vector, for eventual introduction into human cells. Initial attempts with 
MIGR1 (a backbone provided by Dr Capasso, Barts Cancer Institute) proved 
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unsuccessful, with low volumes and subsequent negative transformation of bacteria. 
Change was made with use of PCDNA4T/0 (Invitrogen #V1020-20) as the vector. 
Although initially high volumes and long digestions were used, eventually success 
was made with low volume of pIgR and PCDNA4T/0 (Figure 4.39). 
 
4.10.3  Optimisation of Transformation 
The cloned sequence was introduced into pCDNA4/TO (Invitrogen) in the 
presence of T4 DNA ligase (NEB) and transformed into TOP10 (DH5α) Escherichia 
coli (E. Coli) cells. Transformed cells were selected on a LB plate containing 100 
µg/mL ampicillin at 37°C for 16 hours. Positive transformants were inoculated into LB 
broth containing 100 µg/mL ampicillin for plasmid propagation. The following day, the 
liquid broth was centrifuged for 10minutes at 5400rpm, half of the product being 
retained for glycerol stock (500µl glycerol and 500µl broth media) for long-term 
storage. The other half was subsequently processed using QIAprep Spin Miniprep Kit 
(QIAGEN, 27104) as per manufacture’s protocol, to generate enough DNA for 
subsequent introduction into cancer cells. 
 
4.10.4  Other methods of pIgR expression 
With inconclusive results, 3 further methods of pIgR expression were sought. 
The OSLO vector (Human pIgR cDNA-containing pcDNA3.1 (+)) was a generous gift 
from Dr Finn-Eirik Johansen (Rikshospitalet University Hospital, Oslo, Norway) (179). 
After sequencing confirmation (Figure 4.41), Hela, AsPC1 and Capan2 cells were 
exposed to OLSO vector, as described in material and methods.  
TrueORF pIgR plasmid and HaloTag plasmids were introduced to Hela cells, 
AsPC1 and Capan2 cells, as described in Materials and methods. pIgR expression 
was manipulated in Hela cells only (Figure 4.42). No expression was seen in AsPC1 






Figure 4.39: Confirmatory images of digestion of pIgR cDNA. 
Attempts to optimise ligation of pBS-pIgR cDNA using multiple digestion enzymes. A) Digestion using 
ECOR1 only linearised the plasmid, but did not separate pIgR from the pBluescript vector, providing a 
band just under 6000bp. B) Digestion with Xba1 and HindIII also linearised, but did not separate pIgR 
from the transport vector, providing bands at 3000bp. C) Attempts to run the digestion of products shown 
in Figure 4.39 B for a longer time in a higher viscosity gel also failed to release pIgR from the backbone 
vector. D) Combination digestion using Xba1, HindIII and Bsa1 revealed pIgR (top band) and separated 
the pBluescript into two separate fragments. E) Confirmatory digestion of ligated products form figure D 





Figure 4.40: Modification of PCDNA4/T0 
Restriction enzymes HindIII and Xba1 were used in order to introduce pIgR, whilst Bsa1 was used to 












Figure 4.42: Introduction of pIgR into Hela cells 
3 methods of pIgR introduction into cells were trialled. OSLO vector was successfully induced into Hela 
cells, which were used as an experimental control, as to a certain degree was OriGene vector (C45 DDK 
is the associated tag). I was unable to introduce HaloTag into Hela cells (results not shown). This 




4.11 Discussion  
Technical aspects 
I encountered a number of technical difficulties which I tried to overcome with 
guidance from senior colleagues and my supervisors. Some of these technical 
challenges remain insurmountable, but gave me valuable training. 
The first problem was unavailability of a second pancreatic cancer cell line 
with endogenous pIgR protein expression. I expanded by panel from initial 5 to over 
12 cancer cell lines. I confirmed mRNA expression. However protein expression could 
be demonstrated only in once cancer cell line. I wanted to ensure that I had correct 
cell lines, and they were repeat STR profiled for this project. I am pleased to report 
that there was no contamination from other cell lines, and the cell lines were 100% 
match with ATCC profiles. Next I ensured that the cancer cell lines were mycoplasma 
negative as this may affect protein expression. 
Ideally, the experiments should be repeated with shRNA to demonstrate the 
role of pIgR on cell migration, adhesion and invasion using another cell line. The rate 
of pIgR synthesis is influenced by a number of cytokines and hormones that regulate 
the mucosal immune system. The HT-29 human colon carcinoma cell line has widely 
been used to model the regulation of pIgR expression by intestinal epithelial cells (95, 
118). Expression of pIgR by HT-29 cells is up-regulated by the pro-inflammatory 
cytokines IFN-γ (275), TNF-α (276) and IL-1, as well as the Th2-type cytokine IL-4 
(277, 278). Studies of cytokines produced by in vitro-stimulated human intestinal 
lamina propria mononuclear cells suggested that the pro-inflammatory cytokine IFN-γ 
was the central regulator of pIgR expression by intestinal epithelial cells (279).  
At the molecular level, IFN-γ has been shown to increase pIgR mRNA levels 
by a mechanism dependent on de novo protein synthesis (280). IFN-γ and TNF-α 
cause de novo synthesis of the transcription factor IFN regulatory factor (IRF)-1 in 
HT-29 cells and that IRF-1 binds to a regulatory element in exon 1 of the human pIgR 
gene (281). IRF-1 mRNA is known to be induced by pro-inflammatory cytokines, and 
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this transcription factor has widely been implicated in the regulation of immune 
responses (282). However, addition of cytokines into PDAC cell lines proved 
unsuccessful.  
pIgR mRNA level was similar across multiple PDAC cell lines. However, only 
in Capan1 was the mRNA translated to protein level expression. Attempts to treat 
other cells lines that were negative at protein level for pIgR with known upstream 
cytokine regulators ultimately proved unsuccessful. Attempts to trigger pIgR 
expression at 2D level with interactions with stellate cells also proved unsuccessful. 
However, pIgR in 3D models is expressed, even in cells lines negative for 
pIgR in 2D models. PDAC cell lines are, like in PDAC itself, amassed with a multitude 
of genetic mutations. Although I was unable to effect a successful over expression in 
PDAC cell lines, it remains likely that previously investigated cytokines are unlikely 
upstream regulators in PDAC cells. Also, in the context of PDAC cell lines, there is 
likely to be a post-translational effects that are controlled by other genes, hence we 
are unable to see expression at protein level. Another theory maybe that pIgR 
expression is associated with earlier, more epithelial characteristics, which 
established PDAC cancer cells lines, may silence post transcriptionally. We have 
access to human PDAC cell lines, but no human PanIN cell lines are available to 
further investigate.  
Initial attempts with organotypic cultures using siRNA transfected cells proved 
to provide no obvious difference in cell counts or pIgR expression between controls 
and pIgR siRNA treated cells. Numerous reasons exist, but namely the duration of the 
siRNA effect may well have worn off. Maximal 2D knockdown was noted up to day 7, 
however, by the time transfection had occurred, and loaded onto gels and extracted, 
time duration was 10 days. The short duration of siRNA was overcome with difficulties 
using shRNA to induce stable knockdown of pIgR to enable long-term organotypic 
cultures and demonstrate the relationship between stroma and pIgR expression, as 
postulated by Kadaba et al., (70).  
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Further issues were encountered to enable stable transduction of pIgR using a 
range of vector expression systems, to get success only in the HeLa cells in the time 
allocated for my PhD studies. 
 
4.11.2 Downstream effect of pIgR 
Inflammatory responses to tumour development are two-fold, initially serving 
to eliminate rogue premalignant and malignant cells (283). As tumours progress, they 
evade immune surveillance, but also provoke an inflammatory response (284). By 
recruiting a variety of immune cells types, tumours are able to secrete a diverse set of 
signalling molecules that promote cellular proliferation and remodel the extracellular 
matrix to favour epithelial mesenchymal transition (EMT) (285).   
Cancer cells undergoing EMT imitate the properties of stem cells (267), can 
bypass processes such as apoptosis (268) and contribute to immunosuppression 
(286), thus providing a role of EMT in tumour recurrence. The role and actions of EMT 
also seem to provide a link between inflammation and cancer metastasis (284).  
Rhim et al, (287) investigated the process of EMT, identifying tagged cells 
invading the bloodstream, prior to frank malignancy in transgenic murine model of 
PDAC. They implied that the epithelial cancer cells lost cellular polarity as well as cell-
cell adhesion, to gain migratory and invasive properties similar to mesenchymal cells.  
The ability of certain inflammatory stimuli to activate and stabilise EMT 
provides a link between inflammation, EMT and subsequent tumour and metastatic 
development. Ai et al (81) identified pIgR as one such manifestation of linkage of 
inflammatory stimulus. pIgR aberrant expression has previously been associated with 
HCC (192). Ai et al demonstrated pIgR over-expression is implicated in EMT initiated 
cross talk of transforming growth factor beta (TGF-ß) with inflammatory mediators 
(TNF-α, interferon-γ and interleukin-4). TGF-ß has been implicated in later stages of 
tumour progression with carcinogenesis and in promoting immune evasion and 
angiogenesis (193).  
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Ai et al also noted in vivo, pIgR-overexpressing cells yielded higher numbers 
of experimental lung metastases compared with control counter-parts, thus pIgR over-
expression can promote colonisation. They also detected decreased levels of 
epithelial markers (E-Cadherin, cytokeratins) and increased levels of mesenchymal 
markers, Vimentin and phospho-Smad2/3 in pIgR-over-expressing HCC specimens 
(194).  
Previous work in our laboratory (70) identified aberrant expression of pIgR in 
3D organotypic culture models and a possible role of pIgR in cell signalling, cell 
growth, death and movement using in silico analysis. 
 
4.11.3 Modulation of pIgR in PDAC cancer cells 
Initial work in 2D cell culture, identified only Capan1, amongst nine pancreatic 
cancer cell lines, to have pIgR protein detectable by Western blotting. Therefore, 
subsequent work utilised Capan1 cells. Initial knockdown with pIgR siRNA in Capan1 
cells identified a significant reduction in cell counts over a period of six days, when 
compared to control siRNA transfected cells. This is in keeping with reports 
suggesting that pIgR is linked to cell proliferation (70). There may be potential off-
target effects from siRNA as noted by a slight reduction in pIgR expression with non-
targeting siRNA. 
In order to counter act potential off-target effects, shRNAs and its longer term 
knockdown was utilised. The shRNA plasmids were a kind donation from the Ai group 
(179), providing a non-targeting shRNA construct along with two pIgR shRNA 
constructs. Initial siRNA data with progressive cell counts demonstrates Capan1 
cancer cells lacking pIgR proliferate at a slower rate than those with pIgR. This was 
also confirmed with a stable transfection. 
  Organotypic cultures utilising shRNA provided interesting observations, 
relating to the effect of lack of pIgR. Organotypic gels, when lacking pIgR had 
reduced cell number and were longer and thicker than wild-type and non-targeting 
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Capan1 cells. However, expression of pIgR and EMT markers, when normalised to 
cell number was not affected. 
 It would appear that lack of pIgR provides lack of luminal formation and 
reduction in rates of proliferation. However, Capan1 are considered well differentiated 
cell line and are more likely to be affected by minor genetic alterations. Interestingly, 
both at 2D and 3D model level of PDAC, pIgR has no interaction with EMT markers.   
 
4.11.4 Modulation of pIgR and its association with EMT 
E-cadherin is a marker of cell-cell junctions and adhesion. Loss of E-cadherin 
is associated with progression to EMT (70). The inherent inverse relationship of pIgR 
with E-Cadherin raises the question as to the involvement of pIgR with phases of 
Epithelial-to-Mesenchymal transition (EMT). Rhim et al (287) investigated the effect of 
EMT, identifying tagged cells invading bloodstream, prior to frank malignancy being 
able to be detected. Their suggestion was a process by which epithelial cells lost 
polarity and cell-cell adhesion, instead gaining migratory and invasive properties to 
become mesenchymal cells.  
They noted circulating pancreatic cells maintained a mesenchymal phenotype, 
exhibited stem cell properties and seeded the liver. The notion of EMT and 
invasiveness were most abundant at inflammatory foci, and induction of pancreatitis 
increased the number of circulating pancreatic cells, and treatment with 
immunosuppressive Dexamethasone abolished dissemination. Further work has also 
investigated the emergence of PanIN lesions and the appearance of inflammatory 
stroma characterised by activated fibroblasts and myeloid-derived cells (288). 
Inflammation is commonly correlated with tumour initiation and progression (289), 
whilst accelerating pancreatic carcinogenesis in adult Kras mutant mice (290).    
Rhim’s work was the clearest confirmation that, at the earliest stages of 
cellular invasion in situ, inflammation enhances cancer progression in part by 
facilitating EMT and entry into circulation. His work also went on to identify markers to 
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distinguish between epithelial and mesenchymal cells, demonstrating E-cadherin, 
EpCAM and CK19 were all used as markers of epithelial cell linage, whilst Zeb1 and 
YFP were to be used as mesenchymal markers.  
As epithelial cells undergo EMT and progressively lose their E-Cadherin 
content, pIgR inversely increases and Cytokeratin increases with loss of pIgR, 
suggesting a pro-cancerous role for pIgR in the early stages of PDAC development. 
However, investigating pIgR expression in organotypics with Zeb1 and E-
cadherin demonstrated no significant change due to expression of pIgR, but a change 
only related to stellate cell presence.  
 
4.11.5 Modulation of pIgR and its association with stellate cells 
Questions arise also about the effect of PS1 stellate cells in 3D culture and the 
effect they may well have on pIgR expression in cancer cell as well as cancer cell 
proliferation. It is likely that as cells are arranged in a luminal forming structure, with 
the enhancement of the apico-basal polarity, the expression of pIgR is more apparent 
(274). Interestingly, the organotypic models lacking pIgR had lower stellate cell 
activity (noted by αSMA and Picrosirius red staining), proving a role for pIgR in 
stellate cell activity.   
Ultimately, knockdown of pIgR in Capan1 cells has a profound reduction in cell 
proliferation, adhesion and its effects in organotypics, primarily activation of stellate 
cells. However, as an independent factor in PDAC development, it is masked by a 
multitude of other genetic mutations and post-translation effects. 
Cell culture work was perhaps slightly inhibited due to the nature of when pIgR 
is likely to be most significant, i.e. during the pre-malignant phases. Unlike other 
cancers such as breast, pre-malignant cell lines are as yet not established for PDAC. 
However, it may be of interest in the future to investigate its function in modulating 





         
I have investigated pIgR expression in human PDAC. Investigating its role in 
other cancers demonstrates varied roles and this may be related to baseline, 
physiological pIgR expression as a requirement for mucosal defences where mucosal 
surfaces are exposed to high antigen load.  
pIgR expression in human PDAC provides no demonstrable correlation 
between pIgR expression and survival. There is however a prominent expression of 
pIgR during pre-malignant phases of PDAC, whilst invasive cancer ducts and poorly 
differentiated cancers do not express pIgR. 
As E-cadherin expression decreases during PanIN progression, pIgR 
expression increases. However, expression of both pIgR and E-cadherin are reduced 
in invasive PDAC.  
 
Attempts to introduce pIgR into other pancreatic cells lines provided 
disappointing results. pIgR mRNA level was similar across multiple PDAC cell lines. 
However, only in Capan1 was the mRNA translated to protein level expression. This 
may be due to previously investigated upstream regulators of pIgR not affecting the 
same result in PDAC, whilst post-transcriptional effects by other genes cannot be 
accounted for in 2 and 3D modelling.  
  
Modulation of pIgR in 2D investigations demonstrated Capan1 cancer cells 
lacking pIgR proliferate at a slower rate than those with pIgR. Organotypic gels, when 
lacking pIgR had reduced cell number and were longer and thicker than wild-type and 
non-targeting Capan1 cells. However, expression of pIgR and EMT markers, when 
normalised to cell number was not affected. Lack of pIgR provides lack of luminal 
formation, correlated with Ezrin expression and reduction in rates of proliferation.  
Investigating pIgR expression in organotypics with EMT markers, Zeb1 and E-
cadherin demonstrated no significant change due to expression of pIgR, but a change 
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only related to stellate cell presence. This may signify that pIgR provides secondary 
signalling pathways for stellate cells in PDAC. 
The exact nature of when pIgR is most expressed and likely to be of most 
significance, i.e. during pre-malignant phases in PanIN lesions is yet to be addressed. 
Unlike other cancers, such as breast, pre-malignant cell lines are yet to be 
established and we would need pre-malignant cell lines to further investigate its 
functional role in modulating stellate cell activity.  
 It would also be interesting to study the role of pIgR in a model of pancreas 
development such as chronic pancreatitis also, which is a known risk factor for PDAC, 
to further investigate its interaction with inflammatory conditions such as auto-immune 
pancreatitis.  
 Its expression is early in PDAC development and ultimately, pIgR confers no 
survival benefit independently. However use of pIgR in combination with αSMA and 





We have reviewed the role of pIgR in PDAC and noted its expression in early 
stages of PDAC. It is disappointing the lack of results seen, as there is interesting in 
vitro data regarding its manipulation of organotypics. Whilst I think in vivo analysis of 
pIgR in human PDAC is complete.  Independently, pIgR expression confers no 
survival benefit in PDAC.  
It would be interesting to pursue the idea of pIgR as part of a biomarker panel. 
Whether pIgR, in combination with a series of other biomarkers, due to tumour 
heterogeneity, could provide us a panel to identify lesions such as PDAC or mucinous 
lesions remains to be seen.  
The link with chronic pancreatitis and PDAC could be investigated further with 
pIgR. To understand the progression from a chronic, benign condition to a malignancy 
and the role of pIgR would be interesting. It may be interesting to look at more patient 
biopsies of chronic pancreatitis and its correlation to PDAC development.  
It would be interesting to investigate pIgR in vitro in cell lines mimicking human 
PanIN stages, which are as yet unobtainable. We were unable to provide adequate 
answers to the regulation of pIgR expression, and this may have been answered with 
adequate modulation of pIgR in other cell lines.  
Ultimately, within the confines of the time-limit of a PhD, these ideas and 
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0 is dea          1 is male, 2 is female 1 is well, 2 is moderate, 3is poor0 is nil, 1 is venous, 2 i       positive total
A 1 59 4647 Neuroendocrine 0 2
A 2
A 3
A 4 57 5295 Ampullary Cancer 2 1
A 5
A 6
A 7 47 713 Ampullary Cancer 0 2
A 8
A 9
A 10 62 41 Duodenal adenoma 0 1
A 11
A 12
A 13 78 35 AMP adenoma 0 2
A 14
A 15
A 16 67 169 AMP adenoma 0 1
A 17
A 18
A 19 43 1099 AMP adenoma 2 2
A 20
A 21
A 22 53 964 cholangio 0 2 2 3 2 0 0 13 0
A 23
A 24
A 25 75 1910 cholangio 2 2 2 2 0 0 0 6 0
A 26
A 27
A 28 53 261 cholangio 0 1 17.9 16.6 0.5 3 3 1 1 1 4 1
A 29
A 30
A 31 58 3785 endocrine 2 1 0 6 0
A 32
A 33
A 34 68 3297 ipmn 2 2 9.5 5 3.6 0 10 0
A 35
A 36
A 37 67 299 pdac 2 1 6.5 5 0.9 3 2 1 1 1
A 38
A 39
A 40 68 1129 pdac 0 1 2 3 3 1 4 16 0
A 41
A 42
A 43 66 2838 cp 2 2
A 44
A 45
A 46 55 #VALUE! cp
A 47
A 48
A 49 60 356 PDAC 0 2 4.9 3.1 1.4 3 0 0
A 50
A 51
A 52 58 8 Cholangiocarcinoma 0 1 4.7 3.8 0.8 <5 2 0 0
A 53
A 54
A 55 67 299 pdac 2 1 6.5 5 0.9 3 2 1 1 1
A 56
A 57
A 58 46 261 pdac 0 1 9.2 5.3 3 3 2 0 1 1 7 1
A 59
A 60
A 61 60 499 pdac 0 1 6.9 4.4 1.7 1 2 0 1 2 6 1
A 62
A 63
B 1 69 798 pdac 0 2 11.4 8.7 2.1 4 2 1 0
B 2
B 3
B 4 67 860 pdac 0 2 6.9 3.7 2.6 3 3 0 0 2 3 0
B 5
B 6
B 7 64 579 pdac 0 2 10.3 7.7 1.9 1 3 0 0 0 12 0
B 8
B 9
B 10 67 827 pdac 0 2 3.8 2.3 1.2 71 2 3 1 1 1 8 0
B 11
B 12
B 13 63 4393 pdac 0 1 9.4 5.3 3.3 1 2 0 0 0 2 0
B 14
B 15
B 16 58 528 pdac 0 1 6.5 3.8 2.1 9 3 2 3 1 2 5 0
B 17
B 18
B 19 58 3912 pdac 0 1 9.9 6.9 2.1 6 3 3 2 0 0 7 1
B 20
B 21
B 22 75 750 pdac 0 2 10.2 7.8 1.8 36 115 1 2 3 1 3 14 0
B 23
B 24
B 25 72 587 pdac 0 1 9.5 7.2 1.8 209 1283 2 1 0 0 0 7 0
B 26
B 27
B 28 47 105 pdac 0 1 9.9 9.1 0.3 32 185 3 3 3 1 2 11 0
B 29
B 30
B 31 79 1171 pdac 0 2 5.9 3.5 1.9 <1 1 2 0 0 0 3 0
B 32
B 33
B 34 77 134 pdac 0 2 4.8 3.3 1 12 1281 2 2 3 0 0 13 0
B 35
B 36
B 37 47 48 pdac 0 1 7.1 3.4 3 8 722 2 3 0 1 8 12 1
B 38
B 39
B 40 66 539 pdac 0 2 6.1 4 1.5 <5 35 3 2 3 0 0 7 1
B 41
B 42
B 43 60 879 pdac 2 1 6 5 0.6 11 2 3 0 1 5 7 0
B 44
B 45
B 46 80 211 pdac 0 2 7.1 4.2 2.3 85 2 1 2 0 0 6 0
B 47
B 48
B 49 54 1190 pdac 0 1 6.9 1.7 4.7 2 2 2 1 7 33 0
B 50
B 51
B 52 69 685 pdac 0 1 13.5 11.9 0.9 <5 29 3 3 3 1 1 8 0
B 53
B 54
B 55 68 1129 pdac 0 1 2 3 3 1 4 16 0
B 56
B 57
B 58 64 2506 Ampullary Cancer 0 1 10.5 6.3 1.7 16 2 3 0 1 3 3 0
B 59
B 60
B 61 69 526 pdac 0 2 6.3 3.8 1.5 10 549 2 3 3 1 8 19 0
B 62
B 63
B 64 71 101 pdac 0 2 9.4 6.8 1.5 2 3 3 1 2 8 0
B 65
B 66
B 67 77 357 pdac 0 2 8 3.5 3.6 2 3 2 0 0 7 1
B 68
B 69
B 70 57 387 pdac 0 1 8.1 5.5 1.4 <5 65.4 2 2 2 1 3 12 0
B 71
B 72
B 73 49 454 pdac 0 1 7.9 6 1.3 <5 2 3 2 1 2 15 0
B 74
B 75
B 76 62 461 pdac 0 2 8 4.3 2.8 <5 2 3 0 0 0 3 1
B 77
B 78
B 79 64 543 pdac 0 1 7.7 6.7 0.7 2 1 2 0 0 15 1
B 80
B 81
B 82 62 341 pdac 0 1 5.3 2.8 1.3 8.3 2 3 0 0 0 6 0
B 83
B 84
C 1 74 599 pdac 2 2 10.6 9.1 0.8 2 3 3 1 1 6 0
C 2
C 3
C 4 80 119 pdac 2 2 5.6 4.6 0.7 2 3 2 1 2 2 1
C 5
C 6
C 7 61 34 pdac 2 1 7.7 5.2 1.2 36 523 1 2 3 1 2 8 1
C 8
C 9
C 10 66 399 pdac 0 2 6.8 2.9 3.2 177.5 3 3 3 1 1 7 0
C 11
C 12
BLOCK PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC
A PDAC PDAC PDAC PDAC PDAC PDAC CP CP CP
N N N N N N CP CP CP
N N N N N N N N N
N N N N N N N N N
N N N N N N N N N
N N N N N N N N N
BLOCK PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC
B PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC
PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC
PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC
PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC
PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC
PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC
BLOCK PDAC PDAC PDAC
C PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC PDAC

TMA Pos Age Survival Diagnosis dead sex WCC neutro lymphocyCRP ca 19-9 differentiationT (of TNM) other N (of TNM) Nodes Total nodes Resection
0 is dea1 is male, 2 is female 1 is well, 2 is moderate, 3is p0 is nil, 1 is venous, positive total (R0/1/2)








































































E9-E14 56 74 PDAC 2 1 4.4 2.3 1.5

































































a1 a2 a3 a4 a5 a6 a7 a8 a9 a10 a11 a12 a13 a14 a15 a16
b1 b2 b3 b4 b5 b6 b7 b8 b9 b10 b11 b12 b13 b14 b15 b16
c1 c2 c3 c4 c5 c6 c7 c8 c9 c10 c11 c12 c13 c14 c15 c16
d1 d2 d3 d4 d5 d6 d7 d8 d9 d10 d11 d12 d13 d14 d15 d16
e1 e2 e3 e4 e5 e6 e7 e8 e9 e10 e11 e12 e13 e14 e15 e16
f1 f2 f3 f4 f5 f6 f7 f8 f9 f10 f11 f12 f13 f14 f15 f16
g1 g2 g3 g4 g5 g6 g7 g8 g9 g10 g11 g12 g13 g14 g15 g16
h1 h2 h3 h4 h5 h6 h7 h8 h9 h10 h11 h12 h13 h14 h15 h16
i1 i2 i3 i4 i5 i6 i7 i8 i9 i10 i11 i12 i13 i14 i15 i16
TMA Pos Tissue Age Survival Diagnosis dead sex WCC neutro lymphocyCRP ca 19-9 differentiationT (of TNM) other N (of TNM) Nodes Total nodes Resection 
0 is de1 is male, 2 is female 1 is well, 2 is moderate, 3is0 is nil, 1 is venous, 2 positive total (R0/1/2)


























































































Plastic a1 a2 a3 a4 a5 a6 a7 a8 a9 a10 a11 a12 a13 a14
b1 b2 b3 b4 b5 b6 b7 b8 b9 b10 b11 b12 b13 b14
c1 c2 c3 c4 c5 c6 c7 c8 c9 c10 c11 c12 c13 c14
d1 d2 d3 d4 d5 d6 d7 d8 d9 d10 d11 d12 d13 d14
e1 e2 e3 e4 e5 e6 e7 e8 e9 e10 e11 e12 e13 e14
f1 f2 f3 f4 f5 f6 f7 f8 f9 f10 f11 f12 f13 f14
g1 g2 g3 g4 g5 g6 g7 g8 g9 g10 g11 g12 g13 g14
h1 h2 h3 h4
TMA Pos Age Survival Diagnosis dead sex WCC neutro lymphocyCRP ca 19-9 differentiationT (of TNM) other N (of TNM) Nodes Total nodes Resection (R0/1/2)
0 is de 1 is male, 2 is female 1 is well, 2 is moderate, 3is0 is nil, 1 is venous positivetotal
















































































































Plastica1 a2 a3 a4 a5 a6 a7 a8 a9 a10 a11 a12 a13 a14
b1 b2 b3 b4 b5 b6 b7 b8 b9 b10 b11 b12 b13 b14
c1 c2 c3 c4 c5 c6 c7 c8 c9 c10 c11 c12 c13 c14
d1 d2 d3 d4 d5 d6 d7 d8 d9 d10 d11 d12 d13 d14
e1 e2 e3 e4 e5 e6 e7 e8 e9 e10 e11 e12 e13 e14
f1 f2 f3 f4 f5 f6 f7 f8 f9 f10 f11 f12 f13 f14
g1 g2 g3 g4 g5 g6 g7 g8 g9 g10 g11 g12 g13 g14
h1 h2 h3 h4 h5 h6 h7 h8 h9 h10 h11 h12 h13 h14
i1
TMA Pos Age Survival Diagnosis dead sex WCC neutro lymphocyCRP ca 19-9 differentiation T (of TNM) other N (of TNM) Nodes Total nodes Resection (R0/1/2)
0 is de1 is male, 2 is female 1 is well, 2 is moderate, 3is p0 is nil, 1 is venous positivetotal














































































































































Plastica1 a2 a3 a4 a5 a6 a7 a8 a9 a10 a11 a12 a13 a14
b1 b2 b3 b4 b5 b6 b7 b8 b9 b10 b11 b12 b13 b14
c1 c2 c3 c4 c5 c6 c7 c8 c9 c10 c11 c12 c13 c14
d1 d2 d3 d4 d5 d6 d7 d8 d9 d10 d11 d12 d13 d14
e1 e2 e3 e4 e5 e6 e7 e8 e9 e10 e11 e12 e13 e14
f1 f2 f3 f4 f5 f6 f7 f8 f9 f10 f11 f12 f13 f14
g1 g2 g3 g4 g5 g6 g7 g8 g9 g10 g11 g12 g13 g14
h1 h2 h3 h4 h5 h6 h7 h8 h9 h10 h11 h12 h13 h14
i1 i2 i3 i4 i5 i6 i7 i8 i9 i10 i11 i12 i13 i14
j1 j2 j3 j4 j5 j6 j7 j8 j9 j10 j11 j12 j13 j14
TMA Pos Age Survival Diagnosis dead sex WCC neutro lymphocyCRP ca 19-9 differentiationT (of TNM) other N (of TNM) Nodes Total nodes Resection (R0/1/2)































































































G5 56 118 Insulinoma 2 1
G6
G7

























H15 H14 H13 H12 H11 H10 H9 H8 H7 H6 H5 H4 H3 H2 H1
G15 G14 G13 G12 G11 G10 G9 G8 G7 G6 G5 G4 G3 G2 G1
F15 F14 F13 F12 F11 F10 F9 F8 F7 F6 F5 F4 F3 F2 F1
E15 E14 E13 E12 E11 E10 E9 E8 E7 E6 E5 E4 E3 E2 E1
D15 D14 D13 D12 D11 D10 D9 D8 D7 D6 D5 D4 D3 D2 D1
C15 C14 C13 C12 C11 C10 C9 C8 C7 C6 C5 C4 C3 C2 C1
B15 B14 B13 B12 B11 B10 B9 B8 B7 B6 B5 B4 B3 B2 B1
A15 A14 A13 A12 A11 A10 A9 A8 A7 A6 A5 A4 A3 A2 A1
TMA Pos Age Survival Diagnosis dead sex WCC neutro lymphocyCRP ca 19-9 differentiation T (of TNM) other N (of TNM) Nodes Total nodes Resection (R0/1/2)
0 is de 1 is male, 2 is female 1 is well, 2 is moderate, 3is0 is nil, 1 is venous positive total (R0/1/2)
A1










































C14 40 48 NET 2 2 1
C15
D1






D8 70 294 PDAC 0 2 8.7 4.5 3.3 <5 605 2
D9
D10







D15 D14 D13 D12 D11 D10 D9 D8 D7 D6 D5 D4 D3 D2 D1
C15 C14 C13 C12 C11 C10 C9 C8 C7 C6 C5 C4 C3 C2 C1
B15 B14 B13 B12 B11 B10 B9 B8 B7 B6 B5 B4 B3 B2 B1
A15 A14 A13 A12 A11 A10 A9 A8 A7 A6 A5 A4 A3 A2 A1
TMA Pos Age Survival Diagnosis dead sex WCC neutro lymphocyCRP ca 19-9 differentiatioT (of TNM) other N (of TNM) Nodes Total nodes Resection (R0/1/2)
0 is de 1 is male, 2 is female 1 is well, 2 is moderate, 30 is nil, 1 is venous, positive total
A1
























































































































I2 73 1376 ampullary adenoma 0 3
I3
I4
P2TMA3 I4 I3 I2 I1
H15 H14 H13 H12 H11 H10 H9 H8 H7 H6 H5 H4 H3 H2 H1
G15 G14 G13 G12 G11 G10 G9 G8 G7 G6 G5 G4 G3 G2 G1
F15 F14 F13 F12 F11 F10 F9 F8 F7 F6 F5 F4 F3 F2 F1
E15 E14 E13 E12 E11 E10 E9 E8 E7 E6 E5 E4 E3 E2 E1
D15 D14 D13 D12 D11 D10 D9 D8 D7 D6 D5 D4 D3 D2 D1
C15 C14 C13 C12 C11 C10 C9 C8 C7 C6 C5 C4 C3 C2 C1
B15 B14 B13 B12 B11 B10 B9 B8 B7 B6 B5 B4 B3 B2 B1
A15 A14 A13 A12 A11 A10 A9 A8 A7 A6 A5 A4 A3 A2 A1
TMA Pos Age Survival Diagnosis dead sex WCC neutro lymphocyCRP ca 19-9 differentiation T (of TNM) other N (of TNM) Nodes Total nodes Resection (R0/1/2)
0 is de 1 is male, 2 is female 1 is well, 2 is moderate, 3is 0 is nil, 1 is venous, positive total
A1



























































































































P3 TMA1 I4 I3 I2 I1
H15 H14 H13 H12 H11 H10 H9 H8 H7 H6 H5 H4 H3 H2 H1
G15 G14 G13 G12 G11 G10 G9 G8 G7 G6 G5 G4 G3 G2 G1
F15 F14 F13 F12 F11 F10 F9 F8 F7 F6 F5 F4 F3 F2 F1
E15 E14 E13 E12 E11 E10 E9 E8 E7 E6 E5 E4 E3 E2 E1
D15 D14 D13 D12 D11 D10 D9 D8 D7 D6 D5 D4 D3 D2 D1
C15 C14 C13 C12 C11 C10 C9 C8 C7 C6 C5 C4 C3 C2 C1
B15 B14 B13 B12 B11 B10 B9 B8 B7 B6 B5 B4 B3 B2 B1
A15 A14 A13 A12 A11 A10 A9 A8 A7 A6 A5 A4 A3 A2 A1
TMA Pos Age Survival Diagnosis dead sex WCC neutro lymphocyCRP ca 19-9 differentiation T (of TNM) other N (of TNM) Nodes Total nodes Resection (R0/1/2)
0 is de 1 is male, 2 is female 1 is well, 2 is moderate, 3is0 is nil, 1 is venouspositive total
A1









A11 32 2479 pseudopapillary pa 2 2 2 x
A12
A13






B5 40 48 NET 2 2 1
B6
B7


















C11 51 473 PDAC 0 2 5.7 3.8 1.3 229 1
C12
C13
C14 56 #VALUE! PDAC 0 2 7.1 5.1 1.5 66
C15
D1
D2 70 294 PDAC 0 2 8.7 4.5 3.3 <5 605 2
D3
D4












E2 32 2479 pseudopapillary pa 2 2 2 x
E3
E4


























































H15 H14 H13 H12 H11 H10 H9 H8 H7 H6 H5 H4 H3 H2 H1
G15 G14 G13 G12 G11 G10 G9 G8 G7 G6 G5 G4 G3 G2 G1
F15 F14 F13 F12 F11 F10 F9 F8 F7 F6 F5 F4 F3 F2 F1
E15 E14 E13 E12 E11 E10 E9 E8 E7 E6 E5 E4 E3 E2 E1
D15 D14 D13 D12 D11 D10 D9 D8 D7 D6 D5 D4 D3 D2 D1
C15 C14 C13 C12 C11 C10 C9 C8 C7 C6 C5 C4 C3 C2 C1
B15 B14 B13 B12 B11 B10 B9 B8 B7 B6 B5 B4 B3 B2 B1
A15 A14 A13 A12 A11 A10 A9 A8 A7 A6 A5 A4 A3 A2 A1
TMA Pos Age Survival Diagnosis dead sex WCC neutro lymphocyCRP ca 19-9 differentiationT (of TNM) other N (of TNM) Nodes Total nodes Resection (R0/1/2)
0 is dea1 is male, 2 is female 1 is well, 2 is moderate, 3is0 is nil, 1 is venous, positive total
A1















































































































H8 73 1376 ampullary adenoma 0 3
H9
H10
P3 TMA3 H10 H9 H8 H7 H6 H5 H4 H3 H2 H1
G15 G14 G13 G12 G11 G10 G9 G8 G7 G6 G5 G4 G3 G2 G1
F15 F14 F13 F12 F11 F10 F9 F8 F7 F6 F5 F4 F3 F2 F1
E15 E14 E13 E12 E11 E10 E9 E8 E7 E6 E5 E4 E3 E2 E1
D15 D14 D13 D12 D11 D10 D9 D8 D7 D6 D5 D4 D3 D2 D1
C15 C14 C13 C12 C11 C10 C9 C8 C7 C6 C5 C4 C3 C2 C1
B15 B14 B13 B12 B11 B10 B9 B8 B7 B6 B5 B4 B3 B2 B1
A15 A14 A13 A12 A11 A10 A9 A8 A7 A6 A5 A4 A3 A2 A1
TMA Pos Age Survival Diagnosis dead sex WCC neutro lymphocyCRP ca 19-9 differentiation T (of TNM) other N (of TNM) Nodes Total nodes Resection (R0/1/2)
0 is de 1 is male, 2 is female 1 is well, 2 is moderate, 3is 0 is nil, 1 is venous, positive total
A1





























































































G5 32 2479 pseudopapill 2 2 2 x
G6
G7






G14 40 48 NET 2 2 1
G15
H1


















PTMA1 I4 I3 I2 I1
H15 H14 H13 H12 H11 H10 H9 H8 H7 H6 H5 H4 H3 H2 H1
G15 G14 G13 G12 G11 G10 G9 G8 G7 G6 G5 G4 G3 G2 G1
F15 F14 F13 F12 F11 F10 F9 F8 F7 F6 F5 F4 F3 F2 F1
E15 E14 E13 E12 E11 E10 E9 E8 E7 E6 E5 E4 E3 E2 E1
D15 D14 D13 D12 D11 D10 D9 D8 D7 D6 D5 D4 D3 D2 D1
C15 C14 C13 C12 C11 C10 C9 C8 C7 C6 C5 C4 C3 C2 C1
B15 B14 B13 B12 B11 B10 B9 B8 B7 B6 B5 B4 B3 B2 B1
A15 A14 A13 A12 A11 A10 A9 A8 A7 A6 A5 A4 A3 A2 A1
TMA Pos Age Survival Diagnosis dead sex WCC neutro lymphocyCRP ca 19-9 differentiation T (of TNM) other N (of TNM) Nodes Total nodes Resection (R0/1/2)
0 is dea1 is male, 2 is female 1 is well, 2 is moderate, 3is 0 is nil, 1 is venous, positive total
A1




























































E2 32 2479 pseudopapillary pancre2 2 2 x
E3
E4




























































PTMA2 I4 I3 I2 I1
H15 H14 H13 H12 H11 H10 H9 H8 H7 H6 H5 H4 H3 H2 H1
G15 G14 G13 G12 G11 G10 G9 G8 G7 G6 G5 G4 G3 G2 G1
F15 F14 F13 F12 F11 F10 F9 F8 F7 F6 F5 F4 F3 F2 F1
E15 E14 E13 E12 E11 E10 E9 E8 E7 E6 E5 E4 E3 E2 E1
D15 D14 D13 D12 D11 D10 D9 D8 D7 D6 D5 D4 D3 D2 D1
C15 C14 C13 C12 C11 C10 C9 C8 C7 C6 C5 C4 C3 C2 C1
B15 B14 B13 B12 B11 B10 B9 B8 B7 B6 B5 B4 B3 B2 B1
A15 A14 A13 A12 A11 A10 A9 A8 A7 A6 A5 A4 A3 A2 A1
